var title_f14_29_14800="Contents: Gynecologic oncology";
var content_f14_29_14800=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Gynecologic oncology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Gynecologic oncology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Cervical cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/54/37736\">",
"           Cervical adenocarcinoma in situ",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/42/6826\">",
"           Cervical cancer in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/3/8248\">",
"           Cervical cancer screening tests: Evidence of effectiveness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/32/35337\">",
"           Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/36/25156\">",
"           Cervical cancer screening tests: Visual inspection methods",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/25/9624\">",
"           Cervical cytology: Evaluation of atypical and malignant glandular cells",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/6/33895\">",
"           Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/54/28517\">",
"           Cervical cytology: Evaluation of high grade squamous intraepithelial lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/60/6086\">",
"           Cervical cytology: Evaluation of low grade squamous intraepithelial lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/15/40185\">",
"           Cervical cytology: Interpretation of results",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/19/44343\">",
"           Cervical intraepithelial neoplasia: Ablative therapies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/21/31065\">",
"           Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/2/30762\">",
"           Cervical intraepithelial neoplasia: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/17/33048\">",
"           Cervical intraepithelial neoplasia: Procedures for cervical conization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/52/16200\">",
"           Cervical intraepithelial neoplasia: Reproductive effects of treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/42/9898\">",
"           Fertility sparing surgery for invasive cervical cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/49/6938\">",
"           Invasive cervical adenocarcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/55/28537\">",
"           Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/42/17064\">",
"           Invasive cervical cancer: Patterns of recurrence and posttreatment surveillance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/21/21849\">",
"           Invasive cervical cancer: Staging and evaluation of lymph nodes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/22/4455\">",
"           Laparoscopic pelvic and paraaortic lymphadenectomy in gynecologic cancers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/14/9449\">",
"           Management of early stage cervical cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/50/7976\">",
"           Management of locally advanced cervical cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/37/33368\">",
"           Management of recurrent or metastatic cervical cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/14/18665\">",
"           Preinvasive and invasive cervical neoplasia in HIV-infected women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/4/36934\">",
"           Screening for cervical cancer in HIV infected women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/45/19160\">",
"           Screening for cervical cancer in resource-limited settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/16/38154\">",
"           Screening for cervical cancer: Rationale and recommendations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/23/5498\">",
"           Small cell neuroendocrine carcinoma of the cervix",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/53/26455\">",
"           Virology of human papillomavirus infections and the link to cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fallopian tube cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/25/34202\">",
"           Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/15/40185\">",
"           Cervical cytology: Interpretation of results",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/8/131\">",
"           Endometrial sampling procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/60/31689\">",
"           Exenteration for gynecologic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/26/37285\">",
"           Heavy or irregular uterine bleeding during chemotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/22/4455\">",
"           Laparoscopic pelvic and paraaortic lymphadenectomy in gynecologic cancers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/2/22570\">",
"           Overview of radiation therapy for gynecologic malignancies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gestational trophoblastic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/11/24761\">",
"           Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/30/23015\">",
"           Gestational trophoblastic disease: Management of hydatidiform mole",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/31/13816\">",
"           Gestational trophoblastic disease: Pathology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/15/42234\">",
"           Gestational trophoblastic neoplasia: Staging and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/1/39960\">",
"           Human chorionic gonadotropin testing",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ovarian cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/39/26231\">",
"           Adjuvant therapy of early stage (stage I and II) epithelial ovarian, fallopian tubal, or peritoneal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/1/24601\">",
"           Approach to the patient with an adnexal mass",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/53/19287\">",
"           Chemotherapy of ovarian cancer in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/62/9192\">",
"           Clinical manifestations and diagnosis of ovarian cancer in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/57/19352\">",
"           Differential diagnosis of the adnexal mass",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/23/23927\">",
"           Early detection of epithelial ovarian cancer: Role of symptom recognition",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/51/18233\">",
"           Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/6/31849\">",
"           Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/23/25978\">",
"           Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/48/36618\">",
"           Epithelial ovarian cancer: Initial surgical management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/52/17224\">",
"           Epithelial ovarian cancer: Pathology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/15/25847\">",
"           Epithelial ovarian cancer: Second look surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/11/21689\">",
"           First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/33/537\">",
"           Intraperitoneal chemotherapy for treatment of ovarian cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/63/39928\">",
"           Malignancy-related ascites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/11/30905\">",
"           Management of an adnexal mass",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/41/4759\">",
"           Management of ovarian cancer in pregnant women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/17/29977\">",
"           Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/21/37209\">",
"           Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/57/24472\">",
"           Neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/37/5721\">",
"           Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/0/5128\">",
"           Ovarian tumors of low malignant potential",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/31/5624\">",
"           Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/45/16087\">",
"           Overview of sex cord-stromal tumors of the ovary",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/26/28073\">",
"           Pathogenesis of ovarian, fallopian tubal, and peritoneal serous carcinomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/25/34202\">",
"           Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/14/10474\">",
"           Screening for ovarian cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/16/33033\">",
"           Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/36/8778\">",
"           Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/22/12646\">",
"           Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/9/32916\">",
"           Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/40/34440\">",
"           Sonographic differentiation of benign versus malignant adnexal masses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/30/13799\">",
"           Struma ovarii",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/26/28070\">",
"           Surgery for recurrent epithelial ovarian cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/35/11832\">",
"           The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/24/33162\">",
"           Treatment of malignant germ cell tumors of the ovary",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Uterine cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/0/41991\">",
"           Adjuvant treatment of high-risk endometrial cancers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/62/13287\">",
"           Adjuvant treatment of intermediate-risk endometrial cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/41/8855\">",
"           Approach to adjuvant treatment of endometrial cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/58/26535\">",
"           Classification and diagnosis of endometrial hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/34/44585\">",
"           Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/51/18233\">",
"           Endometrial and ovarian cancer screening and prevention in women with Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/6/37992\">",
"           Endometrial carcinoma: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/27/18874\">",
"           Endometrial carcinoma: Epidemiology and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/7/36983\">",
"           Endometrial carcinoma: Histopathology and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/23/18810\">",
"           Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/53/38744\">",
"           Evaluation of the endometrium for malignant or premalignant disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/22/4455\">",
"           Laparoscopic pelvic and paraaortic lymphadenectomy in gynecologic cancers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/3/37943\">",
"           Management of endometrial hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/7/21624\">",
"           Overview of endometrial carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/57/15257\">",
"           Treatment and prognosis of uterine leiomyosarcoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/18/22825\">",
"           Treatment of locally advanced, recurrent, or metastatic endometrial cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/23/7542\">",
"           Treatment of low-risk endometrial cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/3/22584\">",
"           Type II endometrial carcinomas (eg, serous, clear cell, mucinous)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/22/2408\">",
"           Uterine sarcoma: Classification, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/3/17465\">",
"           Variants of uterine leiomyomas (fibroids)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vaginal cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/30/31208\">",
"           Vaginal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/27/5560\">",
"           Vaginal intraepithelial neoplasia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vulvar cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/19/6455\">",
"           Vulvar and vaginal intraepithelial neoplasia in HIV-infected women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/5/9303\">",
"           Vulvar cancer: Clinical manifestations, diagnosis, and pathology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/14/20714\">",
"           Vulvar cancer: Staging, treatment, and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32952\">",
"           Vulvar intraepithelial neoplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/12/14535\">",
"           Vulvar wide local excision, simple vulvectomy, and skinning vulvectomy",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-0D86E87186-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f14_29_14800=[""].join("\n");
var outline_f14_29_14800=null;
var title_f14_29_14801="Hip extension PI";
var content_f14_29_14801=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hip extension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 263px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    You will need 18 to 24 inches of rubber tubing or an elastic band (eg, Theraband&reg;) to perform these exercises. Secure the tubing around the leg of a heavy piece of furniture or close it in a door. Stand facing the furniture/door and place the injured leg in the loop of the tubing. You should not have any slack in the tubing. Hold the door/furniture and extend the injured leg backwards, stretching the tubing as far as possible. Hold for 5 seconds. Slowly return the leg to the floor. Rest as needed. Repeat 10 to 15 times (one set). Perform a total of 3 sets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_29_14801=[""].join("\n");
var outline_f14_29_14801=null;
var title_f14_29_14802="Bakers cyst position for US";
var content_f14_29_14802=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Positions for aspiration of popliteal (Baker's) cyst with ultrasound guidance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photograph showing how to aspirate a Baker's cyst in the popliteal fossa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: George AW Bruyn, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_29_14802=[""].join("\n");
var outline_f14_29_14802=null;
var title_f14_29_14803="Cellulitis following pelvic lymph node dissection";
var content_f14_29_14803=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cellulitis following pelvic lymph node dissection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/29/14803/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14803/contributors\">",
"     Larry M Baddour, MD, FIDSA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/29/14803/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14803/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/29/14803/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14803/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/29/14803/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cellulitis can occur in women who have previously undergone surgical procedures with local lymph node dissection for gynecologic cancer. Two reports from the Netherlands in the late 1980s provide the most clinical information characterizing these syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14803/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Subsequent case reports from the United States have confirmed these initial observations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14803/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a series of 270 women who had undergone pelvic lymphadenectomy with radical hysterectomy acute cellulitis developed in 4 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14803/abstract/1\">",
"     1",
"    </a>",
"    ]. Most patients had either cervical or endometrial carcinoma. Collectively, nine women experienced 17 episodes of cellulitis during over 14,000 patient months of follow-up; the average time to the first episode of cellulitis was 29 months (range four to 52 months). Surprisingly, cellulitis developed only in patients who had undergone postoperative pelvic irradiation.",
"   </p>",
"   <p>",
"    In a subsequent study of 126 women who had undergone radical vulvectomy with superficial and deep inguinal lymphadenectomy for vulvar carcinoma, acute cellulitis occurred in 26 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14803/abstract/2\">",
"     2",
"    </a>",
"    ]. Colonization with beta-hemolytic streptococci prior to surgery was the only significant risk factor. The incidence of cellulitis was higher in patients with history of postoperative radiation (33 versus only 16 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Streptococcal sex syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A temporal relationship between vaginal intercourse and the onset of acute cellulitis has been described (\"streptococcal sex syndrome\") [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14803/abstract/5\">",
"     5",
"    </a>",
"    ]. In one patient who was 22 weeks pregnant and who had undergone a modified radical vulvectomy with inguinal lymphadenectomy for squamous cell carcinoma of the labia majora two months earlier, symptoms of acute infection developed within one hour of coitus. One month later, she again noted the onset of cellulitis promptly after sexual intercourse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of acute cellulitis is similar for most patients regardless of the anatomical location of the primary skin lesion. Most patients note the acute onset of fever, chills and systemic toxicity associated with skin erythema and tenderness. Women who have had surgery and lymph node dissection for the treatment of gynecologic cancer usually develop a macular distribution of erythema and swelling over the lower abdominal wall, inguinal area,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the proximal thigh. Some patients may have raised erythema, which is more characteristic of erysipelas.",
"   </p>",
"   <p>",
"    Patients who have suffered recurrent attacks usually recognize the signs and symptoms of cellulitis. Recurrent episodes of cellulitis are similar to previous bouts in terms of symptoms and severity of illness. They usually occur without antecedent precipitating events, although vaginal intercourse appears to initiate the infection in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14803/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, for most patients with cellulitis after surgery for gynecologic cancer specific pathogens are not recovered from clinical specimens. In the minority of cases in which pathogens have been recovered, most of the isolates were non-group A, beta-hemolytic streptococci [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14803/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. These streptococci appear to have a proclivity to produce soft tissue infections in the setting of venous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymphatic compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14803/abstract/6\">",
"     6",
"    </a>",
"    ]. Staphylococcus aureus is also an important pathogen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy with activity against beta-hemolytic streptococci and Staphylococcus aureus should be administered. In addition, therapy is usually broadened to include the normal bowel flora, since the lower abdominal and pelvic regions are often involved; however, these organisms are not usually recovered from the cellulitic lesion.",
"   </p>",
"   <p>",
"    In the absence of risk for MRSA (",
"    <a class=\"graphic graphic_table graphicRef53504 \" href=\"UTD.htm?5/9/5275\">",
"     table 1",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (2 g intravenously every 8 hours) may be initiated. Treatment may be continued with oral therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    500 mg orally every 6 hours) once there is evidence of clinical improvement.",
"   </p>",
"   <p>",
"    In the setting of risk for MRSA,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously in two divided doses every 24 hours) should be initiated. In such circumstances a cephalosporin should also be administered for activity against streptococci (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    1 g intravenously every 24 hours). Treatment may be continued with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (300 mg orally four times daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (1 to 2 tabs orally twice daily),",
"   </p>",
"   <p>",
"    For patients who have received recent chemotherapy and are neutropenic, the antibiotic regimen must be broadened to include coverage for aerobic gram-negative bacilli, including Pseudomonas aeruginosa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal duration of therapy is uncertain. In general antimicrobial therapy should be continued until the clinical signs of infection have resolved. Response to therapy may be slow; in general patients report improvement in pain before there is a noticeable decrease in erythema and swelling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic suppressive antibiotic therapy may be useful for some patients with recurrent, severe bouts of cellulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14803/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The regimen can be tailored to the individual circumstances;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (150 mg PO once daily) are reasonable choices since they have in vitro activity against beta-hemolytic streptococci and S. aureus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22738598\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute and often recurrent cellulitis has been described in women who have undergone pelvic lymphadenectomy for gynecologic malignancies. This syndrome is particularly associated with a history of postoperative pelvic irradiation. In some cases, the onset of the cellulitis may be temporally associated with vaginal intercourse. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations are similar to those of cellulitis in general. In these cases, the lower abdominal wall, inguinal area,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      proximal thigh are often affected. In the minority of cases in which pathogens have been recovered, most of the isolates were non-group A, beta-hemolytic streptococci. Staphylococcus aureus is also an important pathogen. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be treated with antibiotics that have activity against beta-hemolytic streptococci and Staphylococcus aureus, including methicillin-resistant S. aureus in those with risk factors (",
"      <a class=\"graphic graphic_table graphicRef53504 \" href=\"UTD.htm?5/9/5275\">",
"       table 1",
"      </a>",
"      ). The antibiotic regimen should also be active against aerobic gram-negative bacilli, including Pseudomonas aeruginosa, in patients who have received recent chemotherapy and are neutropenic. Chronic suppressive antibiotic therapy may be useful for some patients with recurrent, severe bouts of cellulitis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14803/abstract/1\">",
"      Dankert J, Bouma J. Recurrent acute leg cellulitis after hysterectomy with pelvic lymphadenectomy. Br J Obstet Gynaecol 1987; 94:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14803/abstract/2\">",
"      Bouma J, Dankert J. Recurrent acute leg cellulitis in patients after radical vulvectomy. Gynecol Oncol 1988; 29:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14803/abstract/3\">",
"      Binnick AN, Klein RB, Baughman RD. Recurrent erysipelas caused by group B streptococcus organisms. Arch Dermatol 1980; 116:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14803/abstract/4\">",
"      Chmel H, Hamdy M. Recurrent streptococcal cellulitis complicating radical hysterectomy and radiation therapy. Obstet Gynecol 1984; 63:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14803/abstract/5\">",
"      Ellison RT 3rd, McGregor JA. Recurrent postcoital lower-extremity streptococcal erythroderma in women. Streptococcal-sex syndrome. JAMA 1987; 257:3260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14803/abstract/6\">",
"      Baddour LM, Bisno AL. Non-group A beta-hemolytic streptococcal cellulitis. Association with venous and lymphatic compromise. Am J Med 1985; 79:155.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7645 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-6BDFF69EB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_29_14803=[""].join("\n");
var outline_f14_29_14803=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22738598\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Streptococcal sex syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22738598\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7645\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7645|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/9/5275\" title=\"table 1\">",
"      Risk factors for MRSA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_29_14804="Dipivefrin: Patient drug information";
var content_f14_29_14804=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dipivefrin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/59/27571?source=see_link\">",
"     see \"Dipivefrin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/52/16195?source=see_link\">",
"     see \"Dipivefrin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F161378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ophtho-Dipivefrin&trade;;",
"     </li>",
"     <li>",
"      PMS-Dipivefrin;",
"     </li>",
"     <li>",
"      Propine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat glaucoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high eye pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dipivefrin, epinephrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703793",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have narrow-angle glaucoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694635",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not wear contact lenses at any time while using this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11725 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-221.179.173.170-4115C7D097-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_29_14804=[""].join("\n");
var outline_f14_29_14804=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161378\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025565\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025564\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025569\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025570\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025572\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025567\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025568\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025573\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025574\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/59/27571?source=related_link\">",
"      Dipivefrin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/52/16195?source=related_link\">",
"      Dipivefrin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_29_14805="Dubin Johnson Light";
var content_f14_29_14805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dubin-Johnson syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 252px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD8AZUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6eP1NCkkDFIx4rxL49X9tB4g0S31n4gXHhvRGjLzafpfmC+uWO4BwUDfISAo3DbkN1PTxKcOeVjZ7Ht+fWjJA5NfOP7OXibVZfiP4q8MzaprWo6JbQG4tP7Z3faYtrooBDHK5V+nAOAcDJFfRmc5pVYOnLlBaign8KDyQM4OM0nOQeOOtL6VkMQH3xQDknnpTXP7ykB555oHYeGyD/WjdxmoHmVFBcgD3rPn1EZwuAOxNLmsaQoynsapkVerfrVaa9VQcEmsUXEk0vyncffvV2G2yv7wn/CjmfQ3eHjD4mP8AtUsmcH2xSlZJOS2M84zT08uMcVh+IvF+ieHoi+r6ja22MkKzfOR7KOTS9Soxc3anE3PLCg5Oap3T29lbyT3DfKo5I/pXg/jD9oOKN5YPDNh546faLn5QfcKOcV5LrfxN8TazIJL3U5AAwZbeJdsZOe49KuNKcldI7aWBlf8AeOx9qvf20GGeSCNB/E7gDn0zXPat8TPCOkhhea/Yq6dUjfzGH4Lmvi7xj4y1nxNNFPrVyGWFBHHHGNqKPYetcwbrJCRoxU8kV0QwkmtWZTo0YO0mfXmrfHLQZdZ0+HSLlmgV8STzoUTBrF8SftFx211cQ6JpkVykZIW4llIVz7ADpXy7JdiRNpG3HHXgUQzMxCquFPr/ADq1g0tWzTnw7tFK57Lq3x88YagWNrcWtih4Cwxgn8zzXOSfE3xfczb7jxBqCue6S7B+Qrg7ONjdKAGkx0+tXbuQXUiR+SkciAKdh4JA6n3qnShF2SOuhFcnNazva3c3NS8W63dki81m+uCcH5rpmHP4/pVD+0b2RS24+metdx8OvhkPEdib3Up5LO0JwgVcM3vk9q5jXwmnahd6XZxJDbwuVMrHe7gd89h9Kz9rHm5YI7YYb+d29P8Ag/5nTfAa4L/F/wAMCWbLm4kwvX/ljJ3r7K8VTpAlqZATlzgepxXxl8Bkg/4XD4ZZJGLCd+Mf9Mnr7M8WyxQxW0kibnVmKZOFzjv616uDfM0fPY+lyYmKVtuhzUlrdX3nXh2xyKMFRwNvufWq2v8Ais6X4N1l7+xjvYLSyll8nf5fmhFJIzg7enXB+lTXWrWcNlPHL5ix5DBgRwPU+lcp43uobv4Z+KJonjljOlXDK+7PWMjjFelJaXaMpRunzLYoeF5rrx/4SsPEmk6esD3DNa/Y5JfPKBGK7t+0D35H51uQ6ZJplv5N2IzeuHmlMIyFHTC/iK+bdF8L3M3wmg8QSa3qMb23nvYwQzlI7fa5ydvcswOSCCOOuK9p+DniK68ReArDUdTme6vw72VzNJ94lWBRifdSAT3IyeTWkak7KLFSTunLqizqGo3DMssyfM+GVly6/eA5xzkDPFQTrPqEtnEymKPzVfzB1bjp7D1rZfTp8k8yxKSTlejls4yfbIrCllvLrVJLScJBChyJQvXpgD6c5+lbSSlobxVkdbodxiCSCYh2jd0QKcZB4H4/pW+mm6jYWUN7bW9uRH+8mEvzuwB/hPbiqOmR6de2E4gMEuxdnmIMFZBx275qWHVLifRfsMk0u5vklkIzhR2B9ayfkc81KWiLena0bqSSdoiiNkpGxG5fT/JqxausUMmo/K1zu2rCi5Gfc9zxXIXMVxYyiJXOWIcOeAR2x6dK1NJ16cbLe5SW4JYqTGABGOAWY0pU+sTTkSWhct/HWoWr3c2q2Oy2Q5QgfeHQYI9+KzLXUVvWF/IHcySOZAp5xjpj2qLxrH9osfItCfKk27wpyQd2Dg/hmmaZEuj2kYuP3kpQFcnB3nnkDvirjTgo8yWrF7sZe6rEd9cpcZkEWxRyBnkCrukZlh3JHmCRgSGPeqOnIt3e3KSMsjKCWKjJT2Ira8O6ZLcRzzCMNBDwATjIPcUTtFWL5k1dmd4gCQwhNGhxODtmuHOd59vWrFhaNYTW8d++JWwZCUyoB9K0rK2sitxNqMnlwKuI8nA464981zEt24aURxtMOu5nwTzj/Ckm5LlHCKvodLPFC0zR24jd3YIuBhSPUZ6VALRLO9jGot5GCfnU9R9aymvZbHSWmWMNcXDEhG+YDtge/Sk0PWlvrll1OJZpY8bH759OafJJK/Qm+vKbs11AInFsZp2IP7xQMD1/Gmabe6jbssUUHmTK3mLk8kd8+1MuryG5vLvySsccgXC7cEN6fTNUftz2/wC8WTaVXazg42jvUKOmxSV1Yu6e5v78XdyGaJnKE5z857An0qtqsKWNtcPYR7EBYE43c5yc/X1rE/tWVEnh0m6H7ol1KpkZ/wBn3ps+pzX05i8mVZpVBdAwwOOpB6Vdtb9AdN3JYvtW+K7ikWKQDgj7xroRb3M+ntPczmAIPugdSO5PTBrAsPIt4nV8iGJOrYJJ7kfzrobHxBpzolq/7wTfIgaPEe49STn6U5J9EKTsXocCGNi5TcueOM+9FaFteXOmW0dtc28c237jBd3Hp+FFczbvoiOaXRHQnpwDXkHjv4d+KZfirYeOvBF9o/26K3+zy22riTyx8rJlSgJwVbkfKQR1IYivYj0pp6nPWvlITcHdHFuePfDT4beJ/DPxP1vxRrur6bqcerWZSZ4g8cizlkbhCu3YCrKPmzjacDpXYfCzS/F2k+H7i38e6vbavqjXTSRT25JVYdiAIconO4OenfrXYqOOQR+NKen0pzqynuFrC9BimFsdetBPPXio2bH0rIaQrtzk8iqt1dLEuByxqtqF+sA2qcua4/XNdS3RlkILHg4NZykkehhcFKs1oa+o6nsydwL9vQGqEVxJdPnd8vWuJi1Nr6V2GenJzkGtptSttH0hr7U7pLeOM5fc3T6D1PpWSndnvPBKjBW3O7s5FQAYGQMdK5vxp8R9B8JKBqt1ids7II8M7fh2/GvDPGHxo1fVXay8Iwm0jY7PPYZlkzx8o7fzrx/VEvLi9lk1EzvcnJkeVjknPOc11QpOT952/M5I5e378lf+u56n8QfjhrOtlrfQXbS7DGDt/wBa/wDwLt+FeUSXNze3LXFzLLPI3LPI5Y/rRBaO6M6I0gQZfaM7R70kqLBn5+o454/GumMYR0judkKTgua1oos69pd9p1vYXFzCYor2LzLck53L0zWSuFJIOX9BWnd6ne6stkmpX7yraxiCAMBtSMdh/jVK+gS2lL2+JOMtz0rSm2lyy3Mq0XO9dbfj9yKZbfayK8R8xjhcfzrV8Ow6fLqKjVVnjtm4eSLG5R681lxXtu7HdvQkcHGeathVKD9+TkYYZrSonbl2OfDckpKaalb0/rqT+JdM0y21Jl0W4+1WYbMbOuCR71q+DDoCapCfFUVxPZOwXyrUhW543Ent7VgNEiRFoVc8HAJpLMK6j7QwVl9OQahpuFm3+ppGMY1fdilf7jufiX4Dn8G6zCzJMujXg32kxIJxjO047jNcRLCiSRTQzgk5DLz8oHc/WtiDxNqKfZ7fVfM1OxtCGgtrydmijGRkBc9wMUy+1Gw1LUdSun0xLSG5Rmht7V9scb8Y6g5HXis4e0hpLUt+zqLl2d+zQw69q96otRqd01qo2rCjkDHTGB1rMd54nIaJlQ9WdsE1Ys9NvLiRRp9tPI5O35EJ59BiulfwB4w1CO3VdEvJVQEgOpHv3p81ODtokVy1ZwcpX5l9z++/4F/4CFE+MnhcL5vNy3Xp/qnr7G+JN6LOzsCYRKZZjGATjBI6+/0r5W+DXhrU9O+LXhiXUDFbbLlv3LOu4ny34AHNfWHxFjgTRBfTiMvZP58QkOFL4wM/nXpYGak1bU8TGwdLFK6PAtS1uYzC1khkP2ZvtLzvIUEmScpj0xmtm2L+JLHW9Nt3i03RbvTZ4bR9pMcksg2ktgfwk8Ac1k69pN3L4fF1pN0kmoXr772NAd2c/KvP3U5OaraTruoWcenWMbIwXekoljDRyBX5ZQe4AwPevRcpRnyTOyVKNWlemVl+FXiyx8KxeGdG8X2MmnXHmPexTWx2xljhvJcoWwUC7lO3kH+9UWu+FZdB0XT/AA54M8ST2Vwj77i53NGXBDbi2zkAsRgc8KOTjNep22vSa9YWwSEWnBURY+c85OffHasjx9c+TJpNzDarNljbgYAI+p7+vNaQp20MMJRipcj6q251dgif2Zbb5QeN5fPKnpj3J9DXAeNL6HTJGNs8c1wzL+6PvnOfaumS8isrB4biIGSL5mmV9wUHr7cVxmlxRLqt1cuBcqSdmeQig9Mn+dXrF6dSqcE3eWyNLwxe6p9jF2ZY44SxzHt2KEz6eufWu7trmO/0m2jtI/L2c+Y0nLt34rzbJ1GSVklMGnw3CxvG4Ck4JLBfXOB83QV2en6sbHRYnl0y4Fmgyt35mWY55J45quVyWhlWlGMtTRuoo7uVGvpWiuIuFXaCHHTA9KpWzyQXaoySxyn7oZR+8xkke3HrXQaPfWOpafOjQmeM878YZG98/wAQ9Ko2cAvdSt5JY3uZrNS0YYYYHoP6VCla6ZF7l+/+zxEyudxbayx5wOnA+vrTZtLS5hPn3RMzsJCUHQ+nPpVC+s5l82adD5kb5PXAJ7fzpupX91LbEo4DADKhcYH9fepSelmDV0W59Ih0qW4aNVeJiGLKSGbtng8fjWTrWtanZ6KLXTIGnHnrJIqffKA8hf54+tNv7iC9m0pb6W5iktZtyPCzAS5UjbIB95ec88cCunttIvYgs1kkVyjrwZlGf0qm+WznqJWglzHMy3UFyylkdWfBCt1T1pbyyLyK0oPC4X5ucZ5z7VAtjff2+8FxLEkm/BBOF3eufSrGvt9o1Jml2eVs2KIzkMw6jj+dXHdJGk5JfCJdamZdHTTZIYfLhXCyqcMo55J71naTZkSl7VVO37zAAA98/lTEtTLMZGt4kG1lOX+bb2/ya0dGntlto1NtICAd8287m5xtA6e30qr8qaRKirXQ7UppIWE8Dlif4EGdyntzXJzWM01u5YTozsSyyufmB9x04r0CWykS8hLW5U3EhKJtxj0GfpWdrOiawk93DJDthVVaKdWwpLdc46kehrNSWzLVRI888m40q3j2x+U3m7gzuBlc4OByOa1rHW1u7xo4VMixD55EAHB7e9Tto91cS6hbkos0ESHzGG1uQTgZ4xnPPasTw9FcQQFINqtEweXHzA5zwCeSO9KN07dDdzjNO+50aTvcaa4KkgS/MXOflyOnr71Bptqbgy29ok7qzgKw+VU/E0xNUgELLeEJCylwgIYMO5A610WnatbSCOWF0YovCv3H0rZVLKyOWpSe52Meq/u1M253xtySMcUVyX9qTyqpiYLF1VDztorD2RPJ5HrB/SkPWnUHrXx1jzxm3AGSTjuaQn14FOPBphOOBSsUtRGI61ja1qAtLeRt33Rkn0q5fXHkxk5+bHFeK/E3xgYp5rC3kZWQBpCPX0rKpKx6eX4R1p3eyNLxJ4wjiV0hkAf+J93Az6V5/Pr5urxIY3EwkPyheST/APrrz7xP4i821RYBuJbczlvzG38RzXMvr91CIpbaYpcquxSq8gdc5ohQlPU+l/d0ItbHq+seNJPCcrpeaezX0bAwxOcA57+4615T4u8Raj4l1Wa/v1Ec0pyIYQRGMcdPX3rKub+71CRrnUJpZ7gnmSZizfme1QwSNv8ANeUlxyoXov0rtpYdU9Xqzhq4hVmlsmWjviu1KmUYORngivQ/A+kW/jqWXSZWis5ba2LLLuLPK2cknJ/Qeted+Y00ryyvI7MMsxyT9av2+r3elXQutNu/s9wvKzRHBHH61NWm5pJbnVSq8kZST0PUde0GL4d/DbUHm1OzfUNSYRJEo/eFO+PYDP514feTvNDsVCVABBA61cvbqS+uWkurtrmZhyZXLHP41SDhJts+9Tt48voK2w9L2er1Z52LryqrkvaOw+zlMV1bi5h83IyF6fhV7UruO7vJnsrPyEP3UySF/PrVAxyTBAk6sF6N0bNJFb30d8uXw/Qt1AFauMW+a+plCpVhH2ai3Fta2Te3cWKL99tkaMlRnlMfrTljja3LKjmVT9xRgEfWrV2PN4uPKZl5yO9V9O1C7t5T9kBRTuQNjjaQQf0pJykroqUKdKahLZ36Xf3eXqSS3KJaQNHE0MqDEhaTduz0IGOKjsXeRnDuPKfkYpXiZbpVZnLOMgN0p6jbJngEfeKj9aNLWRUefnTk9Fpb/hvI0LG6it1laWGOVyCse7kKfU+verngqBbnxfpYmtHu0FyjPCi5BQEE8fSqUt1bHT2R7crKzZU5xn8K7L4a3dt4evYvEl7fLDLYsDHZEfPcg8EA9uDXLN8sW7avQ9Tl53GKd1HX/hz6N8X6XoWialYeI/skNvBAQJAmE35HHHAJFcP41+N9tDqNvD4elMcKsRO7RB3K9PlBOMj615l8VfiZdeONRSKOyeDSYxiCLO593dyRxn29K8vuyWvUCLIuBglv6VFLD83xaHnSfJTjKouZrTXz/M+gPhn4v0i6+Keg2+k6OSbu8bzL+/bM7MUckqBwua+g/irpt/qWj2S6bsZ4rpZHiY/6wYPH17/hXyB8D2I+LnhLKlg119cHY1fafjLU20tbKWOSMM7snlOceYCvQHsa9fLo+za5EeXmLlUxMVvoeP6v4e1aPTbgyrNYyXxMamNBl1B3Nu6gZAxXPXckNlNYLDYST3E8ASSZl3suD91gPu+vavWp7mPXNREISZI/s+Gctjb7qe31rz3xf4fu7WCW/s7S5s4oblYDvYMtwn/PTOe+Bwa9WrOT16muGkorkkaPhi8tl1CWS4uS5jk8s2ce4uhbA+bt+XQVoeLBH/Y1/AYpXkikSaNtv3Bnkt7YP61wcMVzpEFzLphmt0uH3zXKgbtuCOh/i5OTxXZ6PM00LI8EtzH9jxPIx+9k4KnnqQciqg++47OEucri1uJfDvkWbotzewMiSHomWwSffGa5i10S6d2s445jAE8sEyDa0nQtwclRjke+O1dlZX0LWmn6LbWjQ3EaEiaeTbhVJySepJ9K6PRFtb+CGy8oW9ygKbkH8HXBH1NOaW76FTqyp37M43XNPjhsdOeMSMsUaxzEpuKkgAfpUk2vajdadb6PFEGiTIiKj+EH+IngV6FrHh37JamWCbKgqHDtwa8z17Xo7XfPo8jMIXMVwrRjAbIG0D39auFeLitL2ONU1WfNFnX6BYoNOht1mbMwJeTd9+TOTj0+pq9au1vfRTQggRKVbc4b5c9z6ivLUgu2ngs4C0VsjPM0Ekhy4xkDI9T/ACrtPDk8s+lyQSKs8kEm2V4+ArfewR+OKh3lds2dPlXkaer+J7xb9rd9KJtpx8kyxk7+e56ZFZupRvCi3CyPtG5TGqbjz3x7H9K1J5pZLGIJckx8PtHAbnoD3xReiMF4rVpCcYO/+I4oVlsCSS0R57FNqMBttSSYGO1Plyb2PmSMW+UkDgDBHB61ZXXtYtkj1BdQuFlL/u4Q3XnnK+ntT9Ugmk0/dCPs8kFxiRYujH+905/LrTPDltcDWI59Xt4Z9OM/7gMxRowRgll78gVtBqN01cmtBzVza1ma61C1udRSVBfGMIDtxh9vvXndmNUnltYYmuJ7pGKxPyTJjO7eegIJNer+J7rT9LElvdzHy5ikUbrx87DP4YFU9YspdO8OzNpduFjbbukzklcjcT696z5ee3RF06ypxdlc4/T7/WpriSNBF9oQrDt80KgY53fXAHWu50O/aNH+0wEPARsIbcGOOT9K4/xBNps1hJaW9hHbQFAY54D8u4nvz35rT8PTW2lW5s7y/NyGPnIJD8yBsfKSOntmqnHl0YRl7WLdrHoV9f3epQQ3tlEivCykDeCWYe1V77UL+8Z/NtLjzlUq6RkMEBHUAc+9YyFTNKbd1V1Bbcr56DoR2rP0calo0PiCbS2OoXGpRbrYvJgwk8Fefc5rNQVtDNUktuhqSSxSWzyPv885G11wX+tc54k0e40HTI7q1RpWkVU8kniJN3zSsemADwPrXYyWF7b+H9Pk1VYZNRjKiQJ/EMDv3PrV+W6s9cKQLEElVNvluBhvz60c3bYlS5XdbHir6bLNqh3M1yYSq28kZI/d5OWGOemOvFdNofhw39rLLCsYBXyYGjbLuFII3n+8SDnFay+B/EFhfv8A2K8Pls5O+VyHiU5+Xp0rT02O40TTXsopd10JfLmkUfKntn1q3GmleDuw+sTk+VM4+/tnSVFurieKUINyw52g5Oee9FbHie5YakLaNI7ZYY1OZ+N5PcZ+lFaKnzK4/rCR7NkfhQePelxTeg5618UeaI3B6c+9VppFVWLHjrzU74HY1zviDUEj2wA5JOT7VE3Y6cPSdWSijK8T63Dp+l3l/MRiFSUHqegH518meLNYnluGYvvkny7kcnJPNej/AB812eOCx06BpESXMsh6ZAxgfrXhdxM1rFFcklRu+Vs85FZUqbqO7PrcPSjhaXM/UtWuqXPh/U0uZLGOVvLP7m7jyrqwx0rBuphKz3LIYZNzMIlX5RnsPan6zqF3qGpxy3d00r7OrHpj0FZzRXc2Gw2ByuTivVp0krSejPIxWLnOUoxTf9LXQsTSxiFPNzvYf5zTracpCsrFGKvjbjg1HbW8bxngtLwTk/dpkzGDiAZjHLbh3q7J+6jDnqQ/ey2t0/Xv+h6V4n+J1xfzWk+l6bY6PNb2xtWW2iDGZSMHORj6elcBbzeaG/0Zih4DE81BuMP+uXazDcpAztoeWWO3Ybpgx5+Ze1ZU6EKatBG8sVJu8noull+N+45/KFw32gLhcHeg5H1q1YRRTXO9DgO23zJPugev0qnYQLPvkeYlf4s8Amrc8Yi8l1lCD7pI6D8KudvhTHh1Jr2zirXv0vv3I5FtUmMcEipcBtu/naabazSNcPHPIGKsAGHepZ/sohDsDMx+Xf61DZW8LweaEYOuRnOMUlbl1G1NVVGFu9le1vNaq/mP1OCN2P2QF3PUg9aitTcywIkWfKUjercHI96t6ekUcbSxK8kSH5sGrFvBLqdwfsaOiNyEA5xUufKrPZdWbLDe1mqkdJS+zHqu6fbv3Io72N5AHUbo+ivx+tQtNdF2HkrsPQhqsAFZnjliLRp0fHWklaEcFDGpGASeWNSrJ6I3kqko+9O1vl5a6MNyKA4SNlXruPINPimN4GIcPt4C+lVoIvsfJcsjk/IBnFP81Ivmk3omedoxQ4p7BCrJW59F1X63/wAywzyqECBBtOcZwc1W1IOoEj71V+do+8TT5n3t5qRFS33XzkYqO5lmuLYPLLJvQBQ7ncMUQTTTFiJqUJQ1fVdtPu/yO7+BEKp8UvCRkExk+2ZGfdG619ifFC2FxploTCZSkpIUHByVr4/+Bd0g+LHhWJ2DyG5ABXkD5TX274js2vbeJFQPtfcQfTFd2Dk1K7PHxjp08RTcHsv6ueW+H5NV0q6ljaJtltGSsrLkAH+A+3+NbviOKXV/C0clwgeNmEkcAbHmMDggnt3P4VftmFhdXKltwf5SOoxjofUVXWN7fTZLaZh5QmV1B6gMOSMdBXqN3dwnPnlzWOIutCvRemC3uY4w8/dyzLHg7x6EcjHpitbQbOx0+3udPkmj2NIQHU4ZwMElz0zknge1Q6/ew6fKYcuYzbSTfa/+WUYX+Fj689KwbDULe8uLe3gnRriaTbFgHa7AfMenYHJraEFJBOTsjb8Z6DLDapNCTI5QtEytgr7D9Kd4UtbzTbGOaTzGuXPmBwCxGeoat+zuIp2kW6lSe3gbdM68BABhFI7Ek59a2NPvGNnJbQwbIrg7VbH3B3zWbk0rNDliJez9nuZGs69cQ6NLLqixSWoi3sdx3bfw7815vqMmkWtyyQIss7r57AKSB2UMT6muzurmxSC9srq8iikRCVRzk46AY/l6mvH9atJYoZhGkot4UihW8l+9KM723L69vXpUTn7NaI2w1GMnbY39U1mZHSeRntxC6xT+X8wjbHJY+nOPw96veBdQZrpxJLcR2khbyioAErgYYk9SD6dvWrkcWmf2LO99YL5N24iRYcuZQSNufQkjn0qnpOnXlhcLHczQpZWod4wpO4AnO38P6VaUm02xtx5eVLU73Rb2y1J5LaytpIvJdo2DIRuPt14z3qW7aSCRzaqpYkYQ/MF9OKz/AA1eRPZyYvysDluQuSDwOT1BGDxW/EBNen7M6r5Shkcxn5h7+x6UPRnPezZxniaGwlt4bi481r63kaP5WwFYjnco+nH6VBp95NdyNZ21us2pMcWsTfuw5wSCxPT1xT9Va21C7e4j2+ck++RYDgvxis7T7SefWI5dNimijedZ5pTuHkbeep/kK6YRXK2yKjlF8pq+MfDc2o6HpsOvWnk3Ubx3MkcUm4eahPQ/Tt3zW7pOr2uo6XE1zkwrlYs9FGOh/wAareLNUm/svz2ixtXG8ncW6j8zXJfD3X7O68anwqbOecS2weO4DYCjH9D/ACqIqU4a9NSmoQpupPe516Wdkn7yC1t5Nx3Eonyue2TXlk2h3sN3ILu4KkXEh+Rsk5OVGereldPrmhXml+fPY3sitE5LqWJ2qOuK2LVIr23guU2zM6fK/U9P55FKpSUkne5rQrum3YzdLvpdLFpDfRGcuxZdkfLg/wB/6frXZ2thDLIzGR1iUfvJIx8qE9Bx9axLKIAK8kKJMpOcHP4/j6VoS3i21lIXJRH5cg8t7Ad6TXRCqe9qiT7bNb3X2ZpTdW0LNhJGyCcdfUiqFobm7n2F4cRSbZGCkNIOoKY4Cj3qhb3LXErOCFQgHhtw9x7Gsu8tHjuo7vTJ7xr+M+a9vnEc8fQqh/hwAOuBmnJcqujKK1sz0TMwDQtqEywbc8PkuMf3q0r2G0OmwWum7ftpZZDGp+6V6kjua53WtVHh3QrrxFPHDIIYxKsDLkAgcg49Kv6B4th1zT7bxDaWtvCRa71Q8k7uuT6cVk4StzJafqYVJXlZepb1qFZ7oNrNtbu20eWXXt35oqnP4suZjunt7RxkhVMZO315oqoxqJW/UmO2qPQ6aeeacaY54P8AKvkDmRS1G7js7SSeZlSNBuYntXj+r+NdIa9Mcl/ELhySOGPau2+JWpJaaI6Mu8sNxT+9j/69fJPjDxfc29/PDYssEwBjZ1jHA6kA/pWEoyqy5Yn0WW04UqftZ9TT+Lus2d5rpM10Hggt1EAhbcXY9z6CvJ5Yrm7Z54sSqg3bQCQB603VJmlhTdncSW+oqG31C6tYmFpI8SOpSQr/ABZ6g16VDDunD3dzLHY6FWp7OpflS6bkKBhcRtI+0vyT6U+RSk5SGUlG75qBSQQ8ibgem7OK0JY1Mj+RaqsrchUYsoB9M84rqk7M8ukudO3e/W/9M6XwNrWh2NxcvrthLcRtHsXy8fKc8nHrWNfWj6lqMv2LeLd2LIjYyB2HHfFUIkByZ0YMx2rnjNdD4Pv4bDXbK51K3SS0hkXzI0GCQOO3f+feuWcfZuVSG57OHqPEqGHr/B5aP5mWmjX0trgJLIA3BVScVp3+hX9laRrqNpcwK6ja8kZXd9M9a+pdI8c+CtXSC00qe2snj5EVxBtB9q72az0/WLEQ6nbWl3DtBXgEfh6VwvF1G7NI6HToYdawlZ6avp+v3nwpo2lXF5MlraIZmkbCQ7c5Nd3B8KPFapK0WkPJGo3FRjrjOBnrX1H4a8EaH4evmuNNskWQj5SVGV/GurBWORmbIHvxiiVec32M/rtHD2jRhzW6v/I/Pa/065tLyWy1Gze3uIzzG6lWX8KrrZ+fG0WxxtHDDgH619UftLaPB/wiza1a2kf2xJESW4C8qnYE/XFfLs9zesFiUErtxu+tb0qs536WNorDzgqkk3fpZP5X/WwllbAXDwSebEMYVQflPHWrkFxNpxKWtw8Uu0g4PODUJ+0mNC4Y4GNxqs8bTXK5kVlxhiG5FW/ffvPQ3X7mCVOLv06aP/LyN59flt/DbWiadZy3JbJuCmZAKxrO+XUIX+0KolUZBC8imMsZlcRTOUA2sVqvAohmb74Ru5IGfeiNKCTstdyauKre0jeV4bNbr1Gxqk0rYup8jk8cCrdtF5t0YVklIK87hnJptvBBHeKFV1T7xYk4NWp5tPnmhNm86yIDv5yCR6e1VOWtkZ4eiormm1e+13r6XIJf9HjCT73jJxgDrTZnt9o+zIwUKA0ZXnOOePTOf/rUsUsM907RvINnzMGHAHqankt9uZbORWVj83HIpX5fiLUXVu6TTS06N2/P5fmdh8Dig+LPhZYotgN4OMYx8rV9t+KRI0ECxsw3FgwXqRt6V8UfBNJo/i34YUurIbwZ45+6a+2fEZhBs/NClw5ZMjJ4HIHPUiu7BvW54mYJxxEU107HO6fbpqDugcy+RGF2r3+p706KKWaC81KykjgtlzGBjIYL1x+PFJZWtzp0sl7ARuKs7W8Z6rnp9e9VLm5aHwBerbDM0ALZT5tqs3Lj3AJr1N3p5HNOTWq2PO/Feq2PlXGj6kjSnyxI8f3FO/kLu6ZaofDkJfWUmjtpoxIRbwwxSqVjQjknGD1HUU66t8HUNtqiWtunmLely5Zgv3TnqT09jVvwTpFpepfzX4ltNR8tYpLrzvmePGf3JxwMBQe2c1vUTg12OunUTptI7HRI0WwvbZFULG/nTMBgu3TJp15cXFnZtExIS4AWPjCnpyD6UkJuI4opYmZnVSPMZQN/UsT61Jf21trdrLb3CSraYTCCUg8EEnPocDIrO+t2ZONjyu600a54h1Ka4iVJBbDyEmcRl5A2ExznpzkioodB8VSyQm609k01WRXFxIPMV25OMHJPB6+1dB4l0eTQdQt727gjg1C5gz58AL+YA3bPQhdvStbwdqF1cXM1pdRtPGylyzfM74Gcgjtk4q/Y3XtClimvdiVY2htLdp4jcJCw8tYZFJOd2NwHqSenuKuaPoc2piObVNNO1VyN7bXjO7BVlU46AfnW7cR21mTdGdYrRQvlrIowOMLGP1NWodRljieS3LSArjeAdvPp71Mm7aE899FucZqMSWerCzskEUdtMbiOQqGEUuAeSeAvJ4rtdN1L7dpcGoTSIJZHCuq/dHOMj271z2ozaLc3cltqkhjnkhaRwCRvUDkccE47H1roNLNne2sMdo9u0KRqyvGQFA6YGPwp1HFxStqTZ3uy7YWvhXRLm6leSG2mvCC8Up3YOcnaO2T2qaC0s74SHRJ7d7VG2uyEYz6e/wBa8/8AGFmjaYdU1BWnhQkJIpwY3Jxz6j2rA8KzzjVI9N05y0Dp5sjjj5jwB+tCo8yupa/gDoys6jl2SPQtdeC6UWdvbi6jEu53J+V5OwFWdMWHRrhtQv8AR4EJ/cm5twPMQdO3anCCf+yZYIof+PckZOF8s+vvxWbpOszR3ltG6tPEhJMUnT6+/NJJuLSIcbqx0OtaZp2p2v2uxkjeJhtK+vtWIdNOnoDHZF7dYiBgfKmepPvirF672F2ZWRksLx8bVGPLkHQ/zzXX6fb+bAWeUvEYdpj6jvmocnTjvdHPKrKk0t0ed3OxSJijR27Y27+T+nvXLAS65awXM87RqHlRRH8x2lu/o3FdbrlpPaX6Wunz7JlcY3DdhTyFx9D+FU77SbnQLZPtKWySTu5ViflJPPzAdWraNnbzO32qSuZGm6Vquo6i1to1kDGnyy54Re4O/pn25610UOi3mmIYNUiW3V42+dG3IxzuA9z2rW+GutWdtZ3VhPshdHEglPyq4IA5z0PHStLxHrdnezx2dtNHKYm3TegGOKzlOaqcttDndScp2S0OdutHOr+Er2S6mWWKUbbi3Y4HljGRnrn0qJ10rRbPS4Jo00zTlBEUa5dyp55rD0vxJI+t6jorZNtLMrEgccEHAP07VL45W2try0urRpbhixjMZPzKTzn2xjqPWtuVxfLN6bjTcm2tzs9MtvD+qxvJZ3TOqEBi+V5IzRXJeFdXi0q2mihljE7vvkj252D+EZ/OispQnf3XoHs5HsTGopWwmeMe9PesXxLeNb6bJsIEknyKfT1P4CvkZOyuzGjTdSaiup4X8cvFwgtrk25ZpHfy0I6bVPX8/wCVfLtxcLLI5nbzFkJyerD616J8ZNYW9182drIwggXYozwxBOTXl+zfeICNuTg4P9fWt8JT93mZ7WMqeyUacF5E728cTI6TEA9d3p6fSobmAfZ1ljJbJ52jAxUUiSK0qRl2VThuKXfP5asXPz/Iq+ortSejueXKcGpQcLFhXnmtY4kG9MfMzDgU2GPySjSPKrE4UY6inWobyUTYQok/eENU9zqCzyRrJGFZcIGYYwB3qHe9ktDpioOKqVJe9ZWvf+v+CbFtaSXG5obaWeNIy7YX7qjqx9B71JbiH7ZGzRrBC5GGEZO3j071pa1r9udK07SLFUE1qJBNd2rsBcq+0gNkDpgjms+AKBGRJLsB4Bbn8K4G5WvJWPqaXJKVqbTt6f1+JoQM2n6t9r06BLq1hIf/AEiPcB0GWHbk16zrXxB1Tw5p8Wn3cCaferEp8ry8ltwyGXnAX35rxiKeWSWQvCNsfTcxG/646jNV9Sumubkm7uJbi4kPzSSt0x0wTWTpe0av0LqSjGN7aX0v93+f5n0P4P8AGnjOz0+41DVPsV5Yo+Askwjcj1X1rpLD4weHvETf2bHLLbXUymMJIn8R9DXzn4AkmTxBDNHPEtouUuGuRvi2kHIPYE4496qeJrt9O8Qvd6JHFYGBhJEI2LtGR0G7ue/pWao+84JnNVoUZR9u4bdv6/Q3PiPr/iaHULvQ9e1KeexhkwiMSEkA+6feuJtrq4Rzv8sRdAV5x9ab4g1q9164F1rF3dXF2xDtvH+QBUUls0hwYmOBuHOAa7YUY04KLRzrEznNypdO3n0dkSeWZMo3nPBu5KdqVtM0/aXt2MhI4XOCKrxz3BYxxmNIRw/zdKjlM28eW+YyMHtV8sr6OxDq0XG8qfN6rVenl8i3HFNbJ5VvCoywznnNbOneFNf8QNcS6NpM10sA/fbYyfL/APr+1fQvwY8FeHdL8JafrzTQalqMqZlyRIIwRym09CPWuzsLnT9N8Ca7q3g3yVSVZZYRxgzKpH8x0rkliJJ3S+Y51IKPsop7pJbJO+23421PjB1lgbymZWKnDhhjHqKV41yXjYR7uygcUl9Je6lfz3N24lluHMshwBucnJJxVBzDLcpCoAlXn0XPoa6oxuE63Jo49bK7/Iux2j7Ge4McrE/KPatXwvd2Vjq9o+s2u/T0mDSxxnllrPhkmIVZmRWUfdA4xUjwxMpnmAdPRe1Zzd9JfgdlKko2nR0fW/433Z9G+CfD3hO/8c6Br+gJd2oF2GiXrE52tx/sn2r2H4nmA2Ngl0mYnlYM2SoQbCc5HI9K+WvgPc37fEjQrbTnlSwNz5k8f8JAU819X/EDQ7bW7Ky+1Xktq1tMZIzGNxdihXG3+LrXZll4XvrqeLnNo4qm/L799e7MvQ9bs9SxZ6RH50tuULyzZ43Lkc8ZHHSmpDcaRe3FqiRXCyRlpIFH34+cqPcZ6DtXKxWVzpqQWU81w/kiMvO2FaRgT8zemOwrupJGMKyQM5uLJy3nSDcZD6E+mCRXtSXL8zz5Rs9NmctdeCHm023utMWFoWcSfZ5GZ4wDnhFz1zjrXGR6O8mrrJPeMdRtHxLHFI22IEZ8s+w4OK7PSvGenah441rw9E02n3MB3iNmO2TI++p/hyCDj8qz5fD+rL4jE9zdg2/lOZZVUBQQ5KqQPvFhg568GrlzJpVC8PU0dmGit/aGtW8d3fz3KWn74R8hNx4JGPoQB2xXfahoazMbvR3zIq/NEW4PHQehryTRdSv7GWe9e3VdRcHdNMSNsOflBT+Enr07ivTPAfiMXVldR3VsILqF/wB5tb5SD0I9PpU1ITUedGdeVpe49ilqeg3eu6XG1xhJINzJIZvmjPTb7DH1rk49Wj0CY6bpFpJc6mVPnSDLljnOM4wFHoK9J097iSxkhuYIpbSSRpI/MfaQnUEjrjPI71GkUekXM00wjljnUHekYQIT2HbHSnCra8ZK67GTk7tHnfiLwhP4o0a3j8STSxIjCVIYGaMBvc557f0rq7Uy2Fr5KTRyRTqpaMjnI4AB9wKta/ONkazMrBkyxHVec8isy8ufIgSUrsReSwG0c9yO2KpzlOKT2NacV8TWrON8TaY97Obi8hL6lFmG3ZZiI2VsEKR0B561q+D/AAneW08Fzd3zpMYSrwRH90FAC5PqQB+tU9V1y1ikt78MWgjlXgL1boTjGeld5oqXN86tZxsYpodzGfoAe31qZpR946JVJRhboXNN02KzuxaXOye0nXLQyLuUEnjg1yWoaJ/YvjO5mtIPJErKYAgwgHYD8f5V0uqJcW1xA8t2pkgYMyYIXA5zn9K0fECrNoT3zkF22SQ8fdIIP8qmM3F3vvocMpNST3ucr4jOradKZ7kTZn+6iOP3jcZX8hnnrjFZkl6l1qCsiwq0i7gqj5/l4bPp1HAra8QXl7qqWpYYjUghIlyN3oc9KyrbSpUmF78hjUbYo2A/cnB3e+SfWtYaR13Oinf7W5Zu7mSRYtzFokcOw65IrudS1dLXQvtdntMkoG0e5rj7KLzSRb+UxSPfukOQR6UsM6SaTFbebIxboFXJAzmonBSt5E1Kam0TQq0TLdyup1AsZAWGQSOoJq/Oi+LZI7eZ1heEb3j24ZXHcHv+dZVzcI8EkhVt0QL46s2B0xXnlr4sv9N8RpewSs1rLIcg8krgYUfrxSlprs+hp7B1Ph3R6bqnh2LRtHe5lYsC+Zl67st1461yOm3cFqDcHZ5ZcqZFP3s9cj1z254q9retajr0i/Z5lE1sdpijyVVjz8/OMD9Khg0j7PqFteXgaGKJw8jIB5UhYAEgA4xgD6VrHmS9/cindRtPcrS+H/L1CLUbYFC4LSgjvjg49MCt/VtupaLDHCY21VmBjCJuwO4I+ldTcWsPn21nDbXLx3C8THHloMcHP9K5S3hk0y9uLSSErKjc89iO3saSqe016oiDTehxl3JI215YAxJbEg534OO1FdLfSyeew2W5QfdR1wF9cY9aKvlb1OpV0lY9YfoCOK8q+N+vnQ/D8lwMbyPLiB/vHqa9UlI5Jr5k/ap1I7tLs1l6b5HTPfgCvjJK9kZ5ZH97zPofN2t3c19PJcT5ZmOS/YZNUFbyXDeYhEZ+UDvV2ZDNEyKm3vjOM1VshGzOZACoGApP616cLKPoGIjKVZO+r6+gluwImkd283G7ZjhvrT1lMlrvCKZEb5ccY/Ci4nMap5YjSUjB288dqRiiwW81suJtxBHXmnvrYlPlvFS2WvndrXXqvkTfY1uoEmX92WzuHXJodFijWB7qFgwBOBnbjt9altbgRbpL2DLrypOQvPY4qPdaXN2ry5LN1AXCms7yvrsjqcKXKnCym9HdteTuvP5mjcSQrAjsCrum1SpAAx03D0p1hc4AhBAlb5lJHAPtQ0JNvIHEbQAAqx6023lkiUGExsnXc3J/CueycbHspzp1lNuyt218/wDhzXhuNIcRedFf25SB/METBxLNztIBA2r0yOe9Yl/ZNKE85RHLwSc/dB56U+2numZmiYyyAkmIDgA96uq1qIzJKQ8pGMLjG73/AAqFek7ovlhiqdp7eei/XX0tYXRL2SRH0dLuS1t7h1Ew6IwHRj9KhaQLG8a/P5f3uxwKLZEFqZfMjSRXx5YOWHfP0qvPMzF1eIM5Gdyjr7Zp2vLQUZunSTk9X+Xb1+RU86Xcbh3WOAkEL1Nd1qPjeTWvDdvY2+nW0IhCr5iKC7EDBxxwOnFcJMT9kzJEsCSPtPGcD1xVrR7dIZIm+ZVZuZHJAUepxV1qcJR5pLVbHLg61WFbki9Grt9bvqu33Ic67XcbxkjlHHf60kcZmiRnG0r0VDxUlzeR2ryodt7AzHDhSQffNZ6ywhWntZGhVDyvVTn2pxUmrjq1KUJ2vfe6vr3v2f3r0O/8F+N9R8OabqGk2f7u31CMoZNu5oWPG4D6VTsLa00azuEOtX9xdSx/uUsiUiRm4bzN2O3oK5GwO+6M0MjqoPLtwp/OtuS5jnPkXRRVYZVlPNYVIOLsuu524NUq8faT0aej6P5r03t6FaZJoJRskiMS+vX6VVuYLea+U7GEjEEkdMe1advaabdnEl35QTgFwTurotR0vRJ9Htf7EvWfUol2vH5ZJlOeq+nFT7ZQdtb+h0Twjqp3s43ulfm+7scxcbVMSCVBEflJYZNRW0xgkaNgSjHCEr1rqdR8A69baFb63e6fI1mefMAHA9SB0FUdXltb3V559MszaW8irtUgYRtoDYHpnJpc8bW3LjTnOpzwdvx6ar+vvPRv2c7mdPiNZRzxIYyGUMOAG2nH49a+mPHGuWeiT6O1+fLSeZ4lmP3YjsPJr5g+AGqxWPxD0vT7qRmE8xKHAxvKEDNfUfj20sruwtRqFuJ40m3gMMhSFPNejlSXM+ZaX/Q+bz9N4uCvrb9WY/j426aTbyWsvmtK4jkmQCQ465NL4KuiumtaSlFs5BxJL8rMMYJ57dhXA33jewuNOmv9Dh8uKPKn7TkNI5OFZF6FfUnpxXMaj4nZtKij1G/nF/Ewzb22UaXP3dzAYUeuK9fngqfK2c0MDOS5f+HPZdM8L6LqOrRao8MA1i0ia0SderpklT/tDH8qkvjMYUZ+FVcBsjkjrkda5/R/E+m69daWLO8ibUxGJzBnHGeAGIG4jGSPSt69e7TTmkit/tN0hZxbEgBnJJ2qffsfSqu27t3OZQcJO55p8R720E1zFYvuvViT7Us/yRbeqYb+InHQEY4p2j3Ig0WWZ5mt3mK5dnw2NucAfwgZIB71T8SaTq8lzC2s20cNrdZu75XlBFsyniNUXq2PzzV97KO80qSKCLeHbKruBZiMDA7A5rSnOck03odcoU1FNbnX2HjHT7Tw6kerX0U+tIFDxSR+W4JyQhPPzKuM59vWnS+LdHvPD3264uhbwPsikSRmWJc914+Zgew9a8p0jwbr+p3F5d+VBcSu7S3FvNMSAWOFKucDOM9DngVrzaLdQxWNh4n2W5Cfa/su/McShgqB2yQWOO3as4Wav1OedGEZcqZ6FcQEW4uFXf8AOG8xuhH9T0pk1p/aySRMrsJExJubAYd+frXF6DqJvPEC3dx9puLWIG1tCu47lLk7zj5duT9RgV3q+dbSskgKqASVVt3B7e/riruXZx33PM9W0CGya8jub92nlaR42MeTATwMDOOB616J4Q1dNKs1EMrXkDIAJC5PIGDx2z6VyniLRtQfXWn0+FryKf5XKg5UkYxg8g1oeHdFksQLTVIjbtGDIyZ+Xbgde3NbSp0+S9yZVHU92ex6C93v8P3l9exKslwhCjBzsPC/0NcjpOuT3kE+lamIv9EcRxMqYwgGOvftU8tzeXWlLHFKxsVGwB+MgdMd+K5u61e1h1Jh9p8qG3i3ys3Eak9z3J+vvWUIJJ3JhSSTujsb6Ro7R5IAqlYsqRxtTu231965+yupp2CTqVD9Iycbhj73t1zW5FqTTxwPIsZSSMBnB+8p5PPqeOlUtc1nTNEs5Ly8jNrbgBmlRd0gJ4CKPU8demacL/DbUV+XV9C1FYgqtpESrKoJwdxZegA9/wDCthZLHRJcqyJIRgozbmbHJ69M1z3gnWodXmkudPRrdPuZnfBIHOcn61PNpc+oPcaluyhba/mHAKjgUpRtLlnoK/Or9B3jW907VLDzYlKjaAXU7C2T93juK4U2MUcKrKg2o2+NiPu4Gfx6Vt6lia1W0ViBG27jgnn19Pas64ae4lZIlaQr+72gYVWI5zjnoa1hBRRrT9xcqOZ0KQWni2W683daXEEnnxs52XMpH3dnc9gD0r0XQfG+ivOLRhK3nxIoSaLCITxtPYY9K8417SH0t5J3tZZbS2VPICyFWd3baMnpkHJx1xzUVpd+Rax3GoqTawQi4/d4MjIrDGT9f5VMYwbcZPzLrQdRJxXkejarZtcK1nb6vLaxwNutTNu2A9QDzxzxntWo91c6hdW8N7ZyRXSwGM3seZA+0Zwexye+a870fXpdS1iSdGZ45FPmxOSFJHUgH06D1/CvQNG1Z9N8uTTZJHgZB5ttMcKSf7o7GpvzK8dSalOUFZrUtyWOorHF5+mqw2/IQm5se/p9KK3ZtS1ZtklnArLIoZlyDtP40VCnPy+85Ly62Ni5b92x9u9fHH7QjS3fi67m3o6q4giQP8y4Genoa+wNUfy7Z246V8R/GS4VvHeozoFcycrvPAJHUYr5VXc0ejlqShOT9Dzq7Z4FKyEyKchhjBX8aypE2t8uGz0AOcVrXKyiHavlsMZPzdfX61UdFQRzxERSNyqV6NOVkYY2m5y8l/Ttff7xEcfZ1eSGMoBtJX7wpYIdtsJoHZpgckL0Ue9WraNmQtdBQjksAB3PrTZoruEbIoVCNy3l9xS59bItYdqKqSTat21T76fqVzIzOTGpmhJBIb19/SrVncM+97oLHboNu1VxUiw28jm1w0IADk+vtVj7MkaGN4tyMcj0NZynG1rHXQw1ZS51LRfdfs+trk12i3Nh/ozDymGApNUoY3lMUTwhWjO3zFPH/wBeup8IWRnnnhubF2VomSFgDtR8fKxx71W1TQdU0uaOG/06ZCiiUyKuVAPQ5HFcsayi3A9erhPaKNZrfRq3Z/evI5yyaWCa6SJ1DAn+Hk1JNcQ7bcXcG1WbLEDHNWriF5ZVMLqI1OXI6n2qo7W8v2tpohvi4BY963TUnc4JQnRj7NPTW19n18/Tpcke8Rp2METRogzmQdqv2dl/aFzBaWqSXE10wAjg6j2GazFnebTC4gJlY4DKK0LOe8sZY7y2le1uEAKvG21lPtjpUzVttDajUdTV+8mr7Wtf8Ni2PDWsfbm06CxneeANI6bN7AA4OPX0q3N4R8QpE7vpOoJCynkwk161+z1caRJqtwklxLd3skHnSh8qUIblQSfm65r6GvUgGmXEqTxwosbNulwFj46nPauWVaafoKtXpUJKKi2n56drbHwBPbtaW8ULb4yOCcY/A1TktILeMMLd5WPQbq9E1H4irqfgq+0XXtJtL6UTFoNSQeW454JwOf04rgLOXzJAyM24DKBuwrrpynZuX/DmNVUZyUUummza6bPT/gk1laTT2he3jYKDloyOBUcsmy9RY0CMFxlhnJq7p+qyWd8JILhluFHG08fiOlWr++ttRkjmaGM3CHBSJcAn1PvUOUlLVaHVCjSnSSpztJW+du1tn5IzpTEpxJbyKT1I5Br1b9nBtNg+IVq96Fl86J44gwz5b44J7cjiue0HwT4g8QaVJrC2iw6TC4R7mRgFHODgdTjPavpz4VfDaz8IWnnSrDd3MwDeeU+Yew9qwnU5vcjv+AsXKlRpylKW90tLO/6b9TurmytjayW/2dGtnUgxDG3nt9K+R/G/w68S6PcPdTxKLN5SsZjcHYpPAP4V9d6w8UWl3LTOIoxGxL5xjivnD4m3evXPwq0s68lxG5uSA/8AE6YO0uKxr+7NW3McinU1191vXVp7N6a/ecd8J7JYfiZ4eIK5j1CNWbOcnn/CvrXx8rNaWYjP7wzEKP7x2nivj/4OywL8SfDSpI2838WVbvzX2F47cRW9jKWRNkzHe38PyNyPevYyxSTd/wCtDHPZReKpONtunzPLNU0O3tLSyguLE3btN5UIKkKpb+92C/1FZMGh/Ky38jWKNuBmlQK6yE7cDseMfhivTdG1K3u9MmiVBK8K7g7g5Xnhvz71V8QeFbe+hllgnurZpgq/aTHyvrsDccjPPvXsSS2kjhhiWnZv5nNWNlp1lfadNBp08zW7lVnWIu0TYwCV64PPNdfoo16KKCfU4VinlBjHlt94c9PQkYrM0nwpLa69da5CL1jLGsO6WQFfLHcDsTgfSn+JfEj2cUD30pKJOI4mHykH+8T+FUo8z5Y2Mpz5tfvuaGp6WmoT2i3kciraZYQIQGlduhY98YqpBo2k28kcFpYw2tzC7YjQk7QevJOOlWLXWZL1/NVY5mcb8rxg46n/AD3rREMMifa40c3gkX742opxzn1//VU2cdyeZpD9OurWDZZXrSeYpKpsUlZU7Dj+L3rn/GGlW/iK1vfKgNjIYo0aRh85hVs8e/8APitxNU07Tb5AxM945wsoHygt2GO/9K5bxJqZtJrT7NfRWr3jMJIGYBpEA/g/3Tg0uXqyaWs7xMzRIho+zTbhrcQtcM5mEu11PykK6D7pJ5Ppmui0zxHYHxDFJOy+VuZUYpwh6dfSvPBp99JY6hNKxmaSNBHHI26b5TkgFsgeue/FP8HLda94hsba5jkt4495niWLbGEzwCc5JzgfrWseVe7M6KtJyjzL5nrmt2z3U66hYO8ZDqmQME+5PtXEw+I5tY1W8trw5WMtEr5++VODx+Feha4wttIFvHJypIXaPqD/ADrHvdMgSMrb2MC6jLCEuDFjcUUfe/OlSkkveXocak1a236GHd3N3HpjW8U62+CB5qYzjPI/LPPbNcjJbpAHQWS3dzeOzlH+XfzzuPoBmu4vplvbe3tvKkEsIG8beSDwPz4rFukSwuriFkT7YhAkbfnaOoX0rWKv01OpTSZd0y0t4rV0uLottxtVuD/wH2H41aa1W+ga3nFvcLcMY1iZAxcd/pxiuf1PVYLOKNIZVa9mIUJtyIuepJ4xjmol1S80ybTPJYSXbXHl+a4yFHOW6HPH0pWe9xSXMtDuk8LQ6fY77qMW8KqFHkvyh9T61RLQ2t0YYLqaS0ZSzLuOSOxP/wBatnUtYuNT0CEw22+KU+XMQwyW9Bg9OM+1U9csXksbe4M4t2QJgJjkjg5ArKMpP4zGm2l7xz0drunk27WYYUMw+Uk/0re8PadbNbzeduinjyUZGyGOP15rJ+2Q2jRzSOQkbDgAkHmuis7aRrYX97KtppwXcCuAducgHPcmrqSdtS6mi3MYWkWpw3NrcW63f2fkoy5T73D474ri/iFpUf2JYy62mniRYiFwolUnkYPpgcV6ZDdaDdFH0S9SDUBxt5LMD1DD0965zxDop1Z4YZreC7kt5VJxJnHq/vx2qPiTWxrQrOM7vSx5p4KlZtPuLu+3W7yZIR12tIThQ+D/AAnIA9662Fvt4htbeRWlKgEg8ZGCVPHHAz1zxWpaaLbrdO9yv2m4kYl85+Zs8DHoB2/KqLusEyRW8Qt42Z1EcaHDHqST69a1oxaXKi69ZN8zRv3lzcxMPJV3U5GFHAx7+9FOgnmuLSCdVm3uvzYzjjgdO+KKLWOds7HxKQNNnB4yhH6V8g6joEHiK/8AEt5P5P8AoyiOB3ufLCMB1xg7uK+svGL+XpzEsV4OSPpXyLrl1B/wr5o/KtZLiW9kbzNoWZBnjnqc18W2+fQ9XK6adB8yvqeWSWblIljlXeSwUEYyD1IqCaFIWjgkBlcHkL1+laU9uqNDO5DLu2gqRwa0b1dCj0W1+yJqY8RPMzTO237OYe23vu6V6Kq7dTCpg0ruyT089PTuznp9gMSW4lDKd5Vu3tU0dwkkyhXKlScD1OKRY57/AOeTEcMb4JH3hQsZF8Zbd4WVuArH71U7Ws9zOKmpc8F7ra6W0XVK/wDw/wCBbjtBLGskkYkkC4Y56GrmlSG7ura23ZLSBMIucZP86eb2KK3KzbImPBji5Y1reFdJmsVGv286w21vIJG8zqBnqB3Nck52i3P5HvU6CjUiqDT/AJuj+f8AwfuPs3w/ommaRotlbWVsnkxRA8jljjqa+d0m8TaDq/iNdcMWm6TqSTKsFyN67DnaIx7ZrN8WfGfWtctorPQy9haRpzMsn72THcnt+FeaTa3rOr3KPq81xeMq8yTyFyF9BmuVYeck7pL8zDCz9hU5qrcuZ+bWnd/O4SIls3mAboCcjnrWVqAgTa32dvKckkqe9XnSU28jRKZVJ+VA2AB9Kox5tIT5jhnfgxnnFd9JW1vqZY2XMuXltHe9k7ffun2RPYiOFY5bd2KsDlPerMhM0ziNDEjgAFjnJptq32S3jWKM3Cuc/KvSrFsJyhdXjjQEkCT72aib1cjpw9P3I0vm0ltp37ejNeaxOiGwtLL7XHq+T9qdJRsIbBQIV5PB5z3r6ytrWwtPhck/iAPexfY/MnW5O/LbemPrXxhZfaprpp2vPm4ICNjvxXf/AGzx9rfhG7CzX1z4ctMrO5AYD19yB+lc1aGurQTputTi4Jxjdf15feefXc/2nzGECruY7VAwiZPYVHaxRqf3siZIwNgrdv8AxH9p8F2/h5bCwj+z3Bla8WIiZh6E/j+grBsrbdPvtmHkLwz45P4V1Rdou+hg7zrRsuZ/106279C1HFCjrE0ah26MwxTbu2htVCwyxhid2R6+9TXEslgh2os7OflD9RmnSJINPjnu4IHWXcFjQ/MMeo7dahN3Tvod04U7Onb3l5PReq7liw1XVrfTxYS61OmnFxKbdJDsJz129DX078OPi3/b09hodtp1zc3MceJJ9yqGUcBsZr5g0V7OC2Z7+yhnXYyxwyOyEMRwQR6V2Pwo16LRfHmnahMEsLLeUYliQikY5J7VhWWra0+4iWGhVo8so30uvibvb8D7JvVjFqDcBfL6sH6Cvmb4yeOf+EvurfRdHgdrSBjIZBwZSAeg9AAa6H4z/FyDcuj+FrqK4Lpma6jO5V3DGB7968IngurHEi3kbgoGyhyQCOQazkuZ6bdPMzybAeyj7eom3+Xr/X4nU/COG3uPiN4YmNyPPi1CICNkxnnsa+xPG9mbzS40ynyybtrZ+c4IwPfmvj34RLbp8Q/DbqheZ9QhIbd8qjPIxjr05zX1t8Rku5LPTBZ3HkKLsGUrw7AK2Arfw8459M17GWN82nc8/P4NYqk9Ltf1+Bz2iT6fbn7D5ElsGUPdPu3uVz8q5/hXI/Gulv8AXI5LTLxlLcOBv65H+ea4G28T6XHDqsr3P9oT28EjGZV/d4Uk+UCOrD1PrxUmiXY1zwta6mv7mF/3pUMcbcHk5+ley0pyuzzHh0tWjqLrxSqI9rArC0IIa7kZUVB6gHtWVq3h631KyK3brdWzRh2kQcJxwc9DxWdYyWupofs8iXUyvuWGM5DkA/mPWr2iabLeavY6peS/aLuGBoQgBjhKN1/d9MjoDTt7N+7oLlik+U57wVquiabc3WmaRNqP9oRybJzc7QrJjqv+enNej2S3Gs28Tx7YYHJGQuc4yPwrz46BbprA1SGcRzSsQ6EE8g9RxjkYya7/AMP6wlnZC0NufMjzk7uG57fnVYjX3obkSg4Q93VmZZeF7Oxl1GWeMf2gWEiv5hIHGBtHQHHt3rlPHnhi7sLVry1aOeUI6QxzyDhn5IUHpkDHHtxXoGoz/aUicqqSyb8sh6YxjJrlviLbP/wj5E8MLyRH5N8jJtJHykEdj3zWE3KS1ZdBtTXmeRSvLLeymydTJCwMoRT8gABKhj2wMZHPT1rvfA2ryXVwIoJ0aCF2MjMjCRmb5gBnkgDjNcboE/8AYkKiS+jla4jKtvBaSI/xEZ6rk4Bx0WtfRrj+z9Xs5LGQrBIskZO3buUAAE9zjt9aVGLilruenWSmmu23n3PYrry7i2hlgid58ZZumGzyPTIrUiSHylvZGw6EpI6rnK9cGuL0iN5BK7XbW73BaRYg252yMfKD0HTOK0tNuZo7C8spWMUk0e1SwzjI4NXKHS549Sm2tOhkfb7Cy1xjqU2LPLIG8wrnHKkkdsVjRRwatcXU+j3lvcojMrXG47lz1yPQccnima1oT+VYRX2140do5lU5+Qjg5+tReDNEh0K21NEmlu7a8jMKnByMZ4b1Pb8q7LRUeZPUlOTkr7GZfWyz7Ftl+1PGf30iqArtjHJ78cegpdlndtK0c3zLGYDtkyik8EY6E1gajrsOl3BsLUWskc1wIBN5n3XK5w/oByB7iqujeRY6jmaKOa4mMcsiHIDFDnBwcduopQ99tLXudluRXenY9L0C0k0PQLjzWRIhOXEETMSUIB3HtuPPSvQdTg0iy0xVupo42nTbCX6k4z8q/lXl2pXuv3y20mnIsFlKVcttXgDtz6egPNdPd6VP4hvrTVGtrgfZEKEIigMSOWUZyayqU7Wbdjml78rydkaWkWtktuyyGOXcxBDYwB/+uqHim3hvvDd5pslwYImZTGRls4OQMd6VpLWO2jtEiukMTEMzffbPPOKxPE+v2nh6S0u7uP7VbtIIjbD/AJZgjOWz2qdndmkU+ZNb9BfDPh210pJ3e9aKQx8qDuaQcntjHvj1q4s1mCUgbacAnB5Gccisr+1hdiRlMJtfmUPGc4B6c+vP6VDYWEVvOlzcMULr8ojIO444z6CtuTq2XKpKcuaWtzp4JHG0lBJboAu4/KSOw/D1rWbwtZ3kT3c84S7c71CuNo44H4ise3eacworouwAK7cAZ/nxT7XSJrm+eOFSiu5ZCc446fnjNYu62diKiv1sNl025vWMUcDP9nO0qBjaT/8AqoqS4bUNHuXjS4ljmfmQg7t3Jwf50U/f+y1YG5PaxP8AFC5S28PXTO4QPG0YY9iQcV8reMYTD4Z0u1voooLuMNsdYCGmjbrlj6duK+j/AI8z+V4OnG4IxdCD+PWvnH4pabFay2Mh1Ge4uJLeNhLIzOHBGSBnpgnoOK+OXxnt5Zph1oebSyCNpI4yHXpGrgAkVbktjdaYkt78jJ93Ye3pVC+gOQ8iMxQ5+UdR3p9kIL95vPv/ALBFDEzIGUtuYDheOmfWu/lulJMx9v7OcqdSN7qyV7ed3ft6kcifZ4Xm8/y45DkRr1BqgJoFCFFbeM5Y9c1KYM2zvOkrOBw/bPYVFsnKiOQSKC4baFwD2zXRBLqzycROba5I209ev4eiNK1aMFHtyqlRl3f7xp8+szXFu1usnlwsRtBGc4z/AI1TUNZz3B8tnTHOT0+tOjt1kuYnhGzAzzwKycIt8zO6Neuo+ypuzbs0r+mn9eppaC9veh4J4QH24Zhxilh0+W2lZJJpEh3fKvXP41nQwH7SfJdzMpzJt5BPtirqajKqefcbwS+1V7VlOMuZ8j0fQ78NWpOnFYiPvRv7y6rre3b13J9Ss3EMGydDLnjsT7VYtdD1OTQ77Vv7ODWtqypcTZxjccAfjVFvtlzAzME3q26NhXU+DtH1zxWbzTdOlizBF9pljlm2K6p6g8E88VlKUoR1a03OiUaVSbmk43Wl9u3XqcnbXEZhMSObcLwcnkU+ZxZYWVNzk5XHPFWtQRhEsr2i+cxyhJxRblroJDf3EUcbkLu258v3OOcVXMn73QHSlC9O/vJaO2nzTsl8rj00i9WzW/jtTDbS8pL2POD+tdVd+NNXtPCkegaAsthaSQ+XdkSbjdOepGRlfTg81xV3NKUS2cyNDHxGdxx16itTwtrj6VrVjfW7IZbF94S4XcpI7EVnODa5mr2Ki6TvRV03521+63nczobVizjyXluCPmkJ4GKrhFgQiA3EjsOGH3QTXZeOvFsfi7VUuo7GHSUfHmRW4ys0gz85PrzisjQNPvtc1iHSLENJdzN5cMMfH4n2xzTjOVryVg9jTaTWnnp69197u2UIrO5VEeWMuy8lnPeq7R3yTNcz7m3HCKh4Fej+JvhrqfhbRLu71DUtPlNoyebbLP8Avfm6YHeuA1KOW6VEtDISG3YLYAHpShU5n0sXOnTlR5qTk2raJ3u/u1GhLVoVa+jn3t0LHpV3TJ5FmSSABjC25PlDfmDwfxrPk+3LMEvEIiBAwvNWLo+VE0cZdiw+gpyV9L7/AHGlGfLeXLZLe6tJ+vf7i7BCTNGxSP8AeNjanJLE0raXftq72Sxz/ank8v7OEO/Ofu49aoI0k8KQqYkMeCWBxj/GtzwxrV1pmu2+oQXSrJCfNE0ke75hn8+aykpRu0dSqQqJJLT9ba/1Y6b4eQTWvxa8NWMyyxCz1CKMrJCEZTu5Vvx9TX1146iS4sba3YPvmkZEYKSEOxvmJHTHNfKHwmvdS1n4qaTMVN3Nc6gt3cvjhQCSW9gMmvrLxrqkmmWlmY4/M86fyyu3P8JI/UCvRyzmvY+bztf7TStvZnMW3hCDTNMmlhZpVuj5k5JC7sjBIXAx/Wud8Q6W9v4Sgs9PE62iTI5ETFiIlBAyOc8nNdldC5m0bNxew/NhvJVsH1w3pWzolxpkukKyooKrtlDrkg45/wDrV7UZunaSVzy6lWXK+bXU8NuLz7PcpJYxSIY2EmYflEeD8x9wR/XiuovfE1/penCS5Rp7ZY8TtbqfOlJPAQHoMck1r+L5rCy0K5uZZIYogwUzS5yASOBwST0rzzV/Ei3NpJBtV7gssKRxsRI82N6MmOijHOe/FbTqKauzWlS5ul9T1Xw9rVjrWn6bdrYyQ7XCtDcqMw8dMd/XJrtG02J33SEsP7u0BemPSvnc+LNR0KexhaBLO7WON7qKQFjcFh95mP3STnIHNe76F4osNVsIrhJAjkYkjPVGHUf/AF65qsJcqnHY48TCcJWjcp3VqbabyLnBXP7ll6sD2A/n+FQ+I7WHU9JSOWRg80fludmQPw6damv9QXVr6OC02KIWJ81+gNVf7UiGrT6V5jmMbSXGHUHuf/rCkk3a+5cebRvdani/i/wxcaN4jk+0fatVkniEpuiuPLJDBQo6fwjI6Y7VY8GWss9tJLMu+eGYhpOMMw/hC57AjJ717Xqen2/iO1ubGePzLVwI3VXKllUgjPcZIH4V5vZ+GNV0tr+C+jMN3MHkgNkuEESjC5PRWyeB7c06TtLU7I4r2kOWW43w3caVDM814Y5dad2nyHMhVN20KOw9x7131o8OqjZEixEBjIw5Kg8j6/Ss7TdGtItNMF89q0oYSZ2hX3FATux15zyO9dPpNpp9nob2aSlxLuVs/K7Mew7/AEqpySjfqclaprdHOatpr2NxNCJFkjeMSbiNuQOx9/pXHXclz/wlEVrhkiaAtKinG3HOfbnFdcttJDZSWiB5YbbKKTJny8ncSM8tyOlVvB+mF9fvriVUmM0YA+b7qD/E1tTnyxbkOV+XU4/xToMEktleWrLHCkiv5K26GDKKWzITgqWJ2596890m52QhEaCe/ctMbREfzIxvO5QfQjoPWvf/ABbodm58vULKK6sJCP3L/dPQ4OO/HXtXmWqxW3h7xPLBoghvbu53ypbufng+UHZu64ztUDNZwm4yUouyOujKNWHK1ft/X9ep0PhLxhYv4nh0J7KEz2EDecvm7BDJgYVVOd7AfKT2NeuWGqWk1p5wKwjPKEjI9K+XPDlkZvFAuJtOuGvYJDNMY0x9mlIztdj1H+fWuu0yW+i1a3nMhePzR8hbGT7+lONJYiLltY58bh4Rko3O78a3Ntp+pahdXlyLW2SDdJIwJCkjA6Z9RXk+so+u3FuuoRRS2vkFA6SMPtCg5B/H1xmuz8Qz3Ws7rW/uo4DqEjiKUJwyrjEbIev3h+IrHuoLi1kvWutGnNnZuEzA4BuVAC7gmMqSx5UdPatYKKXLNChzwS5NzhfD+pappaXtneAjTLHbJIrJgLGxxjj2OR34r1vRbKDUtLhu4b1LiN0DRt90sOwx24rLGg3GoaveX+qPJZRzILdLWBwy+UoGHbPRiOK7PQ9Ht2s3e0aCCK3O1bccLgc7R+FZwlKCs3odOIqQl71rMfZWrtGI/J23E52wg9FHcn6CuhtIbq2tvPsrhZERV3Lt4cgYKj2rEn1GVJraa2iHl25O3b1YEYx+VXTqU4RLeKePyGiD56tnuPc9c1E02cc1KRqWc1vNbrNqkUX2piVJIAyAeP0NFcncahH58nDTjPDIeKKPYth7HzZiftFBD4JJlPHnoPl+934FfNvjKdtSjWUJNNBFCkTGSVj9ncjt7fpX1D8coUfwxaNIPu3sR6Z7mvF/jVaRJrIaMIbNwgnaICKQ5A4I6Nivk+a0j3sstKgk/M8ZYx2toWWd0JUo21sk56j6Gsq48pomR4wIwR84X5ifStm9trMXc0aTbY4gSHuDjzMHjC44PtVO7tIrPVZbe1ulvYg2BMiny24zkAjPFddNpahiouTUUlbb+kUrSKbzfKDMIByMnkn0rY8P6hZtMRrNg13axbgUico5O0heewzg/hWELORnlKs5ReVcH7tWdNkWIulxlN/8Qb759a0qxUkzmwk5wmoNOKd99V5L0vt/md94l+GGqaJ4J03xHNdobW7IMsCglod33SxPXPf0ri7PQ7y9uVlt7ee4IBKrGhYsB14HavUfD/iPW/GPg6/8PX15E1tEscVqjRgM8gJKgtkAD5Tya4zwj4y1bwPqF1e6LJAbmVDBIroH2DPUflXLTqVbOPVHZUoUlFVJru1r227/AIIxNL0+4uorpoWlVIAZXKDBQZxz+Jp8M8L24iMqs3YkcU6LUr+1kvJwd8F8CJgyghsnOcduefamxobWyClV29RMe3sKuV3v8v1N6HuK0Vsne99unXZ9yKGS6iadYwXGPlOMDP1piT3yurR7o3IIdkOM+1bMeh6hP4Wn1bzoEtbeVY5P367iW6YTOTWdexW8ptPsC3DzFCZ/MACBsn7pHUYx1pxlFt7EVIzSSUpdNL93fzehMEW6t286VTOB98t0HpXRfDjwzpet6yqa/df2bYRRs/2qTKo2O27pXIaTYmR5zcpyT91TzXY614nv9W8M2nhtbu2i0ywO6JDEEmfsNx79ayq3T5Iv/gHTCMq1ONWULN3Xm/PVWvsYV5HZQ3VxIha4McjRwSJnayg8MR6EVWiWeQyTmKN0X73HAFTLciC1FhNIqxMd5YKN5YdOeuKgvVubK0SWOGSCOTo7DIf6URT2NZyjFc8tlq7b38/+DYjtvKkmZkjkdj/q1B+VK0dNvdU0GeLVLaeW3vVz5UgGPY4Petrwjo+g33hzVrq+1O7tNcjiZ7O1jh3LNhSTk/h7Y681y17eXdxBa2l0s8lpFllDZwCeuPrinfnk49PMx5lTpXe/ktNer08/RbHSeJdK8SR6DYeJNagaeDU2LQyvMHc98kZyM1zaTyzOzlhEg5BbgitZ9SspPD7WE32p71ZB9lkEzFIY+dy7enJwaxbNFg/d3MyOrnAyMmlBe67r/hinKamo81111SV+l+vX/hh1zHdCBpIZTOc7s+oqex1QT6f9nukQCNiw3KN2Tjqep6dKihgFs8kUM0ktw/3T2rqNVsH0TwpHpus6M1rqtxMLuK4kixI8ZGMbuwyOlOco6RffTowpxqRnzxdtHdN3X39/vOcsLQajdxwwxO0rsFiiiGSx9AK2/ET3v7rRdSto7I2RKCNIhHLz/fPUmqFjd3Ok3yTWLfZLpcFJScMuR1/Kn3l1PdvJfXU8l7czMWlkkPJPrk9aiTbkmdVOmkmmr73sv6Z6V+zzrn9j+PdOsjbIsV0xt/MH3yW6ZPoMdK+qPGE1tDZW/wBqgWYPLtUM2MHa3P6V8a/DOwubf4leE3vIGhL31vLHkn5lLjB96+pPjXCbjRNOhSz+0yvdMqEuUEf7p8sSOcYyD9a9HLbXbXVnzudU08XT0tp+Cv6GbDq2nQXUCxNEXkUADyyVJbOOeRzitKd7ZUnunnFrtO0tuGwNx/8Arrxw/bo7exuGuzDaW8DFvs7Mu1sYAX2xgY711V9a/wBpTWzW8MkFo22a4R42U3DEYJYE9SPUV79Sk4nElGT0ZuavcltN/ebHZ/ljUqJN+RyQvdevJwOa4jUIE1CKS8uLmbTbIxhCkduqmMKRuBPUknGDnvin3sT2msLbRR3uotK+biXy9/lRY+aMn+BcZGB61F4X0+e5vvtEs10bWN5GjhuFHCschMeg46VimpS5WjpjF0486ZTg0GaC+kOo3S3fh6Ii4eZ8y3Ic/cC9+4OOleyaFo9jCqmJykRUFVb7xyOpHauK1HXbTSPs0NxaSXM0jrmOKP8Ae/M+3OOgOc478V6VCVjFsulzRyM7lcMctFgZIPfFVJ8q5Uzjr1JSs3pcoxwx29xfJan/AEhkMcC4yqkjGWrjNH8Rw+Gr9lW0e8EDNHLLuCkN3KjHQe5r0LTFFpqN1JeSB1cYDEbcnNec/ELTlbVbi4sbVZIrgZWGO48uWSTuTnt9KdOUbuM1dGS5ptwXU63StcTWo7y6MUsc/nmJNvy5xjDA+nIrct2QxLDe3Nw6nJ35yOn/ANevK9LinsrJ1tZZIpphkJO+7yzjBUnv9fetbwnqn2GRNMurj7TaxCVmnkcAg8EKBx0yeMmplTsXKlo+Uf45GsxXNleeGXN3b48uURorOrA+nXkfSul0afW/7JSXWLVLOeVcA8FiMfU4NW9Hhih8SLHEITHMgdg685APH1HXPpmt7WJIILE2yKDxtVFOSPQAUp1dFC3zOZyamo7nK6jPZ2mlMLlzAEXMjEE/Mc46dSTXK+BfEzXsMc0u2z1OPJaBMlXUHsfp1H5VvX/hfxLdXEcU15btpDyATW8q5aQZ45HTHH5Uah4As9CePVNMklLRDEqM3BB4yPz6VcZ0uVxb1ZbnaSV00zS1wsbZLq4lm+y7eGbrk+9clcXFlpEtvdXN5HCdRYW7rHBvO0f6v5iOG3HnsRXYXUC3mhuLyZ2tUTzDg48vH+Fc/wCGfDmoFhNZX9pqmkS54DBgG7HrwRSily3b2KjVUPdlsaum6aY1ljS0TIRmcbdu/nB+p9DS6Z4Strq1uLu5f7K53ANGPujH3ua3f7P1aa2ET/Z4goC7dxwy9wSOa4z4qt4n/wCETlsdC0q4MrfLNPbks/l85C/56UU25y5YySuY1K7ldpl7R4raBRjbJGqkqOCx7Ag/h2rHvfEcR1A2RkWKSWN2jV1Lbio5YHsB71Q8F2ZfwvZQNI0Vw8TRs7jBSQkgkDtzjipNJ0XW5tQktdWmiOmJB9lS5YBZpier9eFxkY9q1koxk7m6jfVnT+Htc066gsYpJLNLidsQTKQwnbGCV7Ef4Vd1O2hmu5GiMcEYURR7c4kI6k46YHFVV0Kysbi0tLK1F08KBI2jT5bdR0wewNaGtWP2K1iZmRpmwqiMEEH+tYXXNp1JvFSXK9zDOi3U8gup7podMs93lJuG/eOgz3yfXtT1tI3d7poztBClCxAGR1z2yf51rJp97eEy3MW/ykwI2O1V46fXis2YmKSVRKHDAlsNkEdxWnO3pcumtXrqMWHBOy2Lx/w4bGPXtRU014ibEXbtVQBuyTj8KKNSncsfFGPf4b3hEdoriJwrjIyG7+1eJfFSZLDVxLd2kMN23+sKR5QIR8rpnqwNfQfjCPzNCugRuwAwA9jXgv7T9xFHbaSrRsJpEzuDZwoxkY9ea+NlG8z0sqrKNNRa7/oeLeJ7K8uL2Brq5gna4XMU5ZAML2cjgH1rAniuba2trvcgSUttVHG444PA6fjTPt5Fystqioiv+7SQByf97sanWOCa3ke4kWBuXRghJZx/BjoAf6V1xi4JKR3TnGreVPf7v6+ZHa+IrnS4r+wswiW+oRLFOHjVsjOeCRx9RWeVjEyQ+SZcjgkYC596TUNv2si4dPu8KBwDjrU0NvPcW5lkkjEEaguuQpYE4G0dT+Fb2ikmtLnmuU5VJQetnpotF1v2/EbcRLZReW05BLdFbI61Z09la5J3KADgqRg1HClsspt3R8gZBbpUsdtJsZZZIwx5RlPOKzk1azO2jTlGalBKy6Lo10b0/I9e+HXwhttY0WPxB4i1xNP0e4ZgqBhlecDczcD6V5n4gjgs7u+s4bmO/tYblo4ph0dASA3HqK2vCOnz+Jbn+xf7Z+y2oIPlTSN5bNkDIXpuqf4jeDX8H+IV09LlL+3MavHLEmMZ4wy84bj+VckZWn771O1U5RvGL0d9Oluve/z+SRxljLYabfRSPBJfwhjujVyoI9MjpSXV2bmRZ7dXt4lJ/d5zkdhXY23gHxGzAJot2sDrvjYJjdxnpV3XPAdppHhKe91HWYV1dShXT84faTz75HU+lafWKXMtbsh4WrGDUWlHsl1Xnvb8DhbJpZYfNVvKLnJPoPeidEuEF0PlZOCyHg/WtLQdA1bWblLDS4Hv2mBKQp1wOuaqhlto5rG/sWjkiYoQeCpB5BFU5Lmbj/SKUfcVOrpp179HpdLq79RujWRv5yIt7TBSQTjHHPGamlv7yRHtLi4LQRD5EYk7T/siug+GGu6boHiyzvtasftmnLuQIFDbCejYPXFeqan4B0Txxe6z4i0G4j02wZPNRpSsaeZgliV/hXNZVKlp+8tC6cowgo3t3fR30tbfqeM+HNN1TX702VqkbHaZMysI1AAySSelZUTSX12RK0iovXaeFxSh72ISzb/mJ8vKNwe341vweNbz/hDofDenWViMSPvvFiHmyBuqlj29/pVNSV3FL/Icq1nGNRu29nu+39fiZVvNJFHdLHb28sfO1j1Hv9a7XVNN8Nr8JdF1NBZpr7XJFwiXO6V05yCv8PbtXnr77WEhGRiWw4Pb2rY0vXbWHRpIZNDtZr/7VHPHfMCTGq/wbejA+/rUzpt+9HuOVZNxg20106f8Mv0Or+HvhXRdY0291TXtWk0a0gBFvLgfvpACSAT1xxwOtYPjfxrrXjG4sl1eeJ1s4jFA0cQUkE8scdzgV0EeiWlr4maz+Ikl1ogv1N3G0G0ogbvsXIGelcV4gj06HW7pNHupLnT0fbBJKmxpFHQkdqmnZyuKolJ3ve3a1vk139b7Fa0SWeSK1SAySOwA4yzntx1z9KsXto9u+2eJ/MjYq6N8u0j1Hat74b+IbHwj4kXWruzNxLAreQPNAxIe5B5xjNafjvx/feL1u5G07TbeGSQOPLQGTA9W71VSUuZaaGlCNrw5dN79dPK34s2/BviNtf8AGfgmDUET7Xp+oQQxSQYWMpvB6DqelfWfiO2SeO0d5LRGhl3r9p+6TtIwD+P5Zr4p+FT2/wDwnvhPYrtI2qQAkcKPnFfXfxQ1CPT9LsJJnt442uQC05O37rcYHOTXoZauW621PCzyKliaSh1X+ZUs4Y5dRnjg0q0kuScia2wUTHox4pmp6Ddx3BvJYG8psBo0k3bRnr/9euck+IH9nPAllaRyxMSkeyXcDjscdePx5rc03xLHqunypqcr2ggBlY7vlwTnr7Z717sqdSPvW0PJ5mpe7t8zm9e0a7lna/spXuFVfLcqMqoH+yOox7ZrMi8Oaxo1n9t0eHUL2Z5jI9sHBMm4g9x8oH8q7a7vDbac2p6K0N1bygxhUIPnHk9M9eoyP61R8MeKb145Hlsr2CNSF23URTdk8hc8Gm+Zw06Gqm09NTiv7O12fU50uLWULaxbxMWDJ5u7dwMdQD1rttAuzo4f7WZJpZFxI3V1J7J6Vb1vTLLXb5p0WVZyuwyRz4ypzyQvB5yeeKfbaVaNMjXhfylACuhyQQMc59fUVKnePLIU2pK5LbRT3UrsJA1uMrvPb2qhc6TFqyG8hji+2WYMcbeZsZQ33sfXFdBPJp1vaxwWSmRkUI6oCPl7knvWReXFgktvNIrW1kh/eyOoA29/nHWpvzEQk1qcHomkanZqsl3ceazyyFo87yuTx83sOvardjb6Pr11FJc28l9FZu6xCRmEYk4znoG7HB46U8S2er3uoW8Gsh2kn/dBofLiSLBB2jP+sweta9zMdM06C30yK4vGR44xB/FMcckscZOOc1bTiuVr7zqU+bVPXy0Nnw5plxdxrBJJLNNGObmdySAfpwT/AIV0s+lWtvBI1pc7J1bJllkyQR29q5Y3d9bROlvPLGgGwAdFP19c9xXM23jCb+1LuBLZ5VVCss8qsGaTdjAB6jk5aocZSe5hKlUm7p6I9Em8QSxsftQKReWTHLGDhyO+enWsnVfGCC2Inkj8kjgDkufTFc1Pr4eFoLx1nAXcsEXzSLjg7V/iPOAtXLvwrBIqvAJJop05QEqygjr19/wq40oRfvkOlFbI3tChi8R6HPaFpVs7uN4pNpwwU8HB9af8I/AR8A6Tf2b373puLkyqTwEQDCjH97HU96n8J6lpujaE1tKBbLaKevJZf6n/APXXSaLrFlrVmtzp8wkjIz7j6j8Kwq1JpShH4WcOIUue7RoUUUVyGBiaz4et9QYyxH7Pcnq6qMP/ALw/rWGPDF4sqecyODxuQk4Pv7V29BOAe9axrSirG0MROCsmcOTc6POImcZXDjdzn3+lXrCV7+8FxdEidfuKiZA4q0YbfXridyCsUB8rcCN24dfw5rPhsL2O7ZLGaREHAlkG3j/PSt+ZPfc6lKMk76SL3iKR49NSJQAmMH5uc+4rAaIXAQW9svCfO5B4NbeoaLDa6bJLJJJPJGPvO3Qe1ZGj6+tzdqkdsyL5Z2FeM4Pp61VP4bxHTmlH3NSO3toogxvIHZicAQt0wO+e9FdFJGnmMWiUg84XgZ7n3oo57j576k2tRebp1xH1yhrwP456Aup2ltq39praBbMuscilhKwH3F9DX0PKuVYeoNcB8QPDUHiHwkliSkTI/wAkzf8ALP1P5V8nO97o6ssrqElGXf8AP/hkfHWjaZCLqCK6eGFZ5ViWaRgVQE4L4HJxWj8SNCsPDuq/2bpWrx6taOiTGaL7qOc/KSDjPf8AGvXZfhDpkVrLrug67Z3MljGS6uQYOFOcsM7eOa8B1PzLW5urUFcCTgI25Tj37j3rSDc53PoPaQdNxi9NVt+d0mZ5sjcSKGy7sQYyR9/nGBXSeMPCWreD76O21i3EcksSywkNuUqeo+oPFcqBLFOZH49lbPPrXoXw/wBN8UeOtVvJlkj1F7aAoX1Bi6ouDgDPf0req5RSlfQ5MO4OfLblbvr+uv8AW3z7T4P+ANC8eaJrE2olItVclEjT5RBxw4Hfmn3/AMAdTttbggtLuGSx2L5l1KhUKT1wM81zeh65qvwtTTdQtJbSe41ESCezkRgybTgbv/rV7F4U+JV14ltNR05wg11YhKsVuhk8zjJC4yBgYGSeprjcmlzJ6HRUjWjVbjZpWvdbP+tTzjx38IrjwDpw1201zzXimQoi25XBJ5Ockcdea4mTx7q1xrMs17Otw07o1zK6Lyq8Dbgcceletaf8S7bxdp2q+FvGckWl+asiC9n48sA4ClQPv14nq+gQWeiQahaG5mRppY/OltykLBT8hVj1JGeKpcsnap8jShKvTj/eW78vLT7/AE9D6M+Kniqw0vw3oer6Jexy36sPsqxShlbK/NvAPIx+teO+MPGX/CZ6FbWOqWNtHqUM2/7XCu13znIPt0/KuB33MUdrdq/kTht0RBx09KlP2ieJpTITKTudieTnnNJYdR96+pth1CK5HHmt33s9bd+u3zOo8HW/iLw9qEuraPBNLHYEh5kQvHjuCRxirnxO8Wab4pj0+TSdAi064hjb7RJxmVjj06455PPNa3wu8djw8s2kahHdXWh3md8NqgaTeRjA56GsxPh5qOt67J/ZOj3ltp80mUe6O0xrnvUqXv3mbTppXSVrbO/R/Lp/wdzi9LuJbGI3UkIVgCIsjjceNw9xVT+07ryZIZLx1hkI3oshw3sRnnnmvWdd+DOs6ZpN5qaNDLaWaH90pPmOoGWfHTjn8BXl8a6cEilWN3/ik3JtAOegPfjvW8KkZXdjldP2iShNaab/AORVjtZop4t7fuW6DOAKuXel3VrewWTKsMs21kVRnfu6VrrDourWWoXV5enTEt4s2kCL5rSydlJ9Pf3rnZJ52uYLowvLsxlietOMpSKqQpUrxjqtHfV6PfbodN468Iap4RW2TVoIDLcx+bGYXBAHfPoRXP6U13pphvJbQTxKed6loyfQ12luLv4geL9OsldYri5jWImY/JGFHIHOTwM4qXX/AAhqmh+Ibrw/azzatZoVWT7GCEEhHCt1AYVkqto8szd0VKqmpe9bp+bv9xc+LVrb3droOu6OEma4s1W5MccgCPn+Itx3wMelcZ4h0G70W7S11m2WO+khWZFjYN8rdDxx616b8Q/E3iW3+HOkeH9cj06Bbhfmlgl3zFI+xUcKemfWvJU1GS+ubeG4vH875YUluCcrHngZ7AUqPNy6dCFJXtU2d92nf8tTPkV4W8sWrzO3rWhbq14FXY8Uy8CNR1P9abq1sYbm7Aut8cMnlrJGciT3BqSxSAJvRWZl53u3StpyvG/UrD0mqzh9ns7bfJX+8634UaPfN8UfC+IpQ0F9FI0ZQjagYbmNfWnxS0htbi0S0zNFH9raR7mFtrwBYZMEeuThce9fI/wj1XVE+KHh14rmSOGbUIYXOf8AWIXAKnPWvtjxO8qWkIhZVBk+YuOMbSea7sDFvSZ87ms4xxVOVJNaPf8AM8V8TeHrzQbOylk/s2OyLhBPPAVd3Zs/Lt6EjgGl0mBHkuLuQmKxlGXtySwTGQRzyVxnPvXomv6jc3dnBbTSQxRMA4lUByD2JzwCPp1rldR0CXXLe4sJAkOlxsrR3KybZnkK5L4Ucjdnr65r2E5RjZ6rt/X6mEKnPaU0k+/z/P0LPhrVNLbw/cvcfYFtRN5cPl87VCjGOOvfj2rF8WazZre2y2moWsenSlV27HeUtjj5vQ9CKbr3ho262q6UqL5abJYC2FfjG8DoCec1wfibTv7NvBDeh5RKglWO1yVDk7cA/wCzgdKudoQU763LoUuerZbf15ncXWqy6Qwntw7xEYaIOQuRwv4f/Xro/BXiye5vpLTU0ibELTLLCMdBypHeuNN/GNOhurt2jsA+xpQvmbh90kjrjP8AWuh0yzsIVgnsrVSJ0EgkB6IRw3ODj2rVqDTi9zCrBuzZ6Lo19bWugtOFjWV2YlCfvc/yrgPF9zcapoq6fLMqkSKsTKmFLZyAcdvftWpbyeadszSx233QQCATXDfEK9u9OitI9PkLx7me48pQ+VXHynPTPt1rBWpNzZeHwyqVOVbsr6RolzFeRy5tGC/PtV8h3AGM45xnFd5DBe3cNpFczATTOV8yP5AWbsD24wOa8s8BahO0r2rxwxxxXEhmkkz5pZyNi57DA6V6bpNx5llNb26HM0yvLK5JLMv3QM9vpWjre2Smb4jDPDvksdBeTPaolq+mGI5GZHGfMPT8cn9a801TS7/T7y/tbFVm1HUC5iimu1YQtyBgHtjBx/hXba9q8v2WIztF56vu80yfMQP4V7V89eM9fgvIr6/N20cl95eLBEG9Spx8z/w4APA65rNtwjf+vxMsOtbP9Xc6Pw7ZpcLc3U8r/wDCS25kaaAkqxQHa7jpyeuBxgV3Hwxnm/tx8TkROpLws/Abjge45rxPwtrqweINLuY4VsksisYu7mUzMinjBHcYJwMYr0bQIb03UsttAZLNZ5HMqKFUqpycHuT0+tbYecZ05QReLpVNJzWtvuPWNQ23F/KSEVCwU7OBW94eZoZLSCARJAxZjtwDjn+teTeErrUtd8ZPdLDLHbEbZU7dMKo9fX2r1hbKz0e2t2vpi16xAVUwcH0HtzyaivDktB7nBUkpRszrqKr21zDNJLDHKsksBCSgH7pIzz+FZ/ijxLo/hbTjfa9fw2dvnCmQ8ufRQOSfpXnqEpS5UtTzG7bmxUF7cLaWks7glY1LYHeuCtPinpWoyRS6UhurFgQ0qnkHsPT8DzXYafrljfoGgk64yrjBGfatZYepT+OJSi2ua2hV8PTxvHGkeEBVmaNeAvPpjk/jTNT1J9NuYoU2knJEZHDAng+oParOsSpbWVxLZzRQ3aoWXdjBPpivN57nVNQs5pLiZ7e6cMI5GAcxemPX1FbU6ftHzdDqppTk5NaHc3sl5fqsUhEEbKd4C5B4964C0jex1G6+xTSGTJXfJljt77fTHpVDSdb1bR7u2sdeljuzcyFIWjVndhkDLcYGM9+a39Xt5bu7Bsoo4NpWNypI4zz9PX6Vukqd4308jppwt0LdjrxhiKlct3VyWxRWBNpF5McR7xGvR4Gwr59+/wD9eipaj2NOSL1uevtz7Vg6xbm4sr6329VbBz6g1vn/APVVKdCs2RzuXH5V8i9UcdCfJK6PiHQrvUbFfEGkrez21k0Ej3ESvjzNp4A9e2RXL+IdQtbu/eWxtxbRSKu5fQgDOB25rvvizpE9p8SJ7VA1zNM2E2KAzFugwO/NeY6vata/aYLllhuEk2eQ6kNnnvjjFa0bTldn1taTpUOaH9f0tCnbsqlo5pA3ORjqRW3oHiHU9Bv/ADtK1ObTxMVWR0GBt+neuXi+RHlmUlh8qnPertlMssLJOrySYzkjoe2K66kNL7nkYbEc1obPpv8AczrfEeta14pvIpbiWTUVtFKo6Q4Crn7xwOM+9angHxPqnw68T3cr2J+3SQ+W0FyuPvYZT6jsa2vgZ4ui0a9v9H1Ftmn6pGyHYo3I+MAbj2Ncb8QZri/8Vai8qLboCojEb7xtCgLzz2ArhWsnSa0PXesPaNX8umq19P67noPgr4dT/EK/vNavr9Lc3LzSSpFhnWXOfu9lJNdN4a0Lxl4r8AL4auorC20VJNgnmQ+ayq3GAPfvXn3wVt9eTWUudMvWtrcyJBcsjjc6sem09vevpH4h6Vr9/YWmi+FGSxicZnuQcGNBwFX3PXNc9RNS5b7CrYjk5dElLVXW1t35vXTbqcHF8B7WCOaRZLRmkt/IVZY3dUbvKDnOfbpVHS/gEtvqKzatrCy2qjBjgiKlvbJNeleDPA+t6NEjXPim+nbvGwDL9PmFdi1u0UQafMj55AHB/CqtLuzz3mVRO0ZL5JHE6d4V06MR2vh/TILCGEgNc+UN7fQ9/rXWva22mWZYMzyKNxZ+c49a4P4xfEK98HWNtJZ2sbPKxRVkHHT2r548YfFjxB4kRPtF4LS2UbfKtspvz696cKbd+VFuNWsourK0d97v5npHxr+JFvqmjXGjaXeyC98wrKbckIUHVWPfPpXz9JvntkjAcBjtYdBVq2meCdZ7WWMyk7whGcY9c1JM6apeyz382yRssI4EwC/pgYAreC9nueh7GKhyQ0vpbp9/p03H6pdaVc6Zptpp+kta3Vtu+1XDTlvtB7YU8LitOPUdDPgtrS6S8/t43IeJk2iFYsDIPcnitPWtQ8N3vheU2ejJp+oQJFGD9rZmdsnc+09c4/CuKtYbh1K2cUsrtlgeCVxSilUjrpZ9xvmoztHqui6ei/zLaMpugYXePA3b1YgqfWus034oatpXg+fwrZ28EyyOWa8AIlwxyTnPXPeuPcs+nvmYC4U87hgH2qjAxguS9w5YuNoSIVagpfFrYWJnZxS0u7300+V9015stXF2q3fnyyOsuMlT8xP41LCUBNysBZ2HEj9B9BTbx7bzIo2DQKRzuHLfjVy5SN9LWayUkIdgBcfOf93rik2rLTc6IRfPN8yfLr539P8AgLyHCMNEiTMWcnIKDp9aihETxNb3LAyDJA+6DVCG7kF0ib2dl6jjbViSeL7Z+9haSU9H7LSdOS0NY4ulNKS9Hf8Ap3Z23wiskk+InhuS7uo4RHqFuUiwSWbzBgCvsrx1eW1hpUVxfbhbpMNxXqPlNfFnwlC/8LI8N7mMhOp25BzwP3gxX1v8YlY6PpRWTyyL9B0zuBR/l/Gu/L78zPn84SdejbTR9bnPR+KNMs75kiiS5jmXcJwMqD1wR7Vu2vlapZpLY7YJx8xTna2ecHsK8w1hzZwrFFGiM7ZKqMsB6gGptMvLzR4o0jkmDsoK5br7ntXtOOtjm9jeKlHc9Ujs/wC1WLMwiuozhoyQpP0HvXlFytvrGtakZImjt0YIzO43QkAq6hckA9evGa6Hw9rCTalCmo36hw2Cm7G4Y7k+9a2t+HdNuLmK5aAxW07GKZ1GBzxuqXFpq+xMJezk03/wDxibxBbXN0LXUGGl21rIpT7PKWj2HopXBLNwf1Peu60fxDbRah/Z89/ZXMiMHjFrCyLHFgHaQ4G5v5Uan4F06a51N5njuPNCbOMEKowMetZ+j+GU0u6S4S4+0S+UqfP821snJ+p6GlTVTmvJfj92lvyOqo6Mo+63ttbr6/5nXX3ia+vdJuoLKIpJb52M6YDEjPHqBXjza1c3lw8mrSxSvEwdNjjzBk8AKMEDNeg+JNIu44Ekt2uZbdneU7eoB7Y/ujoK5efwB/bWmRahCyW9/FONssi9UA+6R9ea1nCyU47dULC1IQvGyTez7Hn2uau8mpEi4BId2RooyxZwcBe3bv8AjXb+AfGFrZ6BdJq2oJG8GZBCpJ2Ke4JJLEk1yev+CdU0m5JmEkl5NKzLKD8zRoeZAB0HI9eM9KybTQ7qS8AmnaVLkkGVIjskxhmUHA56dMAcVxe3lCV2tOx1yhCa5bq76/1+fr5np2p+OLbxDeG0XBsIo28hh0lcgEFh25OPwrmz4Ttm33VssqPKxXIYNtJ65J9+/vV6Dwtpy3C3kUEqx7FG3tjIOeepA5yD2r0PwH4YuNQV47gk2KkeVE6hTJGMYYH16Hmtm/ae7URkpQwqc4O+26ODg0vQ7SF5pZlsJo/KguFVS4HzZ3AAccjn/wDVXs9lZL5MEFnEmwpkbAAHJ5J44568etWbbwZpMUN/qEzRtMZzKzSIMKp/hAPFavhsS3dylxbRL9lhHlq33Rx6eo/SnF2Tdjir4pTWj2NCygsdFsYnYrJcE7gsYBYsegA61zoEiXzzXb7LhW3sGbafXr2q/dS282ot/ZxDzAkST4+RDnovqfeud1DUBcSNDN8wI8syd+T1zVwi3qclNbt9SGHxJBZpcxWEy6eksvnTzAlnmc+rnuf0qvqunWXibbLdeVqVv1HnNvw3c89K57UfDA89DFefaPKcyGNyFBPTIPfFdD4Ojh0/zQ8sbuSJCgYnYB0+p5rqcYxXNB6go2exc0bQdN8J3Uy6bBGsU4AnijPyse3ynuKNRafZcGwuVhWaNljk2n93wRnHt6VJeoZZfOUEqxPTkHPQiuZ1W4aS0WC1u4UnnLRRLOTtYgjf074/Ks22/eeptCCbRoeENXSGxj02/eSbULaRVa6OGM27IUJ6kdT6V0sl9pbXUsdxqUX2njbjhScevT1r5/1zWbvRLqLUVjFxA0+LGPayrGYzg9ec/wA+9ad55lhYWst3aXEcTOsxeQEbVZcjPoeeQe9Z4blrXTeq/q+ptiaEoNOK0fl+H/APbbizXCM/CnDK44B7jFLHId3nLIHjLAiRCCu73xXnVhrtxJoumpYamjp5wW6DDcFQfwD3xXZfD1ro2l6LiwEFg0jeWwBTcd3TaegxSlJKXKtTFxlGPM0dfFcAr8zxqfbAorA8R6Gt+1vLa38kBAYNHGxwOmOlFVGnCSu5HM3roj0Ug1XmXI7cd6sHpTHAINfJWOSLszyD4y6cbLZrtlb232iAKzXLAb4grZ+X3I4r5U+Id7car4tvb2/jkL3DCUNKNpIxgEcDtX258QNIOueHLi0WUwyJ++Rtu4Bk+YAjuMivjD4o6/qfibX4rzVmt5JreMW+IU8tAFJwMfjmijpUPo8PN1cL3t/X9ehwFwCbx1UnlgeTwatKs0XmEFfJPJLDJwfSrFs1u1wn22KTLqcCPGcgcde2agV2EDwzgb34wxGR6V6Dk3pY440oxbk3vf8A4Cfrcda3I8s7Ds3ttDHk04Xc5tPIkEh8pufx71Wt2hVHW7HKHKheOa6ez0nTJ/BU2qxXwj1X7UI/szOOY8feA6nmoqOMNWupvh3VqpKMtbPTy9Ntz3D9ljWISdR0Z7UfvV84TmPL9htY9hX0jb4VFBPTjr1xXwV8PfGWr+DNUku9LmjQOuyQSLkSDPQ16/ffHa7vtIQ6To86XcTqXuPMzGD6ED1PauGpBxk2iquEninGUfT7utu2x9OM2BkCszXdb07Q9Pe81a7htLdBy8rgZ9h6n2FeBal8YPE2n6Jc2+tWqafrdwivZp5BC+Uf+Wm7OPXivHJtduda1Vr/AMR6jNeRwMHdWYlnGeijoP0o521dCoZPJtOpKyOt+LvxKk8ZI2n2IENnFOWjLqAWXGAT3z9K4LxV4R1Pw5Z6ZdajFa774MY4xIDIm3Gd69utdfp3hi18f+OrmPwgBDbmHzmbUX2ndjnAXPetDxP4A1/TfC1pqdzoqWq2e+O5lE+95cnhyD0HXn3qY1VTsl8z1nQpTtTul2/4Z9fvPLLdkQRpJIxYnJUfdz/k1MLhredLuGQRTRtlVU457Gq7bZFZg/ltyfr9KoNEGMMs4kbJxtBA/GutRUnqYTryox5YK/W/3avqaF60s0jPcLJcSyHzCI1zz7+1T6XPqFnKLi0QxTuNieSTuOeMetavgzWNZ0FdRu9EvbaF2URFJVDyOrZ+6CD0qPwPdw2vxA0WW6vo7ZIblJJJ5E3KmDnJFQ9pRtsVzOLVV3V9Ftv66tmRqmm6vYXgtNWsZoJ5cSCGeJkIU9G5q55Mggt4ljihCZ3y7cMR7nvXa/HfxbbeJfHEstjexXFraQrDFLAhG/ueT15JGa4i7nlSO3+1WkqvKoYedxuQ9CPap5pTSdrGmF9lBOVRvm08/ldK+/oUbtoWUbpTJEjc8ZJ+lalmIJY5wZWQpFlFC5LH09u/NZ8CSSTyLBGI0HGD3p8UswuDFDbytKRj5RnNVJXVkXRqckvaSWj02fTsRpbN/aKeVGgRFyQx6/WpGmkuZClrtVRwwA4HvXrfw7+HWl654I1LU9QQ21y4ZYHeQgLgdcDrzXmIit0DQRKcq5DFON2Kz9spPbY0pUN4RlbXXp00S0XzNv4TR+X8TPDCrcbgup2wK7eD+8WvuPxYu+0tlVA0hm+UYyQdrdPwzXw38M5Ej+KPhUKflOq2yhRz/wAtF619ofEqeSCy0vyskteBSFOCR5b9K9PApuV31Pn8yiniYU49L/1qcHrXhszytdBXMoIH71uBzyfqATVmbw672DDyR5Z4TrnjHPHQV2Oj3FvcQSRToI5nXaGk4wfU/WjyjCPMjmH2iM/P+8HJPp7V6ym1dGDrO9n0PJrvwZcrKXglSS3kfJZyQU9jgc11usa/HZaTDYM53Ouzl/mYgfyroHXG7z03RldyIvy7j7+tYF9pNvqN39pliHmbuPatHUc0uboVBQc7z2PN/Euv3ekaP9strae7nY4VY1JP4+lWvDWs6hq+mW1xNZT2nJ3oF2sDnrz1/wAK7uDSrW1lkgIVlxhQScDvmlfTkQQiF0742g8/Wr9orWsbyqx5m0tCCfxPJpcZiNqXEiYY7Qc8cGqljeH7ZHGMeW4LYcfdPoa6pbdFhjR1jky2xlkGCCRwRVS6istpaWKCBVXO4HBX8+SazUo9EcsJJN36jdTsoNVtpYbgpDNIhj3hQzKDjO1h/eGQe/NYCeBo4LySewt7m8ZgVitnlCiKNiMjGOmAOevrXUWVrG8askk/K7lZQMZHcj0rodPuL61Ly+Slw8xBcj5DgfoKxkrbClUcNY62OI0jw3JFMIb2GQGCUiOSY/MVPOR2x24rpZZILO2jjjRvtCcRrjCqenFXjriSzTyvbK08TBVU8lazHukN5JI+Xu2Pyx9AnufT+dNXe4uaU/iRNPI0NpGdWk88FcxwOfvfUDrTo4dX1y2+zBI7OxUD5IwVDexPX8BUdnp891qUc1/scL/cOVxXdRBBGojAC4wMelTUqcm25zV5qFrLX8DitW8NXKaa4spEWZVwBs+Ufh/nrXmmt/aRrElkswWTC7Y1BLKf7xOOhz0r3+aREU+YwA968j8c6tHBqcaWaxpcyZXeHA2+gPqKqhUlLQ0wtZzdpI4y7hjjltI/NUyMCJHHOT0/n1rR06S5GoJDFBJLLK2yKQDexbOMjHG3HrXPrbyu6CFjJO42SRFV+Yeqeh713Hw/sToGopeTRSnCBWCybuxByOnvxVOpJu0UehNJRvu+x0baZfWNgjagrKJGAA3gleOhxx78Uafp1olnFG0Vs32cuwM2Mpnqw9zW74lvI72K0jgw+9w23POPcVk31uIvLthLuEh3E7NvAPGaUW5L3jhhOUo66MzNS06+vbC2n0uzSJ4TviMi5Qg9cj1xnFeVSeGNQt9f1KWdBIbh2AWSbJ+9ncfw4xX0gmnzm3BurgjjBVVyB6Y9K888bQW42CIyB0b5pVX1HXJ/z1rJqNT5GuFxTTaWv3nE2VlbafLNJEoVpJGlMZXALcDoPevStNWWOxUu5yQGxjuexHrXE6SJJXgj8tVuFYbyVLfLkcn25HNd8bZBv+c4XrjncK30StHRFVm3K8tWYX9ryrcTN9tms0Jwo+Uq+CRken0+lFbN1oChUWURzAZ2NkjK9s570Uk0ZKUH/wAMjuzTSPfn0pf4qQcrmvlVqecZupP5QL7GkGNpVRnOa+Rfj54efTdZWcWAitgozJHHtQKTlc/7WSa+xblQUPUdsivCP2npGt/CawqSyTuu/dz0ORUbTTPayyo9afdfkfKFzOpSNkZVz8qsOqfWqj2zyv8AcJkJ4IOd3+FOTHlSkgHDdO1QxgyK0m5lbdjCnAr1IK2iMsRU9paVRXuaFxptrFa20iXbvO+83ELR48oA8fN/Fmq6S74CkVqxG3CnPWokmkkinjdyVyD+tejeHNAh13RFS8urtI7S2mkhSJlUKQc/3TwTWVSbpr3tTehCFW7pe6rdvl1v2v6nFxWN3d6bLLFZSutqoaUxglUB6FiOlW9O1K7061dbVV/fjBWQZA7hh/tDsaprqF7Y2ctna3lxHbXuFuY1cgSgHIDetdB4ThWW/t0flXuI4yCAeD16is6zcYttXR34KCr1eWLadkr6f1sR6le6trsT6hqFxc3cqKIzK5JVFHRc9APascl5W8mInc3B29P/AK9fbng7w1pMPhXUNJWziNnclhMCoy+5ec/0r56+L3gDSPBmgLqmiyXizteG32yyBkC4J4GM549a5aVdNpW32NpVFKUoq9o6Pz9DnfhLrH/COeNtJubh5YozKYZWXglW45/Gvor4zeP5PBUa295pEGo6bqduyRBpcfMBghhjkcjpXxyLmWZEDsctySOtXbu9vdV2f2lfXd35C7YvOlL7B6DPQVtKg5O7fqc1V05yjyrZdfv/AAKUl0zhneFUcudu7gAZ6CpBCRAJZXRwvJyvP/6qz5V8zU0V+VyOKs3xYRSMrFTnHFdLjsl1OeFe6nOevLp/wR8Jul1GOa0ZlVsFSeAKnvJ5lu5wbcfaH4DhflqHSYxeoomLfe6qcU5wx1CSJpZDGBjBNS1eXobxk40k02ud6fNdrafexY/NRUR40+YHc461Z1LUdQv2sxdXP2traMQ2ySPny0HQAVFZTSQQrGjfKCevNLYyGXUZmYKCo4wKh6Nu2x0RipxhFSfvW+XX5/NbjYJiJ2iiEnmn75PRa63wXfWtn4kS51W1ublz8qmFgu1zwOMfSsbRIEuLrEuW8x1VvoTRjyblVh+QL8wx1zWFVqTcT0cNRlGmqjd1fT+v1PsP4e+F7/QWuhq94t7a3SCRA0QUITztx7dKzfitpvgweCdVu762sU3IfJkgKo5lH3dpHv1FT6Zrt9pfwaTWUl+0XyWxYNcZcZ6dOK+QL29n1O+na7csGdpNgJCgk9h2rCnBSWh5KjUqYiU5y1Ttppe3c6D4TKp+JnhYARj/AImls3qT+8Wvt7xqE+zWBkTcBcfiPkfkV8P/AAtiRPip4VVBtB1O2Y49pFr7f8dqf7KgkV2Vo5twx/uN1r28F8R5+PT+sU4taq5PplubiwSVyqwlPuMg/M1mrGrakIY449y4LcdM/wCNYYupoNLuVjkYKYiSM98VheBdVu5PEUpkk37oG3A9+lepGk7SlfY45RdNvXc7q/i2RbWQhOckN29c1zTXsLidIJopAPmHktnbjrmuoH+l6I3n/MZFZWPqMVzOg6TarcXM2wl48IMnjBohazb6DjJo5zVdQl0y0a7lQtEgBwT1B9T2qho/it7ucQm3WJmG5SrbsjGRketegHTLPUoXtbyBJICNpXHUZIqrdeF9H8N29xc6fZoZEty480lsnsD3x+NbKrC1mtS5TOY13WdSexm+y9iTIvAdlxxg9uT2rmk1KS3uPtV+4kuHQr5SncoU8j8cj9aj1u8mlunugVjfbwqKAo4H+NX2062m01LiVN0k4AcE8Hj07dKz5rt8vQ7KdNKKv1Mq/wDFd/cqsEFy9rGF2yAKQSc5GfTgGvQPAOo3o0x7O7lmeMHfAZTlmjOMEH0+tcjbaFYMwHlY2EMuD0IPX3/Gu70Oxhg2zR7hIqBc57HkjFTGcmrTHiKNOKvENVea3umijaPeMKWj44xnBrr9M+xPpTSyERoRtJCgEnoa5S6G+aaQ5DEZyK0PFc7jRoEXCgsGO0YySvOaco81onDW+FI7mztYrW2jjQEqigZbrTbm7jt4p3yD5a52jrXG+Hb+7uNJa3nuZJI1G0FsbgMkdetalhKxjuWf5yqjaW7VhKk4t8zOL2L1lJmF4k8WQ/ZiI8lgOWx0/CvL9TkuNQ1FJYljBlAEe8Fm7jp9f0r0K+2Nq88fkxDzkRiwXlSD1U9qp6mixRxTKqmUOq7yMnBIzXZGyVo6HVQSpsw9B0zyrG5leZUu0cYhlxhOxKHrg/pXUeGrW7ufMhjCgMuMlu2eTis62xLebnA+6RjHHWum0C1jjDSx7lZztODjik1yQsXNuT5iDVRLZXawiXLIyqrBQvA/lzipJJbi8vIiFklc4KhRkjnpj096o6xGrTHOc7yM5Oa3/BgxqVz3PlgZPsaiT5Y8wTfJDm6l3UdauYIPLkgCyMpy2Dj/APXXkeqma/1RmgkPAIXdISojHqOx5PSvW/G93Jb2kCIFKu/O4V5nqdlB56yRp5bNGwGw42nOcj3rOnZQukThOVq6Vmy/oGn3EM8cjqGSQ7gImHbsK65rd47d3O0bgQBwTz2rntILv4XSUSOjwzbUK9unrWvc6lNp+kTX0SRPOGVF8xcgZ6nAxzWkrvUU5vVmoZftCoylVUKABuxiisK3uJFDSDG6Q5Oen+eaKXLYOQ//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Cut surface of the liver of a patient with Dubin-Johnson syndrome showing macroscopic pigmentation; (B) Photomicrograph showing pigment granules within hepatocyte cytoplasm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ajit Kadakol, MD, Jayanta Roy Chowdhury, MD, MRCP, and Namita Roy Chowdhury, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_29_14805=[""].join("\n");
var outline_f14_29_14805=null;
var title_f14_29_14806="Ifosfamide nephrotoxicity";
var content_f14_29_14806=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ifosfamide nephrotoxicity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/29/14806/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14806/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/29/14806/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14806/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/29/14806/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14806/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/29/14806/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     Ifosfamide",
"    </a>",
"    is a synthetic analog of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    that has been approved for concurrent use with other drugs (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ) in the treatment of metastatic germ-cell testicular cancer and some sarcomas.",
"   </p>",
"   <p>",
"    Nephrotoxicity due to direct tubular injury is a prominent complication of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    therapy. Issues related to ifosfamide nephrotoxicity will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro studies suggest that it is the metabolite chloracetaldehyde that is toxic to the tubular cells, rather than the parent drug or another metabolite acrolein [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This relationship could explain why",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , although structurally related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , has virtually no nephrotoxicity. At equivalent doses, the rate of chloracetaldehyde generation with ifosfamide is",
"    <strong>",
"     40",
"    </strong>",
"    times greater than with cyclophosphamide [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/1\">",
"     1",
"    </a>",
"    ]. On the other hand, both acrolein and perhaps chloracetaldehyde may contribute to the bladder toxicity seen with these drugs.",
"   </p>",
"   <p>",
"    Another possible mechanism of toxicity may be energy depletion via mitochondrial damage, a mechanism similar to that observed with the mitochondrial cytopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/4\">",
"     4",
"    </a>",
"    ]. This damage may be amplified in proximal tubular cells by concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    administration (due to the uptake and retention of mesna in these cells), thereby resulting in relatively more severe glutathione depletion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     Ifosfamide",
"    </a>",
"    -induced renal injury is primarily manifested by the onset of one or more of the following signs of tubular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/1,5-10\">",
"     1,5-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypophosphatemia induced by decreased proximal phosphate reabsorption, which can lead to rickets in children [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/5-9,11\">",
"       5-9,11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Impairment in proximal tubular function as manifested by renal glucosuria, aminoaciduria, tubular proteinuria (ie, low molecular weight proteins but not albumin), and a marked increase in beta-2-microglobulin excretion [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/5,7,9,11\">",
"       5,7,9,11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Polyuria due to nephrogenic diabetes insipidus (ie, resistance to antidiuretic hormone), which appears to be relatively rare [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/6,8,11,12\">",
"       6,8,11,12",
"      </a>",
"      ]; when polyuria does occur, it is more often an appropriate response to isotonic saline therapy (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology of polyuria'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Renal potassium wasting, which may cause severe hypokalemia [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/6,10,11\">",
"       6,10,11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Metabolic acidosis with a normal anion gap (hyperchloremic) acidosis due to type 1 (distal) or type 2 (proximal) renal tubular acidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The time of onset of tubular dysfunction is variable. In a report in which 27 patients developed manifestations of tubular dysfunction, the diagnosis was made during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    therapy in nine patients and after the cessation of therapy in 18 patients, at a median of 13 months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to tubular dysfunction,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    therapy can lead to a reduction in glomerular filtration rate (GFR) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The decline in GFR is generally mild (usually no more than 20 to 30 percent below the baseline level) unless given in combination with another nephrotoxin such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/6,7,11\">",
"     6,7,11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Risk factors'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Long-term prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The clinical manifestations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    nephrotoxicity are different from the major manifestations of nephrotoxicity induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . Cisplatin primarily affects the S3 segment of the proximal tubule and the distal nephron, leading to acute renal failure and hypomagnesemia due to urinary magnesium wasting. Glucosuria and aminoaciduria also can occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=see_link\">",
"     \"Cisplatin nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Etiology of polyuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the preceding section,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    can induce nephrogenic diabetes insipidus. It is an uncommon complication that typically occurs in patients who have other signs of tubular toxicity, such as glucosuria, aminoaciduria, and hypophosphatemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more frequent problem is the marked polyuria that may complicate the administration of high-dose chemotherapy protocols that include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    . The cause of the polyuria in almost all such cases is a sodium diuresis (not a dilute water diuresis as in diabetes insipidus) that results from the volume expansion induced by saline therapy given to maintain a high urine output, particularly if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    is part of the regimen. Thus, the diuresis is",
"    <strong>",
"     appropriate",
"    </strong>",
"    and resolves if sodium intake is reduced and excretion of the excess fluid is permitted. In addition, the urine osmolality tends to be similar to that of plasma, not dilute as in diabetes insipidus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link&amp;anchor=H16#H16\">",
"     \"Diagnosis of polyuria and diabetes insipidus\", section on 'Solute diuresis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A frequent confounding factor is the presence of orthostatic hypotension. Although this finding suggests possible volume depletion, it is usually due to neural toxicity from the chemotherapy. Volume expansion may minimize orthostasis by maximizing the intravascular volume, but it also leads to persistence of the polyuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    nephrotoxicity are cumulative dose, age under four to five years, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cumulative ifosfamide dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically significant nephrotoxicity has been described in studies in children, mostly at a total dose above 60",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/5-7,9,11,13\">",
"     5-7,9,11,13",
"    </a>",
"    ], with severe nephrotoxicity primarily occurring at a total dose of 120",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    or more [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/6\">",
"     6",
"    </a>",
"    ]. The signs of nephrotoxicity are initially transient but become persistent in some patients as the cumulative dose increases.",
"   </p>",
"   <p>",
"    The high frequency of transient nephrotoxicity was demonstrated in a prospective study of 23 children and young adults who were treated with high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    (9",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    given over five days for 11 cycles at three to six week intervals) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/9\">",
"     9",
"    </a>",
"    ]. Acute tubular dysfunction occurred in all patients and was characterized by increases in the excretion of beta-2-microglobulin, glucose, phosphate, and amino acids. These abnormalities generally disappeared by day zero of the next cycle. Only three patients (13 percent) developed persistent Fanconi-like syndrome or requirement for oral electrolyte (potassium and phosphate) supplementation. The cumulative dose was 70",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in one and over 90",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in the other two.",
"   </p>",
"   <p>",
"    The differences in risk of persistent nephrotoxicity according to cumulative dose were illustrated in a series of 76 children and young adults in which grading criteria were used to define the severity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/6\">",
"     6",
"    </a>",
"    ]. The criteria included the glomerular filtration rate, the renal threshold for phosphate excretion (to evaluate for phosphaturia), the serum bicarbonate concentration (to evaluate for metabolic acidosis), and the early morning osmolality (to evaluate urinary concentrating ability).",
"   </p>",
"   <p>",
"    The following findings with respect to moderate and severe nephrotoxicity were noted at a median follow-up of six months:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At a cumulative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      dose below 84",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      there were no cases of severe nephrotoxicity and 5 of 45 (11 percent) had moderate nephrotoxicity.",
"     </li>",
"     <li>",
"      At a cumulative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      dose 84 to 119",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      1 of 16 had severe nephrotoxicity and 4 of 16 had moderate nephrotoxicity (6 and 25 percent, respectively).",
"     </li>",
"     <li>",
"      At a cumulative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      dose 120",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      or more, 5 of 15 had severe nephrotoxicity and 6 of 15 had moderate nephrotoxicity (33 and 40 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lower doses are safer but may be associated with persistent tubular injury. At a median follow-up of 19 months in a series of 593 children and adolescents with sarcoma who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , the incidence of tubulopathy (defined as at least two of hypophosphatemia, glucosuria, and proteinuria on at least two examinations) was 0.4 and 6.5 percent in those exposed to an ifosfamide dose of &le;24",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and between 24 to 60",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Young children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children under four to five years of age are an increased risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]. In a multivariate analysis of the above study of 593 children and adolescents, children who were less than four years of age at diagnosis had an 8.7-fold higher rate of tubulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/5\">",
"     5",
"    </a>",
"    ]. A possible mechanism is increased activity in young children of CYP3A, the enzyme responsible for the generation of chloracetaldehyde which appears to mediate ifosfamide nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cisplatin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concurrent administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    may have additive nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/13,15-17\">",
"     13,15-17",
"    </a>",
"    ] and ifosfamide nephrotoxicity can occur at lower cumulative doses in patients with appreciable cisplatin exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/16\">",
"     16",
"    </a>",
"    ]. This potentiating effect may not occur in patients treated with low doses of ifosfamide (&le;24",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=see_link\">",
"     \"Cisplatin nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     Carboplatin",
"    </a>",
"    is a less toxic analog of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and it is not clear if concurrent carboplatin therapy is a risk factor for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=see_link&amp;anchor=H18#H18\">",
"     \"Cisplatin nephrotoxicity\", section on 'Cisplatin analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major component of prevention of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    nephrotoxicity is to limit the cumulative dose. Other modalities, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    and N-acetylcysteine, have been evaluated but efficacy is unproven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Limit ifosfamide dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the risk of nephrotoxicity is low at cumulative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    doses of 60",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    or less and, when toxicity does occur, it is usually mild to moderate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/6,7,13\">",
"     6,7,13",
"    </a>",
"    ]. The risk is increased in children under age four to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Cumulative ifosfamide dose'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Therapies of unproven efficacy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Mesna",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     Mesna",
"    </a>",
"    is a synthetic sulfhydryl compound that can detoxify",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    metabolites. The main clinical benefit of mesna is to prevent the accumulation of the metabolite acrolein, which causes cystitis. As a result, all patients treated with ifosfamide in modern chemotherapy regimens also receive mesna. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23161?source=see_link&amp;anchor=H15#H15\">",
"     \"Cystitis in patients with cancer\", section on 'Mesna'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether the coadministration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    also reduces renal dysfunction issue remains unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. In experimental studies, in vivo mesna did not prevent in vitro nephrotoxicity induced by chloracetaldehyde, the metabolite that appears to be responsible for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     N-acetylcysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;N-acetylcysteine (NAC), which is used in the treatment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen (paracetamol)",
"    </a>",
"    intoxication, has been effective in an animal model for the prevention of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/19\">",
"     19",
"    </a>",
"    ]. Clinical studies in humans have not been performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LONG-TERM PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term impact of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    -induced renal injury in children has been addressed in a small number of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/5-7,11\">",
"     5-7,11",
"    </a>",
"    ]. The best long-term data following moderate ifosfamide exposure were provided in a report of 183 childhood cancer survivors who had been treated with a median cumulative ifosfamide dose of 54",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    with only 17 receiving more than 60",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     ;",
"    </span>",
"    none of the patients received concurrent therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At an average follow-up of 10 years, 90 percent had normal tubular function, and 79 percent had a normal glomerular filtration rate (GFR), defined as greater than 90",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    . Almost all of the abnormal findings were mild:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      All but one of the 39 patients with a reduced GFR had a value between 60 and 89",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      Two patients had mild hypomagnesemia",
"     </li>",
"     <li>",
"      Two patients had hypophosphatemia (although 24 percent had a reduced threshold for phosphate excretion)",
"     </li>",
"     <li>",
"      One patient had a low serum bicarbonate concentration (19",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"     </li>",
"     <li>",
"      Significant renal glucosuria was present in eight.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using a combined nephrotoxicity score, 63 had no nephrotoxicity, 36 percent had mild nephrotoxicity, one patient had moderate nephrotoxicity, and no patients had severe nephrotoxicity. No patient required long-term treatment with bicarbonate, phosphate, calcium, or vitamin D. In multivariate analysis, the length of follow-up and older age at diagnosis were independent predictors of a reduction in GFR. Thus, ongoing evaluation for progressive nephrotoxicity is warranted.",
"   </p>",
"   <p>",
"    The risk of moderate to severe nephrotoxicity is higher at cumulative doses &ge;84",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Cumulative ifosfamide dose'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are few data on long-term renal function in adults who have received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    . The best data come from a retrospective cohort of 259 adults who received ifosfamide chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14806/abstract/20\">",
"     20",
"    </a>",
"    ]. The mean estimated GFR fell from 82 to 67",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    after five years; most of this reduction occurred during the course of chemotherapy (likely reflecting acute kidney injury), although renal function continued to decline thereafter. No patient developed end-stage renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       Ifosfamide",
"      </a>",
"      is a synthetic analog of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      that is used to treat metastatic germ-cell testicular cancer and some sarcomas. Nephrotoxicity due to direct tubular injury is a prominent complication of ifosfamide therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal injury is manifested by signs of tubular dysfunction including glucosuria, aminoaciduria, tubular proteinuria (ie, low molecular weight proteins but not albumin), a marked increase in beta-2-microglobulin excretion, and, rarely polyuria due to nephrogenic diabetes insipidus. Patients may have hypophosphatemia due to decreased proximal phosphate reabsorption, hypokalemia due to potassium wasting and a normal anion gap metabolic acidosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to tubular dysfunction,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      can lead to a reduction in glomerular filtration rate (GFR). The reduction in GFR is generally mild unless ifosfamide is given in combination with another nephrotoxin such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      nephrotoxicity include cumulative dose, age under four to five years, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      therapy. Clinically significant nephrotoxicity occurs at a total dose above 60",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       ;",
"      </span>",
"      severe nephrotoxicity requires a total dose of 120",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"       .",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cornerstone of prevention of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      nephrotoxicity is to limit the cumulative dose. Other modalities, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"       mesna",
"      </a>",
"      and N-acetylcysteine, have not been proven to be effective. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Limited studies suggest that the prognosis of moderate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      exposure is good with the majority of patients having normal tubular function and glomerular filtration rate. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Long-term prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/1\">",
"      Skinner R, Sharkey IM, Pearson AD, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 1993; 11:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/2\">",
"      Zamlauski-Tucker MJ, Morris ME, Springate JE. Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney. Toxicol Appl Pharmacol 1994; 129:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/3\">",
"      Dubourg L, Michoudet C, Cochat P, Baverel G. Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. J Am Soc Nephrol 2001; 12:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/4\">",
"      Rossi R. Nephrotoxicity of ifosfamide--moving towards understanding the molecular mechanisms. Nephrol Dial Transplant 1997; 12:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/5\">",
"      St&ouml;hr W, Paulides M, Bielack S, et al. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System. Pediatr Blood Cancer 2007; 48:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/6\">",
"      Skinner R, Cotterill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group. Br J Cancer 2000; 82:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/7\">",
"      Oberlin O, Fawaz O, Rey A, et al. Long-term evaluation of Ifosfamide-related nephrotoxicity in children. J Clin Oncol 2009; 27:5350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/8\">",
"      Skinner R, Pearson AD, Price L, et al. Nephrotoxicity after ifosfamide. Arch Dis Child 1990; 65:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/9\">",
"      Ho PT, Zimmerman K, Wexler LH, et al. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer 1995; 76:2557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/10\">",
"      Husband DJ, Watkin SW. Fatal hypokalaemia associated with ifosfamide/mesna chemotherapy. Lancet 1988; 1:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/11\">",
"      Skinner R, Pearson AD, English MW, et al. Risk factors for ifosfamide nephrotoxicity in children. Lancet 1996; 348:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/12\">",
"      Rossi R, G&ouml;dde A, Kleinebrand A, et al. Concentrating capacity in ifosfamide-induced severe renal dysfunction. Ren Fail 1995; 17:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/13\">",
"      Loebstein R, Koren G. Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. Pediatrics 1998; 101:E8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/14\">",
"      Aleksa K, Halachmi N, Ito S, Koren G. Renal ontogeny of ifosfamide nephrotoxicity. J Lab Clin Med 2004; 144:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/15\">",
"      Rossi R, G&ouml;dde A, Kleinebrand A, et al. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol 1994; 12:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/16\">",
"      Lee BS, Lee JH, Kang HG, et al. Ifosfamide nephrotoxicity in pediatric cancer patients. Pediatr Nephrol 2001; 16:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/17\">",
"      Goren MP, Wright RK, Pratt CB, et al. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy. Cancer Res 1987; 47:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/18\">",
"      Yaseen Z, Michoudet C, Baverel G, Dubourg L. In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro. Pediatr Nephrol 2008; 23:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/19\">",
"      Chen N, Aleksa K, Woodland C, et al. N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats. Br J Pharmacol 2008; 153:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14806/abstract/20\">",
"      Farry JK, Flombaum CD, Latcha S. Long term renal toxicity of ifosfamide in adult patients--5 year data. Eur J Cancer 2012; 48:1326.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2383 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-189.41.172.26-A378CE85E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_29_14806=[""].join("\n");
var outline_f14_29_14806=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Etiology of polyuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cumulative ifosfamide dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Young children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cisplatin therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Limit ifosfamide dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Therapies of unproven efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Mesna",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - N-acetylcysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LONG-TERM PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=related_link\">",
"      Cisplatin nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23161?source=related_link\">",
"      Cystitis in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_29_14807="Treatment and prevention of schistosomiasis";
var content_f14_29_14807=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of schistosomiasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/29/14807/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14807/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14807/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/29/14807/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14807/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/29/14807/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14807/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/29/14807/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schistosomiasis is caused by infection with Schistosoma haematobium, S. mansoni, S. japonicum, S. mekongi, or S. intercalatum. The various species are associated with different clinical complications. The clinical features also differ in acute and chronic infections.",
"   </p>",
"   <p>",
"    The treatment and prevention of schistosomiasis will be reviewed here. The epidemiology, pathogenesis, clinical features, and diagnosis of these infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7398?source=see_link\">",
"     \"Diagnosis of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with evidence of infection should be treated regardless of symptoms, since adult worms can live for years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This includes travelers or immigrants with vague or remote exposure history and patients with equivocal test results. Therapy is worthwhile, even if the risk of complication due to infection is felt to be low, as the risk of adverse events due to treatment is minimal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Praziquantel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of choice for all schistosome species is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Praziquantel is extremely well-tolerated and is used both for treatment of individual patients and in mass community treatment programs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     Praziquantel",
"    </a>",
"    induces ultrastructural changes in the teguments of adult worms, resulting in increased permeability to calcium ions. Calcium ions accumulate in the parasite cytosol, leading to muscular contractions and ultimate paralysis of adult worms. By damaging the tegument membrane, praziquantel also exposes parasite antigens to host immune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/5\">",
"     5",
"    </a>",
"    ]. These effects lead to dislodgement of worms from their intestinal sites and subsequent expulsion by peristalsis. The effectiveness of praziquantel therefore depends at least, in part, on host immune defenses.",
"   </p>",
"   <p>",
"    Since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    has no effect on immature worms or eggs, it is ineffective in early infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Katayama fever'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. haematobium, S. mansoni, and S. intercalatum infections can be treated with 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    in one or two doses, whereas the recommended dose for S. japonicum and S. mekongi is 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in two or three doses at least three hours apart [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    are generally mild, but occur in approximately one-third of patients. Side effects include dizziness, headache, vomiting, abdominal pain, diarrhea, and pruritus. These symptoms may be partly related to the drug itself and partly related to host immune responses to dying parasites. Some data suggest that there may a correlation between the severity of adverse events and the intensity of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    is often reported in terms of both cure and egg reduction rates. Efficacy partially depends upon the pretreatment intensity of infection, but host characteristics and other factors also play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/9\">",
"     9",
"    </a>",
"    ]. In endemic areas, most studies have suggested praziquantel cures more than 85 percent of individuals, and reduces the intensity of infection by more than 90 percent, even among those who are not cured [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. Retreatment of patients with residual infections results in cure in more than 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In endemic areas, the aim of therapy is to prevent the complications of infection, and since these manifestations occur only with high burden of infection, reduced egg excretion without complete cure still significantly decreases morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/15\">",
"     15",
"    </a>",
"    ]. Regression of periportal fibrosis and portal vein thickening, and reversal of hydronephrosis have been documented. However, treatment is not effective in reversing late-stage fibrosis or complications, such as esophageal varices or cor pulmonale.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Use in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, pregnant women were excluded from schistosomal mass treatment campaigns. However, this approach may effectively put women at risk for subsequent disease due to multiple pregnancies. A retrospective study of 88 women who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    during pregnancy, in the context of a mass treatment campaign, showed no increase in the rate of abortion, preterm deliveries, or congenital abnormalities when compared with untreated women [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small, prospective involving 25 pregnant Sudanese women with confirmed S. mansoni infection, showed no teratogenic effects after a single oral 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/17\">",
"     17",
"    </a>",
"    ]. One patient, who received praziquantel at 10 weeks of gestation, aborted. There were no stillbirths or congenital abnormalities in the babies who were followed for one year after birth.",
"   </p>",
"   <p>",
"    A meeting of experts convened by the World Health Organization, assessing data and clinical experience over the last two decades, recommended in 2003, that pregnant and lactating women in endemic areas for schistosomiasis should not be excluded from receiving treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/18\">",
"     18",
"    </a>",
"    ]. We agree that praziquantel should be administered to lactating or pregnant women who have evidence of schistosomiasis infection, although we prefer to administer treatment after the first trimester.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     Praziquantel",
"    </a>",
"    is excreted in human breast milk and delaying treatment until the woman has stopped breastfeeding or discontinuation of breastfeeding on the day of therapy and for the following 72 hours is often recommended. However, no adverse effects of praziquantel administration during lactation have been reported, so lactating women with evidence of infection should not be excluded from treatment, particularly in endemic areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Use of glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of glucocorticoids is considered in two particular clinical scenarios:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Katayama fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the lack of clinical trials in nonimmune populations, the optimal treatment regimen for Katayama syndrome is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/19\">",
"     19",
"    </a>",
"    ]. As mentioned above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    is not particularly effective in early infection, so therapy for Katayama fever is mostly supportive. Glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    40 mg daily for 5 days) can be considered to ameliorate significant symptoms related to hypersensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the optimal timing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    therapy is unclear. If praziquantel therapy is not instituted immediately, it should be administered within 6 to 10 weeks when the infection is established and adult worms have developed. An alternative approach is to commence praziquantel at the time of diagnosis as this may decrease the worm load and reduce the risk of ectopic localization [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/22\">",
"     22",
"    </a>",
"    ]. Depending on the species of schistosome responsible for infection, treatment with 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for 3 days (for S. mansoni or S. haematobium) and 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for 6 days (for S. japonicum) has been given [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/19\">",
"     19",
"    </a>",
"    ]. If this latter approach is used, then concurrent administration of glucocorticoids is definitely recommended to avoid clinical deterioration. A second course of praziquantel after two to three months to eradicate any surviving schistosomes is also required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Neurological disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of schistosomiasis involving the central nervous system should consist of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    together with glucocorticoids, as the inflammatory response provoked by praziquantel can lead to neurologic worsening. If patients present with seizures, anticonvulsant therapy may also be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Alternative therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, oxamniquine and metrifonate were available as alternative treatments for S. mansoni and S. haematobium infections, respectively. However, these agents are less efficacious than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    and are becoming increasingly difficult to obtain since they are no longer being manufactured.",
"   </p>",
"   <p>",
"    Artemisinin derivatives show in vitro activity against immature schistosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/23\">",
"     23",
"    </a>",
"    ]. Although there is limited experience with their use in schistosomiasis, small field trials suggest that artemisinin derivatives reduce the incidence of infections with S. japonicum and S. mansoni [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/24\">",
"     24",
"    </a>",
"    ]. More studies using these agents are required to determine the role they will have in the future management of this disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25241?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of uncomplicated falciparum malaria\", section on 'Artemisinins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oxadiazole 2-oxides are a new class of compounds that show promise for treatment of schistosomiasis; they act by targeting the thioredoxin-glutathione reductase enzyme. Preliminary study has demonstrated activity of this class against skin and lung larvae as well as juvenile and adult worms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports of schistosome species with reduced sensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    in vivo and in vitro have emerged, raising concerns about possible drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/8,26\">",
"     8,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a focus of intense S. mansoni transmission in Senegal, only 35 percent of individuals were cured after standard doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"       praziquantel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/27\">",
"       27",
"      </a>",
"      ]. Therapeutic failure in the treatment of S. haematobium infection has also been reported in travelers from Africa [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. It is unclear if these reports represent drug resistance or reinfection.",
"     </li>",
"     <li>",
"      In vitro, S. mansoni parasites recovered from Egyptian patients demonstrated reduced killing upon exposure to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"       praziquantel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data have practical implications for the long-term benefit of widespread use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    in mass chemotherapy programs. New chemotherapeutic agents, such as protease inhibitors, are in very early stages of development [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient monitoring after therapy mainly involves monitoring of eosinophil count in cases with eosinophilia, and examination of stool or urine, depending on which particular schistosomal species has been identified.",
"   </p>",
"   <p>",
"    After treatment, eggs may continue to be excreted for two weeks, so reexamination of the stool or urine within a short interim is not helpful. Additionally, treatment may cause temporary cessation of egg excretion from adult worms that are not killed. Thus, it is recommended that follow-up specimens be delayed for at least six weeks post treatment to assess cure in endemic areas. In nonendemic areas where there is no risk of intercurrent reinfection, reexamination is usually recommended at three and six months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Assessment of cure can also be complicated by the difficulty in differentiating viable eggs from nonviable eggs, which can be seen for prolonged periods of time. This is particularly problematic for inexperienced laboratories in nonendemic areas.",
"   </p>",
"   <p>",
"    Eosinophil levels may rise after therapy and not return to normal for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serologic assays remain positive for prolonged periods following therapy, so do not appear to have a major role in monitoring patients post treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ESOPHAGEAL VARICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to anti-helminthic therapy, patients with severe portal hypertension and esophageal varices may also benefit from treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    from sclerotherapy or shunt procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/34\">",
"     34",
"    </a>",
"    ]. These modalities are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35689?source=see_link\">",
"     \"Endoscopic variceal ligation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17786?source=see_link\">",
"     \"Prevention of recurrent variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link\">",
"     \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schistosomiasis control and prevention strategies have included water sanitation programs, mass treatment and vaccine development. These measures can reduce the prevalence and morbidity of disease. Together with other aggressive interventions, these measures facilitated successful eradication of schistosomiasis in Japan and have been adopted as a national strategy in China [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because schistosomiasis is transmitted via contact with fresh water containing infectious cercarial larvae, minimizing contact with this reservoir of infection is an important control measure. Strategies include limiting direct human contact with fresh water sources and eradication of snail species native to fresh water. Direct contact with fresh water sources can be reduced by provision of safe water supplies with proper sewage control as well as community education regarding wearing protective clothing and footwear in the setting of fresh water contact [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/37\">",
"     37",
"    </a>",
"    ]. Eradication of snail species via molluscicides or environmental control of snail breeding sites has been attempted, although eradication is difficult to sustain because repopulation by snails can occur rapidly [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mass chemotherapy programs have the potential to reduce the prevalence and morbidity of infection and improve hemoglobin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/1,38-43\">",
"     1,38-43",
"    </a>",
"    ]. These programs generally consist of yearly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    administration to children and adolescents in endemic areas. However, even a single round of mass chemotherapy can have a substantial impact on schistosomiasis morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no effective vaccine against schistosomiasis, although development is underway [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/44-48\">",
"     44-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening is appropriate for travelers and refugees from endemic areas, since many individuals with schistosomiasis are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one retrospective study of 1107 cases of schistosomiasis from Africa presenting to a single hospital in London, all cases were diagnosed by microscopy or serology [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/49\">",
"       49",
"      </a>",
"      ]. Half of the cases were asymptomatic, and the most common symptom in those who were not asymptomatic was fatigue. Eosinophilia was present in 44 percent of cases, and urine dipstick testing was positive for blood and protein in 21 and 15 percent, respectively. Serology was positive in 86 percent, and ova were seen on microscopy in 45 percent of samples.",
"     </li>",
"     <li>",
"      In a smaller study of 137 Israeli travelers returning from sub-Saharan Africa, approximately one-quarter of those who were originally asymptomatic on presentation eventually developed chronic schistosomiasis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/50\">",
"       50",
"      </a>",
"      ]. The diagnosis was confirmed by serologic testing in 88 percent; schistosome ova were found in 26 percent.",
"     </li>",
"     <li>",
"      Among 462 Sudanese and 100 Somali Bantu refugees, rates of schistosomiasis seropositivity were 44 and 23 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14807/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Appropriate screening tools include serology and microscopy of stool",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urine. These tools may not yield positive results in infected individuals for 4 to 6 weeks following exposure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7398?source=see_link\">",
"     \"Diagnosis of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with chronic symptomatic schistosomiasis require treatment.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"       Praziquantel",
"      </a>",
"      is the drug of choice and the dose and frequency depends upon the species. S. haematobium, S. mansoni, and S. intercalatum infections can be treated with 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of praziquantel divided in one or two doses, whereas the recommended dose for S. japonicum and S. mekongi is 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      divided in two doses at least three hours apart. We also suggest treatment of patients with asymptomatic infection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"       praziquantel",
"      </a>",
"      be administered to lactating or pregnant women who have evidence of schistosomiasis infection, as noted by the World Health Organization (WHO) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Treatment should be initiated after the first trimester, whenever possible.",
"     </li>",
"     <li>",
"      Supportive therapy should be offered to patients with Katayama fever. We suggest the use of glucocorticoids in patients with severe hypersensitivity symptoms (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"       Praziquantel",
"      </a>",
"      should be initiated approximately 6 to 10 weeks after presentation.",
"     </li>",
"     <li>",
"      We recommend that patients with neurologic disease be given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/16/25860?source=see_link\">",
"       praziquantel",
"      </a>",
"      in conjunction with glucocorticoids to decrease the risk of an inflammatory reaction (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      After treatment, follow-up specimens of urine or stool should be obtained in approximately six weeks in patients living in endemic areas or three to six months in travelers (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Patient monitoring'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Travelers or expatriates returning from areas where schistosomiasis occurs should be screened with serologic testing for schistosomiasis infection if they have had fresh water exposure since many infections may remain asymptomatic. Urine and stool screening should be obtained in patients with positive serologies for species identification. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/1\">",
"      Brinkmann UK, Werler C, Traor&eacute; M, et al. Experiences with mass chemotherapy in the control of schistosomiasis in Mali. Trop Med Parasitol 1988; 39:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/2\">",
"      Danso-Appiah A, Utzinger J, Liu J, Olliaro P. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev 2008; :CD000053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/3\">",
"      Ross AG, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl J Med 2002; 346:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/4\">",
"      Danso-Appiah A, Olliaro PL, Donegan S, et al. Drugs for treating Schistosoma mansoni infection. Cochrane Database Syst Rev 2013; 2:CD000528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/5\">",
"      Brindley PJ, Sher A. Immunological involvement in the efficacy of praziquantel. Exp Parasitol 1990; 71:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/6\">",
"      Grandi&egrave;re-P&eacute;rez L, Ansart S, Paris L, et al. Efficacy of praziquantel during the incubation and invasive phase of Schistosoma haematobium schistosomiasis in 18 travelers. Am J Trop Med Hyg 2006; 74:814.",
"     </a>",
"    </li>",
"    <li>",
"     Drugs for Parasitic Infections. Medical Lett Drugs Ther; August 2004 www.medletter.com/freedocs/parasitic.pdf (Accessed on March 08, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/8\">",
"      Stelma FF, Talla I, Sow S, et al. Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg 1995; 53:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/9\">",
"      van Lieshout L, Stelma FF, Guiss&eacute; F, et al. The contribution of host-related factors to low cure rates of praziquantel for the treatment of Schistosoma mansoni in Senegal. Am J Trop Med Hyg 1999; 61:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/10\">",
"      Shekhar KC. Schistosomiasis drug therapy and treatment considerations. Drugs 1991; 42:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/11\">",
"      Berhe N, Gundersen SG, Abebe F, et al. Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads and morbidity in primary school children in north-east Ethiopia. Acta Trop 1999; 72:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/12\">",
"      Guisse F, Polman K, Stelma FF, et al. Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal. Am J Trop Med Hyg 1997; 56:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/13\">",
"      King CH, Wiper DW 3rd, De Stigter KV, et al. Dose-finding study for praziquantel therapy of Schistosoma haematobium in Coast Province, Kenya. Am J Trop Med Hyg 1989; 40:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/14\">",
"      Ismail MM, Attia MM, el-Badawy AA, et al. Treatment of schistosomiasis with praziquantel among school children. J Egypt Soc Parasitol 1994; 24:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/15\">",
"      Richter J. The impact of chemotherapy on morbidity due to schistosomiasis. Acta Trop 2003; 86:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/16\">",
"      Adam I, Elwasila el T, Homeida M. Is praziquantel therapy safe during pregnancy? Trans R Soc Trop Med Hyg 2004; 98:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/17\">",
"      Adam I, Elwasila E, Homeida M. Praziquantel for the treatment of schistosomiasis mansoni during pregnancy. Ann Trop Med Parasitol 2005; 99:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/18\">",
"      Savioli L, Crompton DW, Neira M. Use of anthelminthic drugs during pregnancy. Am J Obstet Gynecol 2003; 188:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/19\">",
"      Ross AG, Vickers D, Olds GR, et al. Katayama syndrome. Lancet Infect Dis 2007; 7:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/20\">",
"      Harries AD, Cook GC. Acute schistosomiasis (Katayama fever): clinical deterioration after chemotherapy. J Infect 1987; 14:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/21\">",
"      Chapman PJ, Wilkinson PR, Davidson RN. Acute schistosomiasis (Katayama fever) among British air crew. BMJ 1988; 297:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/22\">",
"      Bottieau E, Clerinx J, de Vega MR, et al. Imported Katayama fever: clinical and biological features at presentation and during treatment. J Infect 2006; 52:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/23\">",
"      Ara&uacute;jo N, Kohn A, Katz N. Activity of the artemether in experimental schistosomiasis mansoni. Mem Inst Oswaldo Cruz 1991; 86 Suppl 2:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/24\">",
"      Utzinger J, N'Goran EK, N'Dri A, et al. Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial. Lancet 2000; 355:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/25\">",
"      Sayed AA, Simeonov A, Thomas CJ, et al. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med 2008; 14:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/26\">",
"      Ciolli, D. Chemotherapy of schistosomiasis. Parasitology Today 1998; 14:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/27\">",
"      Gryseels B, Stelma FF, Talla I, et al. Epidemiology, immunology and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal. Trop Geogr Med 1994; 46:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/28\">",
"      Silva IM, Thiengo R, Concei&ccedil;&atilde;o MJ, et al. Therapeutic failure of praziquantel in the treatment of Schistosoma haematobium infection in Brazilians returning from Africa. Mem Inst Oswaldo Cruz 2005; 100:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/29\">",
"      Alonso D, Mu&ntilde;oz J, Gasc&oacute;n J, et al. Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am J Trop Med Hyg 2006; 74:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/30\">",
"      Ismail M, Botros S, Metwally A, et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 1999; 60:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/31\">",
"      Abdulla MH, Lim KC, Sajid M, et al. Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Med 2007; 4:e14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/32\">",
"      Lucey DR, Maguire JH. Schistosomiasis. Infect Dis Clin North Am 1993; 7:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/33\">",
"      Ottesen EA, Weller PF. Eosinophilia following treatment of patients with schistosomiasis mansoni and Bancroft's filariasis. J Infect Dis 1979; 139:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/34\">",
"      Elliott DE. Schistosomiasis. Pathophysiology, diagnosis, and treatment. Gastroenterol Clin North Am 1996; 25:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/35\">",
"      Tanaka H, Tsuji M. From discovery to eradication of schistosomiasis in Japan: 1847-1996. Int J Parasitol 1997; 27:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/36\">",
"      Wang LD, Chen HG, Guo JG, et al. A strategy to control transmission of Schistosoma japonicum in China. N Engl J Med 2009; 360:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/37\">",
"      Steinmann P, Keiser J, Bos R, et al. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006; 6:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/38\">",
"      Fenwick A. Waterborne infectious diseases--could they be consigned to history? Science 2006; 313:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/39\">",
"      Lin D, Zhang S, Murakami H, et al. Impact mass chemotherapy with praziquantel on schistosomiasis control in Fanhu village, People's Republic of China. Southeast Asian J Trop Med Public Health 1997; 28:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/40\">",
"      Talaat M, Miller FD. A mass chemotherapy trial of praziquantel on Schistosoma haematobium endemicity in Upper Egypt. Am J Trop Med Hyg 1998; 59:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/41\">",
"      Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its control. Acta Trop 2000; 77:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/42\">",
"      Kabatereine NB, Brooker S, Koukounari A, et al. Impact of a national helminth control programme on infection and morbidity in Ugandan schoolchildren. Bull World Health Organ 2007; 85:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/43\">",
"      Koukounari A, Gabrielli AF, Toure S, et al. Schistosoma haematobium infection and morbidity before and after large-scale administration of praziquantel in Burkina Faso. J Infect Dis 2007; 196:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/44\">",
"      Ribeiro de Jesus A, Ara&uacute;jo I, Bacellar O, et al. Human immune responses to Schistosoma mansoni vaccine candidate antigens. Infect Immun 2000; 68:2797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/45\">",
"      Harn DA, Reynolds SR, Chikunguwo S, et al. Synthetic peptide vaccines for schistosomiasis. Pharm Biotechnol 1995; 6:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/46\">",
"      Richter D, Reynolds SR, Harn DA. Candidate vaccine antigens that stimulate the cellular immune response of mice vaccinated with irradiated cercariae of Schistosoma mansoni. J Immunol 1993; 151:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/47\">",
"      Lebens M, Sun JB, Czerkinsky C, Holmgren J. Current status and future prospects for a vaccine against schistosomiasis. Expert Rev Vaccines 2004; 3:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/48\">",
"      Tran MH, Pearson MS, Bethony JM, et al. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med 2006; 12:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/49\">",
"      Whitty CJ, Mabey DC, Armstrong M, et al. Presentation and outcome of 1107 cases of schistosomiasis from Africa diagnosed in a non-endemic country. Trans R Soc Trop Med Hyg 2000; 94:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/50\">",
"      Meltzer E, Artom G, Marva E, et al. Schistosomiasis among travelers: new aspects of an old disease. Emerg Infect Dis 2006; 12:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14807/abstract/51\">",
"      Posey DL, Blackburn BG, Weinberg M, et al. High prevalence and presumptive treatment of schistosomiasis and strongyloidiasis among African refugees. Clin Infect Dis 2007; 45:1310.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5705 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-486B9E35E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_29_14807=[""].join("\n");
var outline_f14_29_14807=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Praziquantel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Use in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Use of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Katayama fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Neurological disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Alternative therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT OF ESOPHAGEAL VARICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7398?source=related_link\">",
"      Diagnosis of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35689?source=related_link\">",
"      Endoscopic variceal ligation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/38/15977?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17786?source=related_link\">",
"      Prevention of recurrent variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=related_link\">",
"      Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25241?source=related_link\">",
"      Treatment of uncomplicated falciparum malaria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_29_14808="Clinical manifestations of food allergy: An overview";
var content_f14_29_14808=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of food allergy: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/29/14808/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14808/contributors\">",
"     Wesley Burks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/29/14808/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14808/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/29/14808/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14808/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/29/14808/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An adverse food reaction is a general term for any untoward response to the ingestion of a food. Adverse food reactions can be divided into food allergies, which are immunologically mediated, and all other reactions, which are nonimmunologic (",
"    <a class=\"graphic graphic_table graphicRef51225 \" href=\"UTD.htm?7/26/7597\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Adverse food reactions are common and often assumed by patients to be allergic in nature. However, nonimmunologic reactions to food are more common than true food allergies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=see_link&amp;anchor=H3#H3\">",
"     \"The natural history of childhood food allergy\", section on 'Prevalence of childhood food allergy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Food allergy is due to an abnormal immunologic response following exposure (usually ingestion) to a food [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14808/abstract/1\">",
"     1",
"    </a>",
"    ]. The terms allergy and hypersensitivity are used interchangeably in this topic review. There are multiple types of food allergy, each with distinct clinical and pathophysiologic features. Food allergies are broadly categorized into either IgE-mediated or non-IgE mediated processes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14808/abstract/2\">",
"     2",
"    </a>",
"    ]. Some disorders, such as atopic dermatitis or the eosinophilic gastrointestinal disorders, have characteristics of both mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic reviews the clinical manifestations of the different categories of food allergies. Other aspects of food allergy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=see_link\">",
"     \"History and physical examination in the patient with possible food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     IgE-MEDIATED REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE-mediated food allergic reactions are rapid in onset, typically beginning within minutes to two hours from the time of ingestion. IgE-mediated reactions to carbohydrate allergens in meats, a type of reaction reported mainly in adults, represent an exception to this temporal pattern, since these reactions begin four to six hours after ingestion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36072?source=see_link\">",
"     \"Allergy to meats\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Signs and symptoms can involve the skin, respiratory and gastrointestinal tracts, and cardiovascular system and are believed to be caused by mediator release from tissue mast cells and circulating basophils (",
"    <a class=\"graphic graphic_table graphicRef79448 \" href=\"UTD.htm?19/49/20251\">",
"     table 2",
"    </a>",
"    ). Two distinct presentations are the oral allergy syndrome and food-dependent, exercise-induced anaphylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11082?source=see_link\">",
"     \"Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26777?source=see_link\">",
"     \"Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H11#H11\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Pitfalls in making the diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Urticaria and angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute urticaria and angioedema are probably the most common cutaneous manifestations of food hypersensitivity reactions, generally appearing within minutes of ingestion of the food allergen. Food allergy may account for 20 percent of cases of acute urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14808/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"     \"New onset urticaria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15641?source=see_link\">",
"     \"An overview of angioedema: Clinical features, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, food allergies are an uncommon underlying cause of chronic urticaria and angioedema (defined as greater than six weeks of regular outbreaks). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=see_link&amp;anchor=H23#H23\">",
"     \"Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history\", section on 'Foods and food additives'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Food can also cause acute contact urticaria. In this condition, urticaria develops only on skin that was in direct contact with the food. In addition to the common allergens, raw meats, seafood, raw vegetables and fruits, mustard, rice, and beer are among the foods that have been implicated in this form of reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14808/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6558107\">",
"    <span class=\"h2\">",
"     Oropharyngeal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oropharyngeal symptoms can occur in isolation or as part of a systemic reaction to a food (",
"    <a class=\"graphic graphic_table graphicRef79448 \" href=\"UTD.htm?19/49/20251\">",
"     table 2",
"    </a>",
"    ). Symptoms may occur in isolation because the allergy is mild, not much allergen was ingested, or the allergen is labile, as is seen in oral allergy syndrome.",
"   </p>",
"   <p>",
"    Oral allergy syndrome, or pollen-food allergy syndrome, is considered a form of contact allergy that is common in patients with allergic rhinitis to pollen. It is caused by the presence of heat-labile proteins (eg, profilins) within these foods that are cross reactive with allergenic pollen proteins. Symptoms are confined almost exclusively to the oropharynx, and include the immediate onset of pruritus, irritation, and mild swelling of the lips, tongue, palate, and throat upon ingestion of fresh, uncooked fruits and vegetables [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14808/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. The symptoms are not typically elicited by cooked fruits and vegetables. Symptoms usually subside within minutes after ingestion ceases. However, progression to systemic symptoms can occur and anaphylaxis has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14808/abstract/11\">",
"     11",
"    </a>",
"    ]. Symptoms may be more noticeable during the associated pollen season. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11082?source=see_link\">",
"     \"Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37430?source=see_link&amp;anchor=H1929141#H1929141\">",
"     \"Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)\", section on 'Patient education about risk of systemic reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As examples, a birch-allergic patient may develop itching of the lips or mouth upon eating apple, pear, cherry, carrot, celery, and potato, while a ragweed-allergic patient may react to melons and banana, and a mugwort-allergic patient may react to celery or mustard. Tree nuts and peanuts can also cause isolated oral symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Respiratory tract symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma and environmental allergies (allergic rhinitis and conjunctivitis) are more common in children with food allergy. In addition, conjunctival, nasal, and lower respiratory tract symptoms are common components of systemic food allergic reactions (ie, anaphylaxis) (",
"    <a class=\"graphic graphic_table graphicRef58836 \" href=\"UTD.htm?22/52/23371\">",
"     table 3",
"    </a>",
"    ). However, isolated allergic rhinoconjunctivitis or asthma in response to foods is rare. An exception is occupational asthma (sometimes with accompanying rhinitis) in food industry workers. \"Baker's asthma,\" caused by IgE-mediated allergy to inhaled wheat proteins, is an example [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14808/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients with these conditions may not react to the food upon ingestion. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Anaphylaxis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38776?source=see_link\">",
"     \"Respiratory manifestations of food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=see_link&amp;anchor=H16#H16\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\", section on 'Allergic history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3198815\">",
"    <span class=\"h2\">",
"     Gastrointestinal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE-mediated gastrointestinal (GI) symptoms, including nausea, abdominal pain, abdominal cramping, vomiting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea, are more prominent features in anaphylaxis due to ingestion of a food allergen. The term gastrointestinal anaphylaxis is used when GI symptoms occur in isolation. However, GI symptoms are rarely the sole manifestations of a food-allergic reaction. More commonly GI symptoms occur in conjunction with involvement of other target organs (",
"    <a class=\"graphic graphic_table graphicRef79448 \" href=\"UTD.htm?19/49/20251\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14808/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The onset of upper gastrointestinal symptoms (nausea, vomiting, abdominal pain) is generally minutes to two hours after ingestion of the offending food, but lower gastrointestinal symptoms, such as diarrhea, can begin two to six hours after ingestion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=see_link&amp;anchor=H14#H14\">",
"     \"Food-induced anaphylaxis\", section on 'Signs and symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may develop a combination of symptoms and signs related to the cutaneous, respiratory, gastrointestinal,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiovascular systems that constitute anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"UTD.htm?22/43/23228\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58836 \" href=\"UTD.htm?22/52/23371\">",
"     table 3",
"    </a>",
"    ). Anaphylactic reactions may culminate in hypotension, vascular collapse, cardiac dysrhythmias, or death. Anaphylaxis occasionally follows a biphasic course, with a recurrence of symptoms hours after the initial onset. Skin symptoms may be absent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=see_link&amp;anchor=H10#H10\">",
"     \"Food-induced anaphylaxis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6556100\">",
"    <span class=\"h3\">",
"     Food-dependent exercise-induced anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are increasing reports of patients with anaphylaxis that occurs only if the patient exercises or exerts themselves within two to four hours of ingestion of food. This is referred to as food-dependent, exercise-induced anaphylaxis (FDEIAn). These reactions seem to be most prevalent in adolescents and young adults, although they can occur in middle aged patients as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26777?source=see_link&amp;anchor=H15#H15\">",
"     \"Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\", section on 'Diagnosis of food-dependent EIAn'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients react to one or two specific foods. Common causative foods include wheat, celery, and seafood. The food can be ingested in the absence of exercise without development of symptoms. Some patients react after eating any food prior to exercise. These patients also have no reactions in the absence of exertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     NON-IgE MEDIATED REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-IgE mediated food allergies present as more subacute",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic symptoms that are typically isolated to the gastrointestinal tract",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    skin. Affected patients commonly present with a characteristic constellation of clinical and demographic features that are consistent with well described disorders.",
"   </p>",
"   <p>",
"    The exclusive non-IgE mediated food allergy disorders principally include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Food protein-induced enterocolitis syndrome (entire gastrointestinal tract)",
"     </li>",
"     <li>",
"      Food protein-induced enteropathy (small bowel)",
"     </li>",
"     <li>",
"      Food protein-induced proctitis and proctocolitis (rectum and colon)",
"     </li>",
"     <li>",
"      Celiac disease and dermatitis herpetiformis",
"     </li>",
"     <li>",
"      Food-induced pulmonary hemosiderosis (Heiner's syndrome)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The manifestations of these disorders are discussed briefly here and reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3198928\">",
"    <span class=\"h2\">",
"     Gastrointestinal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of gastrointestinal signs and symptoms may vary in some disorders, depending upon whether the food is consumed regularly or infrequently. In addition, certain disorders are associated with systemic manifestations.",
"   </p>",
"   <p>",
"    Passage of blood-tinged stools and mucus in an otherwise healthy breastfed infant without an anal fissure is suggestive of food protein-induced",
"    <span class=\"nowrap\">",
"     proctitis/proctocolitis.",
"    </span>",
"    The most common trigger is cow&rsquo;s milk in the mother&rsquo;s diet. This disorder typically presents between two and eight weeks of age and resolves in a few days with complete elimination of the offending protein. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link&amp;anchor=H2#H2\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\", section on 'Food protein-induced proctitis/proctocolitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic vomiting and diarrhea, particularly if accompanied by failure to thrive, suggests disorders such as food protein-induced enteropathy, celiac disease, food protein-induced enterocolitis syndrome (FPIES), or an eosinophilic gastrointestinal disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/12/2250?source=see_link\">",
"     \"Food protein-induced enterocolitis syndrome (FPIES)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link\">",
"     \"Eosinophilic gastroenteritis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H19\">",
"     'Mixed IgE and non-IgE mediated reactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Infants with FPIES are generally sicker in appearance than those with other non-IgE mediated allergic gastrointestinal disorders and they may have grossly bloody diarrhea (melena). The vomiting can be severe and can lead to dehydration. Patients may also have malabsorption. Laboratory abnormalities include hypoalbuminemia, anemia, and leukocytosis. Symptoms of FPIES resolve upon elimination of the causative food, although this may take several weeks (the symptoms should start to improve in at least one month). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/12/2250?source=see_link\">",
"     \"Food protein-induced enterocolitis syndrome (FPIES)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the causative food is later reintroduced, there is a characteristic delayed onset (approximately two to four hours) of profuse vomiting, followed by return of the other signs and symptoms. Children can require emergency treatment for hypotension, lethargy, or shock in this setting and laboratory studies may show acidosis, methemoglobinemia, and an increase in neutrophils. The acute manifestations of FPIES can be clinically identical to IgE-mediated gastrointestinal anaphylaxis, therefore testing is usually necessary to determine if food-specific IgE is present. (See",
"    <a class=\"local\" href=\"#H3198815\">",
"     'Gastrointestinal symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Older children and adults with FPIES typically present with a milder syndrome of nausea, protracted vomiting, and cramping several hours after ingestion.",
"   </p>",
"   <p>",
"    FPIES is uncommon in exclusively breastfed infants. Cow&rsquo;s milk and soy are the most common triggers in infants and children, although many other food protein triggers have been reported. Shellfish is a common causative food in adults.",
"   </p>",
"   <p>",
"    Infants with food protein-induced enteropathy can present with findings similar to patients with FPIES who are regularly ingesting a causative food (eg, chronic vomiting and diarrhea, failure to thrive). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link&amp;anchor=H11#H11\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\", section on 'Food protein-induced enteropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Celiac disease, an enteropathy caused by gluten sensitivity, classically presents in infants and young children with chronic diarrhea, anorexia, abdominal distension and pain, failure to thrive or weight loss, and sometimes also vomiting. The gastrointestinal manifestations are similar in older children and adults, but usually milder and include steatorrhea, weight loss, and other signs of nutrient or vitamin deficiency due to malabsorption. Flatulence and steatorrhea are suggestive of celiac disease rather than other forms of food-protein-induced enteropathy or FPIES. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\", section on 'Gastrointestinal symptoms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link&amp;anchor=H23610802#H23610802\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Gastrointestinal manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3199405\">",
"    <span class=\"h2\">",
"     Skin manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary skin manifestation of exclusive non-IgE mediated food allergy is the vesicular eruption seen with dermatitis herpetiformis in patients with celiac disease. Dermatitis herpetiformis is characterized by an itchy papular vesicular eruption usually located symmetrically on the extensor surfaces of the elbows, knees, buttocks, sacrum, face, neck, trunk, and occasionally within the mouth (",
"    <a class=\"graphic graphic_picture graphicRef74915 graphicRef70783 \" href=\"UTD.htm?4/63/5111\">",
"     picture 1A-B",
"    </a>",
"    ). The predominant symptoms are itching and burning that are rapidly relieved with rupture of the blisters. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\", section on 'Dermatitis herpetiformis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Pulmonary manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary involvement is a rare manifestation of non-IgE mediated food allergy.",
"   </p>",
"   <p>",
"    Food-induced pulmonary hemosiderosis (Heiner's syndrome) is a rare syndrome in infants that consists of recurrent pneumonia with pulmonary infiltrates, hemosiderosis, iron deficiency anemia, and failure to thrive. Cow's milk is the most common causative food, with pork and egg also being reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14808/abstract/16\">",
"     16",
"    </a>",
"    ]. Elimination of the offending food results in resolution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29640?source=see_link&amp;anchor=H17#H17\">",
"     \"Milk allergy: Clinical features and diagnosis\", section on 'Heiner syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of Heiner's syndrome is unclear. Serum precipitins to cow's milk and peripheral eosinophilia are often seen, and deposits of immunoglobulins and C3 may be found on lung biopsy. Lymphocytes from patients show abnormal proliferative responses to milk proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14808/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coexistence of celiac disease and idiopathic pulmonary hemosiderosis, also known as Lane-Hamilton syndrome, has been reported in a number of cases. Idiopathic pulmonary hemosiderosis is a rare disease found primarily in children that causes recurrent episodes of diffuse alveolar hemorrhage that may eventually produce pulmonary hemosiderosis and fibrosis. Diffuse alveolar hemorrhage is characterized by hemoptysis, dyspnea, alveolar opacities on chest radiographs, and anemia. Introduction of a gluten-free diet has been associated with remission of pulmonary symptoms in several patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12089?source=see_link\">",
"     \"Idiopathic pulmonary hemosiderosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link&amp;anchor=H24#H24\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Idiopathic pulmonary hemosiderosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MIXED IgE AND NON-IgE MEDIATED REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some food allergy disorders can have both IgE and non-IgE mediated components. Similar to the exclusively non-IgE mediated food allergies, the mixed disorders are typically isolated to the gastrointestinal tract",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    skin.",
"   </p>",
"   <p>",
"    The mixed disorders primarily include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atopic dermatitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link\">",
"       \"Role of allergy in atopic dermatitis (eczema)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Eosinophilic esophagitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Eosinophilic gastroenteritis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link\">",
"       \"Eosinophilic gastroenteritis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Food allergies may exacerbate atopic dermatitis, especially in young children with more severe eczema. Ingestion of the offending food acutely is thought to cause a flare of the patient's atopic dermatitis (increased erythema and pruritus of eczematous lesions). The flare occurs within minutes to a few hours if the reaction is IgE-mediated, but may take hours to days if the reaction is non-IgE mediated. The patient has persistent lesions if the food is eaten chronically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following features characterize the relationship between atopic dermatitis and food [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14808/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The elimination of suspected food allergens frequently improves symptoms of atopic dermatitis within a few weeks",
"     </li>",
"     <li>",
"      Repeated exposure to suspect foods commonly exacerbates skin symptoms",
"     </li>",
"     <li>",
"      Eliminating foods to which an infant has demonstrable allergy can partially improve skin symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The eosinophilic gastrointestinal disorders are characterized by symptoms of postprandial gastrointestinal dysfunction accompanied by eosinophilic infiltration of various segments of the intestinal tract on biopsy. The pathophysiology of the eosinophilic gastrointestinal disorders is poorly understood. Many patients have evidence of allergic sensitivities to food",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    environmental allergens, but the causal role of these sensitivities is unclear.",
"   </p>",
"   <p>",
"    Eosinophilic esophagitis (EoE) should be suspected in patients of any age presenting with esophageal symptoms. Infants and young children may present with feeding disorders, whereas older children and adults present with dysphagia, vomiting, and abdominal pain. A history of food impaction is common, particularly in adolescents and adults. Failure to respond to antacids and antireflux therapies is an important aspect of the history. Many patients with EoE have other atopic diseases. The most commonly implicated foods in children are cow's milk, egg, soy, corn, wheat, and beef, and most patients with evidence of food sensitivity tested positive for multiple foods. Elimination or elemental diets result in clinical and histologic improvement in most. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Eosinophilic gastroenteritis can present at any age with abdominal pain, nausea, diarrhea, malabsorption, and weight loss. In infants, it may present as outlet obstruction with postprandial projectile vomiting. In adolescents and adults, it can mimic irritable bowel syndrome. Symptoms vary depending on the layer and portion of the gastrointestinal tract that is involved. Approximately one-half of patients have allergic disease, such as defined food sensitivities, asthma, eczema, or rhinitis. However, in contrast to eosinophilic esophagitis, avoidance of implicated foods in those with an allergic food history has limited or no clinical benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link\">",
"     \"Eosinophilic gastroenteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6555155\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of food allergy includes a variety of disorders resulting from nonimmunologic reactions to food. As a group, these types of adverse food reactions are far more common than food allergy. Examples include lactose intolerance, gastroesophageal reflux, and disorders resulting from anatomic and neurologic abnormalities, enzymatic deficiencies, metabolic diseases, toxins, gastrointestinal infections, and a host of other processes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14808/abstract/11,19-22\">",
"     11,19-22",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef51225 \" href=\"UTD.htm?7/26/7597\">",
"     table 1",
"    </a>",
"    ) (see related topic reviews).",
"   </p>",
"   <p>",
"    Allergic reactions to food additives are rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40681?source=see_link\">",
"     \"Allergic and asthmatic reactions to food additives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Migraine headache is another disorder that has not been linked to food allergy, although there are certain foods that can trigger migraines through nonallergic mechanisms due to their inherent chemical properties (eg, aromatic amine content) (",
"    <a class=\"graphic graphic_table graphicRef73282 \" href=\"UTD.htm?1/10/1195\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8600?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of migraine in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The full differential diagnosis of each of the specific disorders reviewed in this topic is discussed in the specific topics on each of those disorders (see related topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/27/35250?source=see_link\">",
"       \"Patient information: Food allergy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=see_link\">",
"       \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Food allergies arise from abnormal immunologic reactions to food proteins. Food allergies are broadly categorized into either IgE-mediated or non-IgE mediated processes. Some disorders have characteristics of both mechanisms. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IgE-mediated food allergy typically develops rapidly after food ingestion, ie, usually within minutes. Symptoms can affect one or more organ systems (",
"      <a class=\"graphic graphic_table graphicRef79448 \" href=\"UTD.htm?19/49/20251\">",
"       table 2",
"      </a>",
"      ). Isolated allergic rhinoconjunctivitis or asthma in response to foods is rare. Specific disorders include cutaneous reactions (urticaria, angioedema), anaphylaxis (including food-dependent exercise-induced anaphylaxis), and oral allergy syndrome. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'IgE-mediated reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-IgE mediated food allergies present as more subacute",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chronic symptoms, which are typically isolated to the gastrointestinal tract. The type of gastrointestinal signs and symptoms may vary in some disorders, depending upon whether the food is consumed regularly or infrequently. In addition, certain disorders are associated with systemic manifestations. Specific syndromes include food protein-induced enterocolitis, food protein-induced",
"      <span class=\"nowrap\">",
"       proctitis/proctocolitis,",
"      </span>",
"      celiac disease, and food-induced pulmonary hemosiderosis (Heiner's syndrome). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Non-IgE mediated reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both IgE and non-IgE mediated mechanisms can be involved in atopic dermatitis and eosinophilic gastrointestinal disorders. Food allergies may exacerbate atopic dermatitis, especially in young children with more severe eczema. Infants and young children with eosinophilic esophagitis may present with feeding disorders, whereas older children and adults present with dysphagia, vomiting, and abdominal pain. A history of food impaction is common, particularly in adolescents and adults. Eosinophilic gastroenteritis can present at any age with abdominal pain, nausea, diarrhea, malabsorption, and weight loss. In infants, it may present as outlet obstruction with postprandial projectile vomiting. In adolescents and adults, it can mimic irritable bowel syndrome. Symptoms vary depending on the layer and portion of the gastrointestinal tract that is involved. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Mixed IgE and non-IgE mediated reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of food allergy consists of a number of nonimmunologic food reactions and disorders (",
"      <a class=\"graphic graphic_table graphicRef51225 \" href=\"UTD.htm?7/26/7597\">",
"       table 1",
"      </a>",
"      ). In addition, each specific type of food allergy has an extensive differential diagnosis that includes disorders that are not related to food. (See",
"      <a class=\"local\" href=\"#H6555155\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/1\">",
"      NIAID-Sponsored Expert Panel, Boyce JA, Assa'ad A, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol 2010; 126:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/2\">",
"      Burks AW, Tang M, Sicherer S, et al. ICON: food allergy. J Allergy Clin Immunol 2012; 129:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/3\">",
"      Sehgal VN, Rege VL. An interrogative study of 158 urticaria patients. Ann Allergy 1973; 31:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/4\">",
"      Champion RH, Roberts SO, Carpenter RG, Roger JH. Urticaria and angio-oedema. A review of 554 patients. Br J Dermatol 1969; 81:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/5\">",
"      Jovanovic M, Oliwiecki S, Beck MH. Occupational contact urticaria from beef associated with hand eczema. Contact Dermatitis 1992; 27:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/6\">",
"      Delgado J, Castillo R, Quiralte J, et al. Contact urticaria in a child from raw potato. Contact Dermatitis 1996; 35:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/7\">",
"      Fisher AA. Contact urticaria from handling meats and fowl. Cutis 1982; 30:726, 729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/8\">",
"      Bock SA. Prospective appraisal of complaints of adverse reactions to foods in children during the first 3 years of life. Pediatrics 1987; 79:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/9\">",
"      Bock SA, Atkins FM. Patterns of food hypersensitivity during sixteen years of double-blind, placebo-controlled food challenges. J Pediatr 1990; 117:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/10\">",
"      Bock SA. Natural history of severe reactions to foods in young children. J Pediatr 1985; 107:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/11\">",
"      Bruijnzeel-Koomen C, Ortolani C, Aas K, et al. Adverse reactions to food. European Academy of Allergology and Clinical Immunology Subcommittee. Allergy 1995; 50:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/12\">",
"      Roberts G, Lack G. Relevance of inhalational exposure to food allergens. Curr Opin Allergy Clin Immunol 2003; 3:211.",
"     </a>",
"    </li>",
"    <li>",
"     Sampson HA. Adverse reactions to foods. In: Middleton's allergy: Principles and practice, 6th ed, Adkinson NF, Yunginger JW, Busse WW, et al (Eds), Mosby, St. Louis, MO 2003. p.1619.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/14\">",
"      Crowe SE, Perdue MH. Gastrointestinal food hypersensitivity: basic mechanisms of pathophysiology. Gastroenterology 1992; 103:1075.",
"     </a>",
"    </li>",
"    <li>",
"     Bush RK, Taylor SL, Hefle SL. Adverse reactions to food and drug additives. In: Middleton's allergy: Principles and practice, 6th ed, Adkinson NF, Yunginger JW, Busse WW, et al (Eds), Mosby, St. Louis, MO 2003. p.1645.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/16\">",
"      Lee SK, Kniker WT, Cook CD, Heiner DC. Cow's milk-induced pulmonary disease in children. Adv Pediatr 1978; 25:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/17\">",
"      Sicherer SH, Sampson HA. Food hypersensitivity and atopic dermatitis: pathophysiology, epidemiology, diagnosis, and management. J Allergy Clin Immunol 1999; 104:S114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/18\">",
"      Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: evaluation of 113 patients. J Pediatr 1985; 107:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/19\">",
"      Du Toit DF. Auriculo-temporal nerve. Clinicopathological relevance to facial-maxillary practice. SADJ 2003; 58:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/20\">",
"      Kaddu S, Smolle J, Komericki P, Kerl H. Auriculotemporal (Frey) syndrome in late childhood: an unusual variant presenting as gustatory flushing mimicking food allergy. Pediatr Dermatol 2000; 17:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/21\">",
"      Johnson IJ, Birchall JP. Bilatral auriculotemporal syndrome in childhood. Int J Pediatr Otorhinolaryngol 1995; 32:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14808/abstract/22\">",
"      Reese I, Ballmer-Weber B, Beyer K, et al. Vorgehen Bei Verdacht auf Unvertraglichkeit gegenuber oral aufgenommenem Histamin. Allergo J 2012; 21:22.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2398 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B3512DFB86-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_29_14808=[""].join("\n");
var outline_f14_29_14808=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IgE-MEDIATED REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Urticaria and angioedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6558107\">",
"      Oropharyngeal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Respiratory tract symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3198815\">",
"      Gastrointestinal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6556100\">",
"      - Food-dependent exercise-induced anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NON-IgE MEDIATED REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3198928\">",
"      Gastrointestinal manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3199405\">",
"      Skin manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Pulmonary manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MIXED IgE AND NON-IgE MEDIATED REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6555155\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2398\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2398|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/2/30753\" title=\"picture 1A\">",
"      Dermatitis herpetiformis AGA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/62/39905\" title=\"picture 1B\">",
"      Dermatitis herpetiformis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2398|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/26/7597\" title=\"table 1\">",
"      Differential dx food reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/49/20251\" title=\"table 2\">",
"      Manifestations of IgE rxns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/52/23371\" title=\"table 3\">",
"      Anaphylaxis signs symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/43/23228\" title=\"table 4\">",
"      Anaphylaxis diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/10/1195\" title=\"table 5\">",
"      Dietary triggers migraine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40681?source=related_link\">",
"      Allergic and asthmatic reactions to food additives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36072?source=related_link\">",
"      Allergy to meats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15641?source=related_link\">",
"      An overview of angioedema: Clinical features, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=related_link\">",
"      Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11082?source=related_link\">",
"      Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=related_link\">",
"      Eosinophilic gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26777?source=related_link\">",
"      Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/12/2250?source=related_link\">",
"      Food protein-induced enterocolitis syndrome (FPIES)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=related_link\">",
"      Food-induced anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=related_link\">",
"      History and physical examination in the patient with possible food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12089?source=related_link\">",
"      Idiopathic pulmonary hemosiderosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37430?source=related_link\">",
"      Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29640?source=related_link\">",
"      Milk allergy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8600?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of migraine in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/27/35250?source=related_link\">",
"      Patient information: Food allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=related_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38776?source=related_link\">",
"      Respiratory manifestations of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=related_link\">",
"      Role of allergy in atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=related_link\">",
"      The natural history of childhood food allergy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_29_14809="Personalized, genotype-directed therapy for advanced non-small cell lung cancer";
var content_f14_29_14809=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Personalized, genotype-directed therapy for advanced non-small cell lung cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/29/14809/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14809/contributors\">",
"     Lecia V Sequist, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14809/contributors\">",
"     Joel W Neal, MD,PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/29/14809/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14809/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/29/14809/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14809/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/29/14809/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H9880656\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for patients with metastatic non-small cell lung cancer (NSCLC) has historically consisted of systemic cytotoxic chemotherapy. Chemotherapy has a general goal of killing cells that are growing or dividing; chemotherapy reduces symptoms, improves quality of life, and prolongs survival in some patients with NSCLC. &nbsp;",
"   </p>",
"   <p>",
"    An improved understanding of the molecular pathways that drive malignancy in NSCLC, as well as other neoplasms, has led to the development of agents that target specific molecular pathways in malignant cells. &nbsp;The hope is that these agents will be able to preferentially kill malignant cells, but will be relatively innocuous to normal cells. Many established targeted therapies are administered as orally-available small molecule kinase inhibitors, but targeted therapy can also be administered intravenously in the form of monoclonal antibodies or small molecules.",
"   </p>",
"   <p>",
"    The identification of oncogenic activation of particular tyrosine kinases in some advanced NSCLC tumors, most notably mutations in the epidermal growth factor receptor (EGFR) or rearrangements of the anaplastic lymphoma kinase (ALK) gene, has led to a paradigm shift and the development of specific molecular treatments for patients. Furthermore, the identification of these patient subsets has led to an ongoing effort to identify biomarkers and treatments that can be used for other subsets of patients with advanced NSCLC. Research in this area and its potential applications to the clinical treatment of patients with NSCLC will be covered in this topic.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=see_link\">",
"       \"Overview of the treatment of advanced non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=see_link\">",
"       \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=see_link\">",
"       \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9880663\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most useful biomarkers for predicting the efficacy of targeted therapy in advanced NSCLC are somatic genome alterations known as &ldquo;driver mutations.&rdquo; These mutations occur in cancer cells within genes encoding for proteins critical to cell growth and survival. Many other recurrent molecular alterations have been identified in NSCLC that are much less essential to maintain the oncogenic phenotype, and are often referred to as &ldquo;passenger mutations&rdquo;. Driver mutations are typically not found in the germline (non-cancer) genome of the host and are usually mutually exclusive (ie, a cancer is unlikely to have more than one driver mutation) (",
"    <a class=\"graphic graphic_figure graphicRef86507 \" href=\"UTD.htm?27/50/28462\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Driver mutations are typically transformative, which means that they initiate the evolution of a non-cancerous cell to malignancy. In addition, driver mutations often impart an oncogene-addicted biology to the transformed cell, meaning that the mutated protein engenders reliance within the cancer cell to receive a signal from the driver in order to survive.",
"   </p>",
"   <p>",
"    An often used analogy is that a normally-functioning cell may have a particular switch in its circuitry which is sometimes turned on and sometimes turned off, but in general is regulated with feedback inhibition loops and specific stimulators. However, in an oncogene-addicted cancer cell, the switch is stuck in the on position all the time and is no longer subject to regulation.",
"   </p>",
"   <p>",
"    Oncogene-addiction tends to make driver mutations good biomarkers for selecting patients for targeted therapies. The extreme reliance of crucial downstream growth and survival pathways in the cell upon a single upstream signal that is &ldquo;stuck in the on position&rdquo; serves as an Achilles&rsquo; heel, making the cancer uniquely susceptible to down-regulation of signal originating from the driver (ie, unable to survive if a targeted drug essentially turns the switch to the off-position, because other mechanisms to keep downstream signals flowing are non-existent).",
"   </p>",
"   <p>",
"    In NSCLC, as well as with other malignancies, matching a specific targeted drug to the identified driver mutation for an individual patient has resulted in significantly improved therapeutic efficacy, often in conjunction with decreased toxicity. Screening for driver mutations thus has become an increasingly standard part of the diagnostic work-up for NSCLC, and the resultant information is useful in choosing between standard chemotherapy in the absence of a targetable driver mutation versus up-front targeted therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9880670\">",
"    <span class=\"h1\">",
"     MOLECULAR TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4850292\">",
"    <span class=\"h2\">",
"     Techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods for screening NSCLC patients for driver mutations and other abnormalities are continually evolving and there is no one standard platform for testing. In general, several techniques have been used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sequencing of the gene is the most comprehensive method for mutation testing. Direct sequencing can be used for discovery when the target abnormality is not known, but this process can be expensive and time-consuming. Furthermore, the mutation must be fairly prevalent among all the cells in the tissue sample in order to be detected by direct sequencing.",
"     </li>",
"     <li>",
"      Next-generation sequencing overcomes many of the shortcomings of direct sequencing. This massively parallel approach, relying heavily on automation, data storage, and computational processing, allows quantitative analysis of infrequent alleles and simultaneous evaluation of multiple genes or even whole genomes, but is not yet used routinely in clinical practice.",
"     </li>",
"     <li>",
"      Allele-specific testing analyzes the DNA for a pre-defined abnormality. The raw DNA is typically amplified using polymerase chain reactions (PCR) before the search for the mutated allele is undertaken, allowing for rare signals to be detected with greater sensitivity. This method tends to be faster and cheaper, but only pre-specified targets can be identified. Thus allele-specific testing cannot be used to identify new abnormalities.",
"     </li>",
"     <li>",
"      Mass spectrometry, a method that analyzes short bits of DNA by mass and can detect when a segment is a different molecular weight than expected, equating to a mutation. This method also can only identify pre-defined abnormalities.",
"     </li>",
"     <li>",
"      Fluorescence in-situ testing (FISH) is typically used to detect gene translocations, amplifications, and other rearrangements. With FISH, DNA probes are used to interrogate the chromosomes for the presence or absence of a specific DNA sequence. Following denaturation, a fluorescent labeled DNA probe is directly hybridized with the chromosomes on the slide (hence, the term \"in situ\" hybridization); immediate detection of the fluorescent signal is possible via fluorescence microscopy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link&amp;anchor=H15538631#H15538631\">",
"       \"Cytogenetic and molecular genetic diagnostic tools\", section on 'Fluorescence in situ hybridization'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Features of the various testing platforms that are most useful for clinical genotyping are those that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Utilize clinically-available samples (most commonly formalin-fixed, paraffin-embedded tissue)",
"     </li>",
"     <li>",
"      Are relatively inexpensive",
"     </li>",
"     <li>",
"      Have clinically-relevant turn-around times",
"     </li>",
"     <li>",
"      Are semi-automated so that they are not reliant upon a single operator",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4850299\">",
"    <span class=\"h2\">",
"     Multiplexed genotyping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiplexed genotype testing allows an entire panel of genotypes of interest to be queried at a single time from a single tissue sample instead of doing the tests sequentially one by one [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This is the most tissue-efficient approach, particularly when dealing with small tumor samples. In addition, multiplexed genotyping is the most time-efficient process for screening patients and thus to facilitate prompt treatment or protocol inclusion.",
"   </p>",
"   <p>",
"    The potential information that can be derived from multiplexed testing is illustrated by a paper reporting the clinical experience of genotyping 552 patients with NSCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/1\">",
"     1",
"    </a>",
"    ]. Tumors were analyzed for the presence of more than 50 mutations in several key NSCLC genes. One or more mutations were identified in 51 percent of patients. The most commonly involved genes were KRAS, EGFR, PIK3CA, and translocations involving ALK (24, 13, 4, and 5 percent, respectively).",
"   </p>",
"   <p>",
"    Screening for multiple genotype markers and using the data to guide therapeutic decisions in a coordinated fashion is being explored in a large multi-center effort called the Lung Cancer Mutation Consortium (LCMC). Thirteen cancer centers across the US have joined in this effort to make testing available for patients in their centers, including current targetable genotypes (EGFR, ALK, KRAS, MET, BRAF, PIK3CA, HER2, etc) and to have common clinical trials open across sites into which patients can be enrolled [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9880677\">",
"    <span class=\"h1\">",
"     NSCLC GENOTYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section reviews the most common driver mutations that have been identified in NSCLC for which targeted therapies specifically aimed at the driver mutation have been developed or are under investigation, as well as some frequently identified passenger alterations that may or may not be targetable.",
"   </p>",
"   <p>",
"    Targeted agents should be considered for patients with a tumor harboring one of these driver mutations. When there is no established therapy for a given driver mutation or when inclusion in a clinical trial is not feasible, patients should be managed with chemotherapy like those without a driver mutation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=see_link\">",
"     \"Overview of the treatment of advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3902134\">",
"    <span class=\"h2\">",
"     EGFR mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the EGFR tyrosine kinase are observed in approximately 15 percent of NSCLC adenocarcinoma in the United States and occur more frequently in nonsmokers. In advanced NSCLC, the presence of an EGFR mutation confers a more favorable prognosis and strongly predicts for sensitivity to EGFR tyrosine kinase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The use of EGFR tyrosine kinase inhibitors is based upon the detection of these mutations. A discussion of the diagnosis and treatment EGFR-mutant NSCLC is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=see_link\">",
"     \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3902141\">",
"    <span class=\"h2\">",
"     ALK translocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Translocations involving the ALK tyrosine kinase are present in approximately 4 percent of NSCLC adenocarcinoma in the United States and occur more frequently in nonsmokers and younger patients.",
"   </p>",
"   <p>",
"    In advanced stage NSCLC, the presence of an ALK translocation strongly predicts for sensitivity to ALK tyrosine kinase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=see_link\">",
"     crizotinib",
"    </a>",
"    , and treatment with crizotinib significantly prolongs progression-free survival. The diagnosis and treatment of ALK-positive NSCLC is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=see_link\">",
"     \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9880686\">",
"    <span class=\"h2\">",
"     RAS mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RAS family of oncogenes was originally identified through the study of rat sarcoma(ras)-inducing retrovirus, with KRAS, NRAS, and HRAS each representing different human gene homologs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/3\">",
"     3",
"    </a>",
"    ]. As a membrane-bound intracellular GTP-ase, the RAS family of proteins is a central mediator of the mitogen-activated protein kinase (MAPK) (",
"    <a class=\"graphic graphic_figure graphicRef53134 \" href=\"UTD.htm?41/46/42724\">",
"     figure 2",
"    </a>",
"    ), signal transducer and activator of transcription (STAT), and phosphoinositide 3-kinase (PI3K) signaling pathways, which together control cell proliferation and apoptosis.",
"   </p>",
"   <p>",
"    Oncogenic RAS mutations, most commonly those corresponding to missense substitutions in codons 12 and 13, cause constitutive activity of RAS independent of upstream signals by impairing the function of the RAS GTPase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4850342\">",
"    <span class=\"h3\">",
"     Frequency of mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activating KRAS mutations are observed in approximately 20 to 25 percent of lung adenocarcinomas in the United States and are generally associated with a history of smoking:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a study of 106 patients with adenocarcinoma of the lung, KRAS mutations were noted in exclusively in smokers (43 percent versus zero) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In another series of 482 lung adenocarcinomas sequenced for KRAS mutations, transversion mutations (G-&gt;T or G-&gt;C) were more common in patients with a smoking history (22 percent) while transition mutations (G-&gt;A) were found in 15 percent of patients with lung adenocarcinoma who have never smoked cigarettes [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    NRAS is homologous to KRAS, associated with smoking, and mutations have been observed in approximately 1 percent of NSCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/1\">",
"     1",
"    </a>",
"    ]. The clinical significance of NRAS mutations is unclear, and no effective targeted therapies have been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4850349\">",
"    <span class=\"h3\">",
"     Impact on prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a KRAS mutation may confer a poorer prognosis than is seen with other NSCLCs, although this has not been uniformly observed in all studies.",
"   </p>",
"   <p>",
"    In patients with early stage NSCLC, a 2005 meta-analysis of 28 studies found shorter survival among patients with KRAS mutated adenocarcinoma as detected by PCR sequencing compared with those without KRAS mutation (hazard ratio 1.50, 95% CI 1.26-1.80) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, in the phase III JBR.10 study of adjuvant chemotherapy, 117 patients with KRAS mutations did not have a difference in survival compared with 333 patients without mutations, regardless of treatment arm [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/7\">",
"     7",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In patients with stage IV NSCLC, the presence of a KRAS mutation appears to be associated with a worse prognosis. However, the interpretation of these results is complicated by the heterogeneity of the comparison group, which includes patients with EGFR mutations that are known to have a better prognosis, as well as treatment arms that include EGFR TKIs, to which KRAS patients may not respond.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the phase III SATURN trial of maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      , KRAS mutation conferred a shorter time to progression than wild-type patients (HR 1.50, 95% CI 1.06 to 2.12) among the 239 patients on the placebo arm. However, the difference in overall survival was not statistically significant (HR 1.30, 95% CI 0.90 to 1.90). [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/8\">",
"       8",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      In a retrospective series of 1036 patients, multivariate analysis demonstrated that the presence of a KRAS mutation was associated with shorter survival (HR 1.21, P = 0.048), while EGFR mutation was associated with longer survival (HR 0.6, p&lt;0.001) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4850356\">",
"    <span class=\"h3\">",
"     Effect on response to therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;KRAS mutations have been associated with response or resistance to particular therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EGFR tyrosine kinase inhibitors &ndash; There are conflicting data regarding sensitivity of KRAS mutant tumors to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      . In the phase III TRIBUTE trial, among 55 patients with KRAS mutations, those treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      chemotherapy had a response rate of 23 percent while those treated with chemotherapy plus erlotinib had a response rate of 8 percent, and a worse overall survival (HR 2.1) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/10\">",
"       10",
"      </a>",
"      ]. In the phase III SATURN trial, subgroup analysis of 90 patients with KRAS mutations showed a marginal trend toward benefit from maintenance erlotinib, with wide confidence intervals (HR 0.77, 95% CI 0.50 to 1.19) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/8\">",
"       8",
"      </a>",
"      ]. In the 2",
"      <sup>",
"       nd",
"      </sup>",
"      line BR.21 trial of erlotinib versus placebo, those who were KRAS wild-type had a survival benefit from erlotinib (HR = 0.69, p = 0.03) but those with KRAS mutations did not (HR = 1.67, p = 0.31) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      KRAS mutations confer resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      in patients with colorectal cancer. However, in subgroup analyses of the phase III FLEX and BMS099 clinical trials in NSCLC, the response to cetuximab was preserved among 75 and 202 patients with KRAS mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      KRAS mutations may sensitize tumors to antifolates [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/14,15\">",
"       14,15",
"      </a>",
"      ] such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      , possibly by upregulation of mir-181c, a micro RNA that can downregulate KRAS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10952586\">",
"    <span class=\"h3\">",
"     Targeted therapy for KRAS-mutated lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple efforts to identify specific RAS inhibitors that are clinically useful against KRAS-mutated lung cancer have been unsuccessful. Approaches tested include farnesyl protein transferase and RNA inhibition.",
"   </p>",
"   <p>",
"    The current focus of targeted therapeutics for patients with KRAS-mutated lung cancer is against downstream effectors of activated KRAS. This approach is promising in KRAS mutant lung cancer, as demonstrated by an experiment in mice harboring KRAS mutant tumors whose tumors were markedly reduced following treatment with the combination of MEK and PI3K small molecule inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence supporting targeted therapy against downstream targets comes from several studies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      MEK inhibition &ndash; In a phase II trial, 87 previously treated patients with KRAS mutant NSCLC were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      with or without selumetinib, an oral MEK inhibitor (",
"      <a class=\"graphic graphic_figure graphicRef53134 \" href=\"UTD.htm?41/46/42724\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/17\">",
"       17",
"      </a>",
"      ]. The addition of selumetinib significantly improved progression-free survival (median 5.3 mo versus 2.1 mo, HR 0.58 80% CI 0.42-0.79), and there was a trend toward increased overall survival (median 9.4 mo versus 5.2 mo, HR 0.80, 80% CI 0.56 &ndash; 1.14). Objective partial responses were observed in 16 of 43 patients (37 percent) treated with docetaxel plus selumetinib compared with none of 40 receiving docetaxel plus placebo. However, toxicity was also greater with more febrile neutropenia, diarrhea, nausea, vomiting, and rash. Selumetinib is being further investigated in a randomized phase II clinical trial (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01229150?term=NCT01229150&amp;rank=1\">",
"       NCT01229150",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      A parallel pre-clinical study using genetically engineered mice found that KRAS-only mutant tumors were very sensitive to the combination of selumetinib and docetaxel, while tumors with KRAS and p53 alteration were of intermediate sensitivity, and KRAS plus LKB1 mutations were resistant to treatment. These results suggest that KRAS mutant tumors may be heterogenous with the efficacy of targeted treatment dependent upon the &ldquo;passenger&rdquo; mutation context.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective subgroup analysis of another phase II clinical trial with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      with or without tivantinib (a MET tyrosine kinase inhibitor) suggested preferential progression-free survival benefit among 10 patients with KRAS mutant tumors who received the combination therapy (HR 0.18, 95% CI 0.05-0.70) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9880756\">",
"       'MET expression'",
"      </a>",
"      below.) While a randomized phase III trial comparing erlotinib plus placebo to erlotinib plus tivantinib is being conducted in non-genotype-selected previously treated NSCLC patients (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01377376?term=lung+cancer+and+tivantinib+and+erlotinib&amp;rank=7\">",
"       NCT01377376",
"      </a>",
"      ), a separate randomized phase II study is following up on the KRAS subgroup findings, comparing erlotinib plus tivantinib to standard chemotherapy (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01395758?term=NCT01395758&amp;rank=1\">",
"       NCT01395758",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The MAPK pathway is activated by KRAS mutations. Indirect evidence supporting the inhibition of this pathway comes from patients with metastatic melanoma and BRAF mutations, which also activates MAPK signaling. In that setting, the oral downstream MEK tyrosine kinase inhibitor trametinib significantly prolongs progression-free and overall survival [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/19\">",
"       19",
"      </a>",
"      ]. A phase II trial in patients with NSCLC is in progress (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01362296?term=NCT01362296&amp;rank=1\">",
"       NCT01362296",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      KRAS mutant NSCLC may also be dependent on downstream mTOR signaling pathways. A randomized discontinuation clinical trial evaluating the mTOR inhibitor ridaforolimus in 79 patients with NSCLC demonstrated a response rate of 1 percent, but demonstrated doubling of progression-free survival for patients with stable disease at 8 weeks randomized to continue drug versus those randomized to discontinue (4 mo. versus 2 mo., HR 0.36, p = 0.013,), and also showed a trend toward overall survival improvement (18 mo. versus 5 mo., HR 0.46, p = 0.09) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients unable to participate in a clinical trial, the current treatment recommendations for KRAS-mutant NSCLC are identical to that of NSCLC adenocarcinoma of unknown mutation status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9880735\">",
"    <span class=\"h2\">",
"     ROS1 translocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;ROS1 is a receptor tyrosine kinase of the insulin receptor family that acts as a driver oncogene in 1 to 2 percent of NSCLC via a genetic translocation between ROS1 and the partners CD74, SLC24A2, or FIG [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Histologic and clinical features that are associated with ROS1 translocations include adenocarcinoma histology, younger patients, and never-smokers. ROS1 translocations are identified by a FISH break-apart assay similar to that used for ALK translocations.",
"   </p>",
"   <p>",
"    The ROS1 tyrosine kinase is highly sensitive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=see_link\">",
"     crizotinib",
"    </a>",
"    in preclinical models, due to a high degree of homology between the ALK and ROS tyrosine kinase domains. There is case report level evidence of patients with ROS1 positive NSCLC responding to crizotinib [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/21\">",
"     21",
"    </a>",
"    ]. The dose expansion cohort of the crizotinib phase I trial was expanded to include patients with ROS1; in a preliminary report of 14 patients treated on this trial, 8 (57 percent) had an objective response following treatment with crizotinib, with the vast majority of patients having some degree of clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An open label, international study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=see_link\">",
"     crizotinib",
"    </a>",
"    is in progress for patients whose tumor contains the ROS1 translocation (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT00585195?term=NCT00585195&amp;rank=1\">",
"     NCT00585195",
"    </a>",
"    ). We recommend treatment with crizotinib for patients with the ROS1 translocation whenever possible. Other novel ALK inhibitors under development are also being tested for activity in ROS1 patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9880742\">",
"    <span class=\"h2\">",
"     HER2 mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;HER2 (ERBB2) is an EGFR family receptor tyrosine kinase. Mutations in HER2 have been detected in approximately 1 percent of NSCLC tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/25\">",
"     25",
"    </a>",
"    ]. They usually involve small in-frame insertions in exon 20, but point mutations in exon 20 have also been observed. They are more prevalent among never-smokers but there is no clear association with other clinical features. Nor is there an obvious association between HER2 amplification and HER2 mutations, and previous trials demonstrated no benefit for trastuzumab in HER2 amplified NSCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are anecdotal clinical reports of patients with tumors harboring HER2 insertions responding to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/28\">",
"     28",
"    </a>",
"    ] and to the investigational agent afatinib, an",
"    <span class=\"nowrap\">",
"     EGFR/HER2",
"    </span>",
"    tyrosine kinase inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/29\">",
"     29",
"    </a>",
"    ]. Larger clinical trials are ongoing to further define efficacy of these classes of agents in this lung cancer subtype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9880749\">",
"    <span class=\"h2\">",
"     BRAF mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;BRAF is a downstream signaling mediator of KRAS which activates the MAP kinase pathway. BRAF mutations have been observed in 1 to 3 percent of NSCLC and are usually associated with a history of smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/1,30\">",
"     1,30",
"    </a>",
"    ]. Activating BRAF mutations can occur either at the V600 position of exon 15, like in melanoma, or outside this domain. BRAF mutations have also been described as a resistance mechanism in EGFR mutation positive NSCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are case reports of a patient with V600E BRAF NSCLC responding to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/32\">",
"     32",
"    </a>",
"    ], and a patient with Y472C BRAF mutation having a durable 4 year response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/33\">",
"     33",
"    </a>",
"    ]. The BRAF inhibitor dabrafenib is being evaluated in a phase II study of patients with NSCLC containing the BRAF V600E mutation (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01336634?term=01336634&amp;rank=1\">",
"     NCT01336634",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other strategies include the use of downstream MEK tyrosine kinase inhibitors for this molecular subgroup of patients (",
"    <a class=\"graphic graphic_figure graphicRef53134 \" href=\"UTD.htm?41/46/42724\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H10952586\">",
"     'Targeted therapy for KRAS-mutated lung cancer'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9880756\">",
"    <span class=\"h2\">",
"     MET expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;MET is a tyrosine kinase receptor for hepatocyte growth factor (HGF). While MET mutations are quite infrequent and of unknown clinical significance in NSCLC, increased MET expression detected by immunohistochemistry, gene expression analysis, or FISH (due to gene amplification or other regulatory mechanisms) occurs in about 25 to 75 percent of NSCLC and has been associated with poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of MET inhibitors are being tested in NSCLC.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The relatively specific MET tyrosine kinase inhibitor tivantinib demonstrated a trend toward improvement in progression free survival in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      as compared with erlotinib alone in a randomized phase II trial [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/18\">",
"       18",
"      </a>",
"      ]. A phase III trial comparing erlotinib plus tivantinib with erlotinib plus placebo has been completed and results are awaited (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01244191?term=NCT01244191&amp;rank=1\">",
"       NCT01244191",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A phase II trial of onartuzumab, a monovalent antibody fragment against the MET receptor, underscored the poor prognostic value of MET in NSCLC, but the addition of onartuzumab to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      improved both progression-free and overall survival in patients with MET immunohistochemistry positive tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/36\">",
"       36",
"      </a>",
"      ]. An ongoing phase III trial is comparing erlotinib plus onartuzumab versus erlotinib plus placebo (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01456325?term=01456325&amp;rank=1\">",
"       NCT01456325",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In addition to blocking ALK and ROS1,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=see_link\">",
"       crizotinib",
"      </a>",
"      is also a potent MET inhibitor and there is case-report level evidence that strong responses can occur in MET-amplified NSCLC patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/37\">",
"       37",
"      </a>",
"      ]. Several centers in the US have a clinical trial of crizotinib open for MET-amplified patients (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT00585195?term=NCT00585195&amp;rank=1\">",
"       NCT00585195",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9880763\">",
"    <span class=\"h2\">",
"     PIK3CA, AKT1, PTEN alterations",
"    </span>",
"    &nbsp;&mdash;&nbsp;PIK3CA encodes the catalytic subunit of phosphatidyl 3-kinase (PI3K), which is an intracellular central mediator of cell survival signals. AKT1 acts immediately downstream of PI3K. PTEN inhibits AKT by dephosphorylation. Oncogenic alterations in this pathway include gain-of-function mutations in PIK3CA and AKT1, and loss of PTEN function. Alterations in the PI3K signaling pathway appear more frequently in tumors of squamous histology and smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series of 552 samples tested for a spectrum of point mutations, gain-of-function mutations in PIK3CA were found in 4 percent of NSCLC, including both adenocarcinoma and squamous cell histologies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/1\">",
"     1",
"    </a>",
"    ]. No AKT mutations were observed in this series, but AKT1 activating mutations have been previously described in",
"    <span class=\"nowrap\">",
"     3/50",
"    </span>",
"    specimens of squamous histology [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In recent analyses of squamous NSCLC tumors, alterations in the PI3K signaling pathway were relatively frequent:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a series of 178 squamous tumor samples analyzed by The Cancer Genome Atlas (TCGA) using a variety of complementary methods, PIK3CA mutations were observed in 16 percent of the samples, PTEN mutations or deletions in 15 percent and AKT alterations in 20 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In another series of 95 surgically resected squamous lung cancers, PIK3CA mutations were observed in 4 percent of tumors, and AKT1 mutation in 1 tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In advanced stage patients, a series of 27 tumors demonstrated PTEN loss by immunohistochemistry in 3 (11 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PIK3CA mutations also may promote resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant NSCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Small molecule inhibitors of PI3Kinase and AKT are in clinical development and hold particular hope for the treatment of squamous cell lung cancer. However, since these alterations often overlap with other molecular changes, they may represent a &ldquo;passenger&rdquo; mutation rather than a &ldquo;driver&rdquo; alteration, therefore clinical efficacy of these agents against specific molecular alterations is unknown. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9880770\">",
"    <span class=\"h2\">",
"     FGFR1 amplification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibroblast growth factor receptor-1 (FGFR1) is a cell surface tyrosine kinase receptor that mediates cell survival and proliferation. Gene amplification of FGFR1 has been detected in 13 to 25 percent of squamous tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/42,44,46-48\">",
"     42,44,46-48",
"    </a>",
"    ]. For patients with squamous cell carcinomas, FGFR1 amplification is associated with smoking and with worse overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Small molecule inhibitors of FGFR1 are in clinical development and a case report of a NSCLC patient with tumor regression in response to the FGFR small molecule tyrosine kinase inhibitor BGJ398 has been presented [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9880777\">",
"    <span class=\"h2\">",
"     &beta;-catenin mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CTNNB1 gene encodes &beta;-catenin, which in conjunction with the APC protein is important for the regulation of epithelial cell growth. Mutations in this gene have been observed in approximately 2 percent of NSCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/1\">",
"     1",
"    </a>",
"    ], particularly in tumors with EGFR mutations following acquired resistance to EGFR inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/45\">",
"     45",
"    </a>",
"    ]. As these alterations are most often observed in conjunction with another driver mutation, a therapeutic strategy targeting &beta;-catenin is of uncertain benefit. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9880784\">",
"    <span class=\"h2\">",
"     RET translocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RET gene encodes a cell surface tyrosine kinase receptor that is frequently altered in medullary thyroid cancer. Recurrent translocations between RET and the various fusion partners (CCDC6, KIF5B, NCOA4) have been identified in approximately 1 percent of patients with adenocarcinoma or adenosquamous carcinoma of the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. In a series of 13 cases, those with a RET translocation tended to be younger and never smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/42/17063?source=see_link\">",
"     Vandetanib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    all inhibit the RET tyrosine kinase, as well as other targets. Large clinical trials in unselected NSCLC patient populations have been conducted with these agents and did not demonstrate a survival benefit. However, trials in patients with tumors know to contain a RET translocation are required and there currently are no reports of response information from individual patients with RET translocations. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9880791\">",
"    <span class=\"h2\">",
"     DDR2 mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DDR2 gene encodes a cell surface receptor tyrosine kinase that is mutated to an active form in about 4 percent of squamous cell carcinomas of the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/42,53\">",
"     42,53",
"    </a>",
"    ]. Dasatinib inhibits DDR2, and one patient treated with the combination of dasatinib and erlotinib had a tumor response [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/53\">",
"     53",
"    </a>",
"    ]. Clinical trials to confirm efficacy are underway. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9880798\">",
"    <span class=\"h2\">",
"     MEK1 mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MAP2K1 gene encodes the MEK1 protein, which is downstream of RAF in the MAP kinase pathway, a central mediator of cell proliferation signals. MAP2K1 mutations may be found in approximately 1 percent of adenocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14809/abstract/54\">",
"     54",
"    </a>",
"    ]. The clinical response of MAP2K1 mutant NSCLC to MEK or ERK inhibitors is an area of investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4850848\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An improved understanding of the molecular pathways that drive malignancy in non-small cell lung cancer (NSCLC) has led to the development of agents that specifically target differences between normal and malignant cell.",
"     </li>",
"     <li>",
"      The most useful biomarkers for predicting the efficacy of targeted therapy in advanced NSCLC are somatic genome alterations known as &ldquo;driver mutations.&rdquo; These mutations occur in the genome of cancer cells within genes that encoding for proteins critical to cell growth and survival. Driver mutations often impart an oncogene-addicted biology to the transformed cell, meaning that the mutated protein engenders reliance within the cancer cell to receive a signal from the driver in order to survive. (See",
"      <a class=\"local\" href=\"#H9880663\">",
"       'Rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best characterized of these biomarkers are EGFR mutations and ALK translocation. Identification of these biomarkers has led to highly specific treatments that have resulted in a major advance in therapy for tumors harboring these abnormalities.",
"     </li>",
"     <li>",
"      The improved results using targeted therapy in patients with these specific molecular abnormalities has led to an effort to identify other driver mutations and specific therapies appropriate for each driver mutation. (See",
"      <a class=\"local\" href=\"#H9880677\">",
"       'NSCLC genotypes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/1\">",
"      Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011; 22:2616.",
"     </a>",
"    </li>",
"    <li>",
"     Kris MG, Johnson BE, Kwiastkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI&rsquo;s Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 29: 2011 (suppl; abstract #CRA7506).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/3\">",
"      Kirsten WH, Mayer LA. Morphologic responses to a murine erythroblastosis virus. J Natl Cancer Inst 1967; 39:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/4\">",
"      Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001; 92:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/5\">",
"      Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008; 14:5731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/6\">",
"      Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005; 92:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/7\">",
"      Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007; 25:5240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/8\">",
"      Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:4113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/9\">",
"      Johnson ML, Sima CS, Chaft J, et al. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer 2013; 119:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/10\">",
"      Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23:5900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/11\">",
"      Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26:4268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/12\">",
"      O'Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011; 12:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/13\">",
"      Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/14\">",
"      Nunez MI, Behrens C, Woods DM, et al. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol 2012; 7:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/15\">",
"      Bacus S. KRAS mutation and amplification status predicts sensitivity to antifolate therapies in non-small cell lung cancer. Mol Cancer Ther 2011; 10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/16\">",
"      Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/17\">",
"      J&auml;nne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013; 14:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/18\">",
"      Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011; 29:3307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/19\">",
"      Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/20\">",
"      Riely GJ, Brahmer JR, Planchard D, et al. A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations (abstract #7531). J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/21\">",
"      Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/22\">",
"      Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 2012; 18:4449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/23\">",
"      Chin LP, Soo RA, Soong R, Ou SH. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol 2012; 7:1625.",
"     </a>",
"    </li>",
"    <li>",
"     Shaw AT, Camidge DR, Engelman JA, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol 30, 2012 (suppl; abstr 7508).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/25\">",
"      Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012; 18:4910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/26\">",
"      Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004; 15:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/27\">",
"      Zinner RG, Glisson BS, Fossella FV, et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 2004; 44:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/28\">",
"      Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006; 354:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/29\">",
"      De Gr&egrave;ve J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 2012; 76:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/30\">",
"      Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011; 29:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/31\">",
"      Ohashi K, Sequist LV, Arcila ME, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 2012; 109:E2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/32\">",
"      Gautschi O, Pauli C, Strobel K, et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 2012; 7:e23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/33\">",
"      Sen B, Peng S, Tang X, et al. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med 2012; 4:136ra70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/34\">",
"      Ichimura E, Maeshima A, Nakajima T, Nakamura T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996; 87:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/35\">",
"      Nakamura Y, Niki T, Goto A, et al. c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci 2007; 98:1006.",
"     </a>",
"    </li>",
"    <li>",
"     Spigel DR, Ervin TJ, Ramlau R, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 29: 2011 (suppl; abstr 7505).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/37\">",
"      Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011; 6:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/38\">",
"      Lee SY, Kim MJ, Jin G, et al. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol 2010; 5:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/39\">",
"      Jin G, Kim MJ, Jeon HS, et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 2010; 69:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/40\">",
"      Do H, Solomon B, Mitchell PL, et al. Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes 2008; 1:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/41\">",
"      Malanga D, Scrima M, De Marco C, et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 2008; 7:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/42\">",
"      Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/43\">",
"      Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012; 18:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/44\">",
"      Paik PK, Hasanovic A, Wang L. Multiplex testing for driver mutations in squamous cell carcinomas of the lung. J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/45\">",
"      Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3:75ra26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/46\">",
"      Heist RS, Sequist LV, Engelman JA. Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol 2012; 7:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/47\">",
"      Heist RS, Mino-Kenudson M, Sequist LV, et al. FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol 2012; 7:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/48\">",
"      Kim HR, Kim DJ, Kang DR, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol 2013; 31:731.",
"     </a>",
"    </li>",
"    <li>",
"     Wolf J, LoRusso PM, Camidge RD, et al. A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-122.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/50\">",
"      Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012; 18:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/51\">",
"      Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012; 18:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/52\">",
"      Wang R, Hu H, Pan Y, et al. RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non-Small-Cell Lung Cancer. J Clin Oncol 2012; 30:4352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/53\">",
"      Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011; 1:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14809/abstract/54\">",
"      Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 2008; 68:5524.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16538 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_29_14809=[""].join("\n");
var outline_f14_29_14809=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4850848\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9880656\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9880663\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9880670\">",
"      MOLECULAR TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4850292\">",
"      Techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4850299\">",
"      Multiplexed genotyping",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9880677\">",
"      NSCLC GENOTYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3902134\">",
"      EGFR mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3902141\">",
"      ALK translocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9880686\">",
"      RAS mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4850342\">",
"      - Frequency of mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4850349\">",
"      - Impact on prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4850356\">",
"      - Effect on response to therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10952586\">",
"      - Targeted therapy for KRAS-mutated lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9880735\">",
"      ROS1 translocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9880742\">",
"      HER2 mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9880749\">",
"      BRAF mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9880756\">",
"      MET expression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9880763\">",
"      PIK3CA, AKT1, PTEN alterations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9880770\">",
"      FGFR1 amplification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9880777\">",
"      &beta;-catenin mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9880784\">",
"      RET translocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9880791\">",
"      DDR2 mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9880798\">",
"      MEK1 mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4850848\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16538\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16538|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/50/28462\" title=\"figure 1\">",
"      Molecular targets in NSCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/46/42724\" title=\"figure 2\">",
"      MAP kinase pathway",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=related_link\">",
"      Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=related_link\">",
"      Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=related_link\">",
"      Overview of the treatment of advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_29_14810="Overview of the treatment of endometriosis";
var content_f14_29_14810=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the treatment of endometriosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/29/14810/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14810/contributors\">",
"     Robert S Schenken, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/29/14810/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14810/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/29/14810/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/29/14810/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/29/14810/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the Practice Committee of the American Society for Reproductive Medicine, &ldquo;endometriosis should be viewed as a chronic disease that requires a life-long management plan with the goal of maximizing the use of medical treatment and avoiding repeated surgical procedures&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/1\">",
"     1",
"    </a>",
"    ]. Despite extensive research, the optimal management of endometriosis is unclear. This topic will review medical and surgical options for treating women with this disease. Clinical features and diagnosis of endometriosis, as well as management of thoracic endometriosis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25254?source=see_link\">",
"     \"Thoracic endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of endometriosis fall into three general categories: pelvic pain, infertility, and pelvic mass. The goal of therapy is to relieve these symptoms. There is no high quality evidence that one medical therapy is superior to another for managing pelvic pain due to endometriosis, or that any type of medical treatment will affect future fertility. Therefore, treatment decisions are individualized, taking into account the severity of symptoms, the extent and location of disease, whether there is a desire for pregnancy, the age of the patient, medication side effects, surgical complication rates, and cost.",
"   </p>",
"   <p>",
"    Treatment options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expectant management",
"     </li>",
"     <li>",
"      Analgesia",
"     </li>",
"     <li>",
"      Hormonal medical therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Estrogen-progestin oral contraceptives, cyclic or continuous",
"     </li>",
"     <li>",
"      Gonadotropin-releasing hormone (GnRH) agonists",
"     </li>",
"     <li>",
"      Progestins, given by an oral, parenteral, or intrauterine route",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       Danazol",
"      </a>",
"     </li>",
"     <li>",
"      Aromatase inhibitors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical intervention, which may be conservative (retain uterus and ovarian tissue) or definitive (removal of the uterus and possibly the ovaries)",
"     </li>",
"     <li>",
"      Combination therapy in which medical therapy is given before",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      after surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laparoscopy is the gold standard for establishing the diagnosis of endometriosis, and provides an opportunity for conservative surgical treatment. Therapeutic intervention is desirable at the time of diagnosis to ablate or excise implants and adhesions, thus potentially preventing or delaying disease or symptom progression. Early surgical therapy also avoids the expense and side effects of medical therapy. Potential disadvantages include inadvertent damage to adjacent organs (especially the bowel and bladder), postoperative infectious complications, and mechanical trauma to pelvic structures that may result in greater adhesion formation (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Conservative surgery'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    After the initial diagnostic procedure, expectant management is considered primarily for two groups of patients: women with no or minimal symptoms and perimenopausal women. Although relief of symptoms is not as important for asymptomatic or minimally symptomatic women, these patients may benefit from therapy to retard progression of the disease because studies suggest that endometriosis is a progressive disease in most women [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/2\">",
"     2",
"    </a>",
"    ]. While most studies suggest that oral estrogen-progestin contraceptives reduce the incidence of endometriosis, some suggest no effect or a slight increase [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After menopause, endometriotic implant growth is suppressed as a result of markedly reduced ovarian estrogen production. Therefore, perimenopausal women with tolerable symptoms may opt for expectant management until menopause to avoid the side effects and cost of treatment. Alternatively, analgesia with nonsteroidal antiinflammatory drugs (NSAIDs) may provide acceptable results over the short-term. Young women with significant symptoms generally require more aggressive medical or surgical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT OF PELVIC PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with pelvic pain and suspected endometriosis may be managed with empiric medical therapy prior to establishing a definitive diagnosis by laparoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. We generally suggest analgesics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    combined oral estrogen-progestin contraceptives for women with no more than mild pelvic pain and a GnRH agonist for those with moderate to severe pelvic pain. The advantages and disadvantages of medical therapy of pelvic pain in women with endometriosis are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef69477 \" href=\"UTD.htm?11/58/12203\">",
"     table 1",
"    </a>",
"    ). Although 80 to 90 percent of patients will have some improvement in symptoms with medical therapy, medical interventions neither enhance fertility nor diminish endometriomas or adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Therefore, women with suspected endometriomas and advanced stages of disease, or infertility, are more appropriately managed surgically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Initial approach",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no large randomized trials evaluating the use of any analgesic for treatment of pain in women with endometriosis. In observational studies, the efficacy of analgesics was limited to pain that was no more than minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/8\">",
"     8",
"    </a>",
"    ]. Although NSAIDs are commonly used for analgesia, there are no high quality data showing that they are effective for managing pain due to endometriosis or more effective than other agents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/11\">",
"     11",
"    </a>",
"    ]. Use of NSAIDs is based on their ready availability, low cost, acceptable side effect profile, and evidence from randomized clinical trials consistently demonstrating that they are effective treatment of primary dysmenorrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28233?source=see_link\">",
"     \"Treatment of primary dysmenorrhea in adult women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Estrogen-progestin oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen-progestin oral contraceptives (OCs) are a good choice for women with minimal or mild pain who also want to prevent pregnancy. An advantage of OCs over most other hormonal interventions is that they can be taken indefinitely.",
"   </p>",
"   <p>",
"    A placebo-controlled randomized trial demonstrated that use of OCs is effective for relief of dysmenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/12\">",
"     12",
"    </a>",
"    ]. OCs may also retard progression of disease, but evidence is conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/3-5,12-17\">",
"     3-5,12-17",
"    </a>",
"    ]. The purported therapeutic mechanism is decidualization and subsequent atrophy of endometrial tissue, including ectopic endometrial tissue.",
"   </p>",
"   <p>",
"    Cyclic OCs may not be as effective as GnRH agonists. The only randomized trial that directly compared a low-dose cyclic OC to a GnRH agonist (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"     goserelin",
"    </a>",
"    ) reported that both drugs provided significant relief of pain, but goserelin was superior for treatment of dyspareunia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Data on the comparative efficacy of continuous OCs are inconsistent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial including 133 women with relapse of endometriosis-associated pain compared treatment with a GnRH agonist plus add-back therapy, a GnRH agonist alone, and continuous monophasic OCs for 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/20\">",
"       20",
"      </a>",
"      ]. Patients treated with a GnRH agonist had significantly greater reduction in pelvic pain, dysmenorrhea, and dyspareunia than patients treated with continuous OCs. The group taking a GnRH agonist plus add-back therapy had the highest quality of life scores.",
"     </li>",
"     <li>",
"      In contrast, a randomized trial including 47 women with endometriosis-associated pelvic pain that directly compared use of continuous monophasic OCs to a GnRH agonist (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      with add-back) for 48 weeks found the regimens were equally effective in reduction of pain [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/21\">",
"       21",
"      </a>",
"      ].",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both trials were well-designed, but the second study was limited by the small number of patients and high drop-out rate (40 percent).",
"   </p>",
"   <p>",
"    Thus, it is unclear whether a cyclic, continuous, or tricycle regimen is most effective [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/8\">",
"     8",
"    </a>",
"    ]. If pain does not respond well to cyclic therapy, switching to continuous OC administration may be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/22\">",
"     22",
"    </a>",
"    ]. A monophasic pill is adequate; there is no evidence that a triphasic pill has any advantages for treatment of endometriosis-related pain. The clinical regimen for continuous or extended use of OCs is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3832?source=see_link&amp;anchor=H10#H10\">",
"     \"Hormonal contraception for suppression of menstruation\", section on 'Extended and continuous use of contraceptive pills'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonoral estrogen-progestin contraceptives (ring, patch) may also be effective, but have not been studied extensively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Failure of initial medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We offer hormonal interventions other than OCs to women with early stage disease who are not achieving adequate pain relief after a three- to six-month trial with analgesics or OCs and to those with recurrent mild endometriosis and pain. The rationale for use of hormonal intervention is that altering the patient's",
"    <span class=\"nowrap\">",
"     estrogen/progesterone",
"    </span>",
"    profile should affect the course of the disease since ovarian steroids affect the growth of endometriosis. This hypothesis is supported by the observation that pregnancy and menopause, physiologic states which cause alterations in ovarian hormone concentrations, appear to be associated with a reduction in pelvic pain.",
"   </p>",
"   <p>",
"    The three hormonal interventions (other than OCs) most commonly used to treat endometriosis are gonadotropin-releasing hormone (GnRH) agonist analogs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    , and progestins. GnRH analogs and danazol induce a state of \"pseudomenopause,\" whereas progestins alone or in combination with estrogen hormonally mimic pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     GnRH agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest use of a GnRH agonist for treatment of moderate to severe pain associated with endometriosis. Randomized trials have shown that GnRH agonists are more effective than placebo and as effective as other medical therapies for relieving pain and reducing the size of endometriotic implants [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/24\">",
"     24",
"    </a>",
"    ]. With add-back therapy, side effects are often better tolerated than those associated with a progestin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    . Similar to other medical treatments, GnRH agonists do not enhance fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GnRH agonists can be administered by daily nasal spray, or intramuscular injections every one to three months. Generally, initial treatment with a GnRH agonist is continued for six months. A randomized trial showed that an empiric trial of GnRH agonist therapy, without",
"    <span class=\"nowrap\">",
"     surgical/histological",
"    </span>",
"    confirmation of disease, is reasonable in patients with dysmenorrhea or chronic pelvic pain who have not responded to NSAIDs or OCs, and in whom other causes of chronic pelvic pain have been excluded by history, physical examination, and laboratory testing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/25\">",
"     25",
"    </a>",
"    ]. Baseline tests, such as a complete blood count with differential and erythrocyte sedimentation rate, urinalysis, and testing for chlamydia and gonorrhea infection, are obtained to screen for a chronic infectious or inflammatory process. Pelvic ultrasound is highly sensitive for identifying pelvic masses and determining the origin of the mass (ovary, uterus, fallopian tube). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31864?source=see_link\">",
"     \"Evaluation of chronic pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed discussion of the use and efficacy of GnRH agonists for treatment of endometriosis can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8761?source=see_link\">",
"     \"Gonadotropin releasing hormone agonists for long-term treatment of endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Progestins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestins inhibit endometriotic tissue growth by causing decidualization initially, and then atrophy. They also inhibit pituitary gonadotropin secretion and ovarian hormone production.",
"   </p>",
"   <p>",
"    In randomized trials and prospective observational studies, progestins alone, at appropriate doses, were an effective treatment of pelvic pain caused by endometriosis: over 80 percent of women had partial or complete pain relief with this therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. The effectiveness of progestins was best illustrated in a multicenter randomized trial including 274 women with surgically diagnosed endometriosis who were treated with intramuscular injections of DMPA-SC (104 mg) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    (11.25 mg) over a six-month interval [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/29\">",
"     29",
"    </a>",
"    ]. Use of DMPA was associated with a significant reduction in dysmenorrhea, dyspareunia, pelvic pain, pelvic tenderness, and pelvic induration at 12 months follow-up, and these effects were comparable to those achieved with the GnRH agonist.",
"   </p>",
"   <p>",
"    The effectiveness of progestins in eliminating implants and the risk of recurrent endometriosis following treatment is less well-documented. A few studies have reported significantly reduced implant scores (determined at laparoscopy) after progestin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/27,31\">",
"     27,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence that high-dose oral progestin treatment is associated with the bone loss observed with GnRH agonists. Indeed, 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone",
"    </a>",
"    add-back has been shown to diminish the bone loss associated with GnRH agonist therapy. Progestins also do not have as detrimental an impact on lipids as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    . In addition, high-dose progestin regimens are typically less expensive than regimens containing a GnRH agonist. However, many women do not tolerate high dose progestin treatment because of weight gain, irregular uterine",
"    <span class=\"nowrap\">",
"     bleeding/spotting,",
"    </span>",
"    and mood changes (eg, depression). For these reasons, we feel GnRH agonists remain the first-line treatment choice, but progestin-only treatment is a reasonable second line treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several options for progestin therapy. The choice depends upon the contraceptive needs of the patient, side-effect profile of the various drugs, and patient preference.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      (MPA) (10 mg three times a day, maximum total dose 100 mg daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"       norethindrone acetate",
"      </a>",
"      (5 mg daily and increased by 2.5 mg every two weeks if pain persists, maximum total dose 15 mg daily; however, most patients become amenorrheic at daily doses of 5 to 10 mg). Treatment is continued for six-months [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Depot",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      (DMPA) is given as an injection (104 to 150 mg every three months). This therapy has been as effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      in randomized trials [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/29,33,34\">",
"       29,33,34",
"      </a>",
"      ]. Side effects include irregular menstrual bleeding, nausea, breast tenderness, fluid retention, and depression. However, prolonged use may result in loss of bone mineral density. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=see_link\">",
"       \"Depot medroxyprogesterone acetate for contraception\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Use of the levonorgestrel-releasing intrauterine device (LNG-IUD) after postoperative treatment of endometriosis has been evaluated in several small randomized trials [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/35-40\">",
"       35-40",
"      </a>",
"      ]. At approximately one-year follow-up, most trials found that the LNG-IUD resulted in a significant improvement compared with pretreatment testing or expectant management in measures of chronic pelvic pain and dysmenorrhea, but not of dyspareunia. The LNG-IUD was equally or less effective than GnRH agonists in preventing recurrence of chronic pelvic pain or dysmenorrhea following surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. Irregular menstrual bleeding and amenorrhea are common side effects, but in contrast to depot",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      , bone density is preserved [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/36\">",
"       36",
"      </a>",
"      ]. Each LNG-IUD has sufficient LNG to be effective for five years. After five years of use, the device should be removed, but can be replaced with a new device if appropriate. The LNG-IUD has few systemic side effects compared to other hormonal methods.",
"     </li>",
"     <li>",
"      A small observational study and a randomized trial reported that the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"       etonogestrel",
"      </a>",
"      subdermal implant (Implanon) was effective for decreasing the intensity of endometriosis-related pain (dyspareunia, dysmenorrhea, nonmenstrual pelvic pain) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. The therapeutic effect and side-effect profile were comparable to DMPA [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/41\">",
"       41",
"      </a>",
"      ]. Pain was reduced by at least 50 percent after six months of use and maintained for 12 months.",
"     </li>",
"     <li>",
"      A randomized trial including 253 women compared the efficacy and safety of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/46/27366?source=see_link\">",
"       dienogest",
"      </a>",
"      against",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      acetate for treatment of pain associated with endometriosis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/43\">",
"       43",
"      </a>",
"      ]. Dienogest 2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      orally was equivalent in efficacy to leuprolide at standard dose in relieving the pain associated with endometriosis, but was associated with fewer hypoestrogenic effects (flushes, reduction in bone mineral density) and more unscheduled bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2349339398\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinical trials of progestin therapy have been limited to 6 or 12 months duration for practical reasons. Based on clinical experience in patients with endometriosis and other disorders, progestin therapy can be extended indefinitely, if effective and well-tolerated. Bone loss is a concern with long-term administration of DMPA or high dose oral MPA, especially in women with risk factors for osteoporosis, but bone density generally improves if the woman returns to normal ovulatory function and estrogen production. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link&amp;anchor=H8#H8\">",
"     \"Drugs that affect bone metabolism\", section on 'Medroxyprogesterone acetate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=see_link\">",
"     \"Depot medroxyprogesterone acetate for contraception\"",
"    </a>",
"    .) Long-term use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone acetate",
"    </a>",
"    can lead to a significant reduction in HDL cholesterol and significant increases in LDL cholesterol and triglycerides [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/44\">",
"     44",
"    </a>",
"    ]. Given these risks, bone mineral density and lipid levels may be monitored, as appropriate, in patients on long-term therapy.",
"   </p>",
"   <p>",
"    Long-term use of the LNG-IUD&nbsp;or the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    implant does not significantly affect bone mineral density or lipid levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Progesterone antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progesterone antagonists and selective progesterone receptor modulators have also been used successfully in pilot studies of treatment of endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/45\">",
"     45",
"    </a>",
"    ]. Use of these agents led to a reduction of both nonmenstrual pelvic pain and dysmenorrhea. An advantage of these agents is that they suppress growth of endometrial cells without suppressing estrogen's effects on other tissues. However, chronic use of progesterone antagonists appears to create histological changes in the endometrium (cystic glandular dilatation) that resemble endometrial hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/46\">",
"     46",
"    </a>",
"    ]. The clinical significance of these changes requires further investigation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25866?source=see_link&amp;anchor=H16#H16\">",
"     \"Therapeutic use and adverse effects of progesterone receptor antagonists and selective progesterone receptor modulators\", section on 'Endometriosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Danazol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     Danazol",
"    </a>",
"    is effective in resolving implants when treating mild or moderate stages of disease and over 80 percent of patients experience relief or improvement of pain symptoms within two months of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/27,47,48\">",
"     27,47,48",
"    </a>",
"    ]. A randomized trial that compared pain sources in women treated with danazol or placebo reported a significant decrease in the level of pelvic pain, lower back pain, defecation pain, and total pain in those treated with danazol [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/27\">",
"     27",
"    </a>",
"    ]. The improvement in pain scores was still present six months after discontinuation of danazol therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     Danazol",
"    </a>",
"    is a 19-nortestosterone derivative with progestin-like effects. Its mechanisms of action include inhibition of pituitary gonadotropin secretion, direct inhibition of endometriotic implant growth, and direct inhibition of ovarian enzymes responsible for estrogen production. Danazol is given orally in divided doses ranging from 400 to 800 mg daily, generally for six months.",
"   </p>",
"   <p>",
"    Most women taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    have side effects that can be dose-dependent, and a small percentage of patients discontinue the drug because of them. Side effects include weight gain, muscle cramps, decreased breast size, acne, hirsutism, oily skin, decreased high density lipoprotein levels, increased liver enzymes, hot flashes, mood changes, and depression. Androgenic side effects associated with use of danazol are not treatable except by lowering the dose. By comparison, the hypoestrogenic symptoms produced by GnRH agonists can be minimized by add-back therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional hormonal interventions for endometriosis have targeted ovarian estrogen production or antagonized estrogen action. Although not approved for the treatment of pelvic pain caused by endometriosis, use of aromatase inhibitors is a novel, promising approach [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/49\">",
"     49",
"    </a>",
"    ]. These agents appear to regulate local estrogen formation within the endometriotic lesions themselves, in addition to inhibiting estrogen production in the ovary, brain, and periphery (eg, adipose tissue) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/49\">",
"     49",
"    </a>",
"    ]. In endometriotic tissue, prostaglandin E2 stimulates both aromatase overexpression and activity, which results in local production of estrogens from androgens. Estrogen, in turn, induces further prostaglandin E2 formation, thereby establishing a positive feedback cycle within the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In multiple case reports and small series and a randomized trial, aromatase inhibitors have been used (off-label) to interrupt this pathway in the treatment of severe endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/51-58\">",
"     51-58",
"    </a>",
"    ]. A systematic review of these studies concluded aromatase inhibitors significantly reduced pain compared with GnRH agonists alone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients may respond differently to different aromatase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/60\">",
"     60",
"    </a>",
"    ]. The two most widely used agents are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22294?source=see_link\">",
"     anastrozole",
"    </a>",
"    (1 mg) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    (2.5 mg) daily.",
"   </p>",
"   <p>",
"    It is important to remember that aromatase inhibitors cause significant bone loss with prolonged use and cannot be used as single agents in premenopausal women because they stimulate FSH release and cause multi-follicular cyst development. If these agents are used to treat pain caused by endometriosis in this population, they should be prescribed in combination with a GnRH agonist or an oral estrogen-progestin contraceptive [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/55\">",
"     55",
"    </a>",
"    ] to suppress follicular development.",
"   </p>",
"   <p>",
"    For patients in whom use of a GnRH agonist or oral estrogen-progestin contraceptive is not possible,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone acetate",
"    </a>",
"    (5 mg) is another option. In fact, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    and norethisterone acetate was more effective in reducing pain and deep dyspareunia in women with rectovaginal endometriosis than norethisterone acetate alone, but letrozole was associated with a high incidence of adverse effects, cost more, and did not improve patient satisfaction or reduce recurrence of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Acupuncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of treatment of pain associated with endometriosis with acupuncture found only one randomized trial that met inclusion criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/62\">",
"     62",
"    </a>",
"    ]. In that trial (n = 67), auricular acupuncture was significantly more effective than Chinese herbal medicine for treating dysmenorrhea in women with endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31431413\">",
"    <span class=\"h3\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no dietary guidelines for prevention or treatment of endometriosis. One study reported that a lower risk of developing endometriosis was associated with a high intake of green vegetables and fruit and an increased risk with intake of beef or other red meat or ham [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/64\">",
"     64",
"    </a>",
"    ]. There was no alteration of risk of endometriosis with consumption of other food items tested, including alcohol, coffee, fish and milk. Several studies have addressed diet and dysmenorrhea, but not exclusively in patients with endometriosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28233?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of primary dysmenorrhea in adult women\", section on 'Diet and vitamins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Indications for surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for surgical management of endometriosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms that are severe, incapacitating, or acute (as with rupture or torsion of an endometrioma)",
"     </li>",
"     <li>",
"      Symptoms that have failed to resolve or have worsened under medical management",
"     </li>",
"     <li>",
"      Presence of advanced disease (eg, anatomic distortion of the pelvic organs, endometriotic cysts, or obstruction of the bowel or urinary tract)",
"     </li>",
"     <li>",
"      Patient reluctance to use",
"      <span class=\"nowrap\">",
"       hormonal/non-surgical",
"      </span>",
"      treatments",
"     </li>",
"     <li>",
"      Adnexal mass suspicious for malignancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Conservative surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conservative surgery preserves the uterus and as much ovarian tissue as possible. A laparoscopic approach offers advantages over laparotomy, including a shorter duration of hospitalization, anesthesia, and recuperation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/65\">",
"     65",
"    </a>",
"    ]. Importantly, optical magnification provides better visualization of implants with the laparoscope than with open procedures.",
"   </p>",
"   <p>",
"    Laparotomy may be necessary when dealing with extensive adhesions or invasive endometriosis located near structures such as the uterine arteries, ureter, bladder, and bowel. Ancillary procedures to laparotomy may include presacral neurectomy, uterosacral interruption of sensory nerves innervating the pelvis, and uterine suspension to avoid adhesion formation from the posterior cul-de-sac (pouch of Douglas) to the posterior surface of the uterus, tube, and ovaries.",
"   </p>",
"   <p>",
"    Pain relief is achieved in most patients who undergo laparoscopic",
"    <span class=\"nowrap\">",
"     ablation/resection",
"    </span>",
"    of endometriosis and adhesiolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/66\">",
"     66",
"    </a>",
"    ]. However, the risk of recurrence is estimated to be as high as 40 percent at 10 years follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/67,68\">",
"     67,68",
"    </a>",
"    ] and about 20 percent of patients will undergo additional surgery within two years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of surgical management of endometriosis was demonstrated by two randomized trials that compared the outcome of women who underwent therapeutic laparoscopic surgery with the outcome of women who underwent diagnostic laparoscopy alone or expectant management:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first trial, laparoscopic laser ablation of endometriotic implants plus uterine nerve ablation was more likely to result in improvement or resolution of symptoms at six months than expectant management (63 versus 23 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the second trial, laparoscopic excision of implants led to symptomatic improvement in 80 percent of patients at six months compared to 32 percent of controls undergoing diagnostic laparoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the first trial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/70\">",
"     70",
"    </a>",
"    ], women with stage I disease (a large proportion of study participants) were less likely to improve after their surgical procedure than women with stage II-IV disease. Most of the women in the second trial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/71\">",
"     71",
"    </a>",
"    ] had stage II-IV disease, which may account, at least in part, for the higher surgical success rate reported in this study. Ablation and excision provide similar reductions in pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of pain relief achieved with conservative surgery may be enhanced by presacral neurectomy in women with midline pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. The use of nerve transection procedures, including presacral neurectomy, is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28969?source=see_link\">",
"     \"Treatment of chronic pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Definitive surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive surgery involves hysterectomy, with or without removal of the fallopian tubes and ovaries. Definitive, rather than conservative, surgery for treatment of endometriosis should be considered when (1) incapacitating symptoms persist following conservative surgery and medical therapy, (2) moderate to severe disease is present and future pregnancy is not desired, or (3) hysterectomy is indicated for coexisting pelvic pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/1\">",
"     1",
"    </a>",
"    ]. The decision to perform a definitive procedure is primarily dependent upon the patient's interest in maintaining child-bearing potential. Young women (under the age of 30 years) who undergo hysterectomy are more likely than older women to report residual symptoms, a sense of loss, and overall disruption in their life [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ovaries may be conserved in younger women to avoid premature development of menopausal symptoms and decisions regarding estrogen replacement. However, removal of both ovaries is appropriate when the ovaries are extensively damaged by endometriosis, or when the woman is approaching menopause. Estrogen replacement, with or without a progestin, to prevent menopausal symptoms should be discussed with the patient when the ovaries are removed, even when surgery has not removed all endometriotic implants [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/77\">",
"     77",
"    </a>",
"    ]. There is a low likelihood of symptomatic recurrence in these cases (&lt;5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/69\">",
"     69",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    There are few data on recurrence in patients with bowel endometriosis. One study suggested that recurrence rates are higher in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/78\">",
"     78",
"    </a>",
"    ], but there are no data to suggest that estrogen replacement increases the risk of recurrence. These patients may have persistent rather than recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hormonal treatment is typically not necessary following oophorectomy. Suppression with a progestin is appropriate if symptoms recur after hysterectomy and oophorectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/8\">",
"     8",
"    </a>",
"    ]. Use of a progestin may be contraindicated in women with risk factors for breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=see_link&amp;anchor=H150020558#H150020558\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\", section on 'Effect of progestins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Indications for combination medical/surgical therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Preoperative medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormonal suppression has been used prior to surgery to decrease the size of endometriotic implants, thereby reducing the extent of surgery required [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/80\">",
"     80",
"    </a>",
"    ]. However, there is no evidence that preoperative hormonal intervention decreases the extent of surgical dissection required to remove implants, prolongs the duration of pain relief, increases future pregnancy rates, or decreases recurrence rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Postoperative medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    , estrogen-progestin pills, and GnRH agonists have been used in conjunction with laparotomy or laparoscopic conservative or definitive surgical treatment. Several trials have reported postoperative therapy using one of these agents increased the duration of pain relief and delayed recurrence of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/8,35,81-84\">",
"     8,35,81-84",
"    </a>",
"    ]. Two randomized trials have found that postoperative insertion of the LNG-IUD results in decreased dysmenorrhea compared with expectant management [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/37,85\">",
"     37,85",
"    </a>",
"    ]. However, a systematic review comparing postsurgical hormonal suppression to surgery alone concluded that, while postoperative medical therapy decreased recurrence rates, there was no significant benefit for the outcomes of pain or pregnancy rates [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is some support for the efficacy of postoperative medical therapy for pain relief. In one randomized trial involving patients with minimal or mild disease, postoperative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26580?source=see_link\">",
"     nafarelin",
"    </a>",
"    use resulted in a higher proportion of patients achieving adequate pain relief than placebo (70 versus 40 percent of patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/81\">",
"     81",
"    </a>",
"    ]. In other randomized trials, postoperative placement of a levonorgestrel-releasing IUC resulted in a greater reduction in recurrence of dysmenorrhea than administration of a GnRH agonist (OR 0.14, 95% CI 0.02-0.75) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/35\">",
"     35",
"    </a>",
"    ] and similar symptom control as depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    injections [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/36\">",
"     36",
"    </a>",
"    ] Placebo controlled randomized trials by another investigator reported that prolonged postoperative use of estrogen-progestin contraceptives significantly reduced rates of dysmenorrhea, but not dyspareunia or chronic pelvic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although uncommon, some experts suggest postsurgical hormonal intervention to treat \"microscopic\" implants and thus delay recurrence.",
"   </p>",
"   <p>",
"    Postoperative therapy following surgical treatment of an endometrioma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5863?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis and management of ovarian endometriomas\", section on 'Recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT OF INFERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although endometriosis can reduce fecundability (ie, the probability of conceiving during a monthly cycle), it does not usually completely prevent conception. The mechanism for impaired fertility may involve anatomic distortion from pelvic adhesions and endometriomas",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    production of substances (eg, prostanoids, cytokines, growth factors) which are \"hostile\" to normal ovarian",
"    <span class=\"nowrap\">",
"     function/ovulation,",
"    </span>",
"    fertilization, and implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of infertility associated with endometriosis involves a combination of expectant management, surgery, and assisted reproduction techniques. Treatment with hormonal suppression is ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/87\">",
"     87",
"    </a>",
"    ]. A stepwise approach to treatment of infertility in women with endometriosis can be found separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=see_link\">",
"     \"Pathogenesis and treatment of infertility in women with endometriosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT OF PELVIC MASS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An endometrioma may be associated with symptoms of endometriosis or identified at the time of evaluation for a pelvic mass. Medical therapy is unlikely to result in complete regression of large endometriomas and precludes a definitive histologic diagnosis; therefore, surgery is the preferred therapeutic approach. Asymptomatic endometriomas are often removed to confirm the diagnosis, exclude malignancy, and prevent complications, such as rupture or torsion requiring emergency surgery. However, ovarian reserve can be diminished following surgical excision [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of ovarian endometriomas is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5863?source=see_link\">",
"     \"Diagnosis and management of ovarian endometriomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT OF SYMPTOMS RELATED TO DEEP ENDOMETRIOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep infiltrating endometriosis is a term used to describe infiltrative forms of the disease that involve the uterosacral ligaments, rectovaginal septum, bowel, ureters, or bladder. The origin is probably intraperitoneal endometriotic implants that have invaded and caused inflammation of the involved tissue. Another potential etiology is growth of retroperitoneal m&uuml;llerian remnants.",
"   </p>",
"   <p>",
"    Asymptomatic disease is managed expectantly [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/89\">",
"     89",
"    </a>",
"    ]. Medical therapy is appropriate for women with bothersome symptoms, except those with obstructive uropathy or symptomatic bowel stenosis. Although medical therapy of symptomatic disease has generally been reported to be ineffective or transiently effective, with recurrence rates approaching 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/90\">",
"     90",
"    </a>",
"    ], endometriosis is a chronic disease and cessation of medical therapy may account for the high frequency of symptom recurrence. A review of studies of various hormonal treatments of rectovaginal endometriosis found that most patients receiving medical therapy for 6 to 12 months reported a significant reduction in dysmenorrhea and painful intercourse and defecation during treatment, but recurrence rates were high when medical therapy was discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Either a continuous estrogen&ndash;progestin combination or low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone",
"    </a>",
"    can be used. In women with rectovaginal or colorectal endometriosis, continuous norethisterone acetate therapy (2.5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for 12 months has been reported to improve pelvic pain, dyspareunia, dyschezia, diarrhea, and intestinal cramping, but did not have a significant effect on constipation, feeling of incomplete evacuation, and abdominal bloating [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical therapy is effective for relieving pelvic pain, dyspareunia, painful defecation, and lower urinary tract symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]; however, recurrence rates of 30 and 43 percent at four and eight years follow-up, respectively, have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/96\">",
"     96",
"    </a>",
"    ]. Medical treatment rather than repeat surgery may be useful in women with persistent symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/93\">",
"     93",
"    </a>",
"    ]. Surgical resection does not enhance future pregnancy rates [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no consensus on the extent of resection necessary to treat deep endometriosis. Extensive dissection in the rectovaginal septum and rectal wall dissection are often necessary and require the skill of an experienced surgeon. Performing hysterectomy and bilateral salpingoophorectomy alone is inadequate definitive therapy if endometriosis involving the bowel is left untreated. In these cases, bowel resection may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/98,99\">",
"     98,99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In women with endometriotic lesions infiltrating the bladder muscularis propria, partial cystectomy has been reported to result in long-term relief of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgery for deep endometriosis is associated with a relatively high risk of postoperative complications, such as de-novo or worsening voiding dysfunction, rectal dysfunction, and rectovaginal fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/99-103\">",
"     99-103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1775021786\">",
"    <span class=\"h1\">",
"     TREATMENT OF LESIONS OF NONREPRODUCTIVE ORGANS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian suppression with GnRH agonists is probably the optimum initial therapy for symptomatic extra-pelvic endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/29/14810/abstract/79\">",
"     79",
"    </a>",
"    ]. However, obstruction of the ureter or bowel should be treated surgically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25254?source=see_link\">",
"     \"Thoracic endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/8/5251?source=see_link\">",
"       \"Patient information: Endometriosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/63/26611?source=see_link\">",
"       \"Patient information: Endometriosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of therapy is to relieve symptoms of endometriosis: pelvic pain, infertility, and pelvic mass. There is no high quality evidence showing that one medical therapy is more effective than another for treatment of pelvic pain due to endometriosis. There is also no high quality evidence that medical or surgical intervention will affect future fertility. Therefore, individual treatment decisions are based upon the severity of symptoms, the extent and location of disease, whether there is a desire for pregnancy, the age of the patient, medication side effects, surgical complication rates, and cost. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An initial diagnostic laparoscopy for establishing the presence of endometriosis provides an opportunity for ablation or excision of implants and adhesions, thus potentially preventing or delaying disease or symptom progression. This approach should be considered in patients with suspected advanced stages of disease (ie, endometriomas) and may benefit women with endometriosis-associated infertility. Early surgical therapy also avoids the expense and side effects of medical therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Empiric medical therapy with nonsteroidal anti-inflammatory drugs, oral contraceptives, or GnRH agonists may be used in women with pelvic pain and suspected endometriosis, prior to establishing the diagnosis surgically. This may provide sufficient pain relief and avoid a laparoscopy. There is insufficient long-term follow-up of patients managed initially with medical therapy to assess symptom recurrence or the eventual need for surgical intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Treatment of pain",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with no more than mild pelvic pain, we suggest nonsteroidal antiinflammatory drugs over other medical interventions (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For women who also desire contraception, we suggest oral contraceptives (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Initial approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with moderate pain who are not achieving adequate pain relief with nonsteroidal antiinflammatory drugs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      combined oral contraceptives, and those with recurrent mild endometriosis and pain, we suggest treatment with a GnRH agonist over other hormonal therapies (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'GnRH agonists'",
"      </a>",
"      above.) Use of GnRH agonists avoids the bothersome side effects of progestins (weight gain, irregular uterine bleeding, mood changes) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      (weight gain, muscle cramps, decreased breast size, acne, hirsutism, oily skin, mood changes).",
"     </li>",
"     <li>",
"      For women who want to avoid the high cost and risk of bone loss associated with GnRH agonists, we suggest treatment with a progestin (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Progestins have a more favorable side effect profile than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Progestins'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Danazol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with symptoms that are severe, incapacitating, or acute (rupture or torsion of an endometrioma), or who have advanced disease (eg, anatomic distortion of the pelvic organs, endometriotic cysts, or obstruction of the bowel or urinary tract), we suggest surgical rather than medical therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We also suggest surgical intervention for women whose symptoms have failed to resolve or have worsened under medical management (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Indications for surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women in whom surgery did not result in complete removal of implants, or when the primary symptom is dysmenorrhea, we suggest postoperative medical therapy to increase the duration of pain relief and delay recurrence of symptoms (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Indications for combination medical/surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Treatment of infertility",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of infertility associated with endometriosis involves a combination of expectant management, surgery, and assisted reproduction techniques. Drug treatment is ineffective. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Treatment of infertility'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Treatment of pelvic mass",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical therapy is unlikely to result in complete regression of large endometriomas and precludes a definitive histologic diagnosis. Therefore, surgery is the preferred therapeutic approach. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment of pelvic mass'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Treatment of deep endometriosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with pelvic pain, dyspareunia, or painful defecation related to deep endometriosis, we suggest surgical rather than medical therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/1\">",
"      Practice Committee of American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis. Fertil Steril 2008; 90:S260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/2\">",
"      Mahmood TA, Templeton A. The impact of treatment on the natural history of endometriosis. Hum Reprod 1990; 5:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/3\">",
"      Vessey MP, Villard-Mackintosh L, Painter R. Epidemiology of endometriosis in women attending family planning clinics. BMJ 1993; 306:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/4\">",
"      Moen MH. Is a long period without childbirth a risk factor for developing endometriosis? Hum Reprod 1991; 6:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/5\">",
"      Parazzini F, La Vecchia C, Franceschi S, et al. Risk factors for endometrioid, mucinous and serous benign ovarian cysts. Int J Epidemiol 1989; 18:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/6\">",
"      American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Number 310, April 2005. Endometriosis in adolescents. Obstet Gynecol 2005; 105:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/7\">",
"      ACOG Committee on Practice Bulletins--Gynecology. ACOG practice bulletin. Medical management of endometriosis. Number 11, December 1999 (replaces Technical Bulletin Number 184, September 1993). Clinical management guidelines for obstetrician-gynecologists. Int J Gynaecol Obstet 2000; 71:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/8\">",
"      Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005; 20:2698.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Medical management of endometriosis. ACOG practice bulletin 11, American College of Obstetricians and Gynecologists, Washington, DC 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/10\">",
"      Hughes E, Brown J, Collins JJ, et al. Ovulation suppression for endometriosis. Cochrane Database Syst Rev 2007; :CD000155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/11\">",
"      Allen C, Hopewell S, Prentice A, Gregory D. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev 2009; :CD004753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/12\">",
"      Harada T, Momoeda M, Taketani Y, et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2008; 90:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/13\">",
"      Buttram VC Jr. Cyclic use of combination oral contraceptives and the severity of endometriosis. Fertil Steril 1979; 31:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/14\">",
"      Strathy JH, Molgaard CA, Coulam CB, Melton LJ 3rd. Endometriosis and infertility: a laparoscopic study of endometriosis among fertile and infertile women. Fertil Steril 1982; 38:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/15\">",
"      Kirshon B, Poindexter AN 3rd. Contraception: a risk factor for endometriosis. Obstet Gynecol 1988; 71:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/16\">",
"      Mahmood TA, Templeton A. Prevalence and genesis of endometriosis. Hum Reprod 1991; 6:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/17\">",
"      Moen MH. Endometriosis in women at interval sterilization. Acta Obstet Gynecol Scand 1987; 66:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/18\">",
"      Vercellini P, Trespidi L, Colombo A, et al. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993; 60:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/19\">",
"      Davis L, Kennedy SS, Moore J, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2007; :CD001019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/20\">",
"      Zupi E, Marconi D, Sbracia M, et al. Add-back therapy in the treatment of endometriosis-associated pain. Fertil Steril 2004; 82:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/21\">",
"      Guzick DS, Huang LS, Broadman BA, et al. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril 2011; 95:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/22\">",
"      Vercellini P, Frontino G, De Giorgi O, et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 2003; 80:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/23\">",
"      Vercellini P, Barbara G, Somigliana E, et al. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril 2010; 93:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/24\">",
"      Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2010; :CD008475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/25\">",
"      Ling FW. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. Obstet Gynecol 1999; 93:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/26\">",
"      Luciano AA, Turksoy RN, Carleo J. Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis. Obstet Gynecol 1988; 72:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/27\">",
"      Telimaa S, Puolakka J, R&ouml;nnberg L, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol 1987; 1:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/28\">",
"      Prentice A, Deary AJ, Bland E. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev 2000; :CD002122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/29\">",
"      Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006; 21:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/30\">",
"      Vercellini P, Cortesi I, Crosignani PG. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril 1997; 68:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/31\">",
"      Dawood MY, Obasiolu CW, Ramos J, Khan-Dawood FS. Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis. Am J Obstet Gynecol 1997; 176:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/32\">",
"      Regidor PA, Regidor M, Schmidt M, et al. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis. Gynecol Endocrinol 2001; 15:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/33\">",
"      Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 2006; 85:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/34\">",
"      Vercellini P, De Giorgi O, Oldani S, et al. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol 1996; 175:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/35\">",
"      Abou-Setta AM, Al-Inany HG, Farquhar CM. Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. Cochrane Database Syst Rev 2006; :CD005072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/36\">",
"      Wong AY, Tang LC, Chin RK. Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial. Aust N Z J Obstet Gynaecol 2010; 50:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/37\">",
"      Vercellini P, Frontino G, De Giorgi O, et al. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril 2003; 80:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/38\">",
"      Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005; 20:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/39\">",
"      Bayoglu Tekin Y, Dilbaz B, Altinbas SK, Dilbaz S. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril 2011; 95:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/40\">",
"      Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, et al. Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: A randomized trial. Obstet Gynecol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/41\">",
"      Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study. Contraception 2009; 79:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/42\">",
"      Yisa SB, Okenwa AA, Husemeyer RP. Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon). J Fam Plann Reprod Health Care 2005; 31:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/43\">",
"      Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 2010; 25:633.",
"     </a>",
"    </li>",
"    <li>",
"     Cirkel, U, Schweppe, KW, Ochs, H, et al. Effects of LHRH agonist therapy in the treatment of endometriosis. In: Gonadotropin down-regulation in gynecological practice. Vol 225, Chadha, DR, Willemsen, WNP (Eds). Aln R Liss, New York 1986. p. 189.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/45\">",
"      Chwalisz K, Perez MC, Demanno D, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005; 26:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/46\">",
"      Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol 2009; 21:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/47\">",
"      Barbieri RL, Evans S, Kistner RW. Danazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up. Fertil Steril 1982; 37:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/48\">",
"      Selak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 2007; :CD000068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/49\">",
"      Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril 2006; 85:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/50\">",
"      Bulun SE, Zeitoun K, Takayama K, et al. Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis. Endocr Relat Cancer 1999; 6:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/51\">",
"      Razzi S, Fava A, Sartini A, et al. Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman. BJOG 2004; 111:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/52\">",
"      Takayama K, Zeitoun K, Gunby RT, et al. Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 1998; 69:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/53\">",
"      Ailawadi RK, Jobanputra S, Kataria M, et al. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril 2004; 81:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/54\">",
"      Shippen ER, West WJ Jr. Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil Steril 2004; 81:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/55\">",
"      Amsterdam LL, Gentry W, Jobanputra S, et al. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril 2005; 84:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/56\">",
"      Hefler LA, Grimm C, van Trotsenburg M, Nagele F. Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study. Fertil Steril 2005; 84:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/57\">",
"      Fatemi HM, Al-Turki HA, Papanikolaou EG, et al. Successful treatment of an aggressive recurrent post-menopausal endometriosis with an aromatase inhibitor. Reprod Biomed Online 2005; 11:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/58\">",
"      Soysal S, Soysal ME, Ozer S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod 2004; 19:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/59\">",
"      Nawathe A, Patwardhan S, Yates D, et al. Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis. BJOG 2008; 115:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/60\">",
"      Mousa NA, Bedaiwy MA, Casper RF. Aromatase inhibitors in the treatment of severe endometriosis. Obstet Gynecol 2007; 109:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/61\">",
"      Ferrero S, Camerini G, Seracchioli R, et al. Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. Hum Reprod 2009; 24:3033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/62\">",
"      Zhu X, Hamilton KD, McNicol ED. Acupuncture for pain in endometriosis. Cochrane Database Syst Rev 2011; :CD007864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/63\">",
"      Xiang D, Situ Y, Liang X, et al. Ear acupuncture therapy for 37 cases of dysmenorrhea due to endometriosis. J Tradit Chin Med 2002; 22:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/64\">",
"      Parazzini F, Chiaffarino F, Surace M, et al. Selected food intake and risk of endometriosis. Hum Reprod 2004; 19:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/65\">",
"      Crosignani PG, Vercellini P, Biffignandi F, et al. Laparoscopy versus laparotomy in conservative surgical treatment for severe endometriosis. Fertil Steril 1996; 66:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/66\">",
"      Jacobson TZ, Barlow DH, Garry R, Koninckx P. Laparoscopic surgery for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 2001; :CD001300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/67\">",
"      Wheeler JM, Malinak LR. Recurrent endometriosis: incidence, management, and prognosis. Am J Obstet Gynecol 1983; 146:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/68\">",
"      Taylor E, Williams C. Surgical treatment of endometriosis: location and patterns of disease at reoperation. Fertil Steril 2010; 93:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/69\">",
"      Shakiba K, Bena JF, McGill KM, et al. Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery. Obstet Gynecol 2008; 111:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/70\">",
"      Sutton CJ, Ewen SP, Whitelaw N, Haines P. Prospective, randomized, double-blind, controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild, and moderate endometriosis. Fertil Steril 1994; 62:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/71\">",
"      Abbott J, Hawe J, Hunter D, et al. Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial. Fertil Steril 2004; 82:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/72\">",
"      Yeung PP Jr, Shwayder J, Pasic RP. Laparoscopic management of endometriosis: comprehensive review of best evidence. J Minim Invasive Gynecol 2009; 16:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/73\">",
"      Healey M, Ang WC, Cheng C. Surgical treatment of endometriosis: a prospective randomized double-blinded trial comparing excision and ablation. Fertil Steril 2010; 94:2536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/74\">",
"      Candiani GB, Fedele L, Vercellini P, et al. Presacral neurectomy for the treatment of pelvic pain associated with endometriosis: a controlled study. Am J Obstet Gynecol 1992; 167:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/75\">",
"      Zullo F, Palomba S, Zupi E, et al. Effectiveness of presacral neurectomy in women with severe dysmenorrhea caused by endometriosis who were treated with laparoscopic conservative surgery: a 1-year prospective randomized double-blind controlled trial. Am J Obstet Gynecol 2003; 189:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/76\">",
"      MacDonald SR, Klock SC, Milad MP. Long-term outcome of nonconservative surgery (hysterectomy) for endometriosis-associated pain in women &lt;30 years old. Am J Obstet Gynecol 1999; 180:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/77\">",
"      Matorras R, Elorriaga MA, Pijoan JI, et al. Recurrence of endometriosis in women with bilateral adnexectomy (with or without total hysterectomy) who received hormone replacement therapy. Fertil Steril 2002; 77:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/78\">",
"      Gray LA. Endometriosis of the bowel: role of bowel resection, superficial excision and oophorectomy in treatment. Ann Surg 1973; 177:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/79\">",
"      Practice bulletin no. 114: management of endometriosis. Obstet Gynecol 2010; 116:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/80\">",
"      Yap C, Furness S, Farquhar C. Pre and post operative medical therapy for endometriosis surgery. Cochrane Database Syst Rev 2004; :CD003678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/81\">",
"      Hornstein MD, Hemmings R, Yuzpe AA, Heinrichs WL. Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steril 1997; 68:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/82\">",
"      Cosson M, Querleu D, Donnez J, et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril 2002; 77:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/83\">",
"      Seracchioli R, Mabrouk M, Manuzzi L, et al. Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom-recurrence after conservative surgery for endometriosis. Hum Reprod 2009; 24:2729.",
"     </a>",
"    </li>",
"    <li>",
"     Seracchioli, R, et al. Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertil Steril 2009; :. [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/85\">",
"      Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, et al. Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial. Obstet Gynecol 2012; 119:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/86\">",
"      Cahill DJ. What is the optimal medical management of infertility and minor endometriosis? Analysis and future prospects. Hum Reprod 2002; 17:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/87\">",
"      Hughes E, Fedorkow D, Collins J, Vandekerckhove P. Ovulation suppression for endometriosis. Cochrane Database Syst Rev 2000; :CD000155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/88\">",
"      Benaglia L, Somigliana E, Vighi V, et al. Rate of severe ovarian damage following surgery for endometriomas. Hum Reprod 2010; 25:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/89\">",
"      Fedele L, Bianchi S, Zanconato G, et al. Is rectovaginal endometriosis a progressive disease? Am J Obstet Gynecol 2004; 191:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/90\">",
"      Shaw RW. Treatment of endometriosis. Lancet 1992; 340:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/91\">",
"      Vercellini P, Crosignani PG, Somigliana E, et al. Medical treatment for rectovaginal endometriosis: what is the evidence? Hum Reprod 2009; 24:2504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/92\">",
"      Ferrero S, Camerini G, Ragni N, et al. Norethisterone acetate in the treatment of colorectal endometriosis: a pilot study. Hum Reprod 2010; 25:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/93\">",
"      Vercellini P, Pietropaolo G, De Giorgi O, et al. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil Steril 2005; 84:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/94\">",
"      Donnez J, Nisolle M, Gillerot S, et al. Rectovaginal septum adenomyotic nodules: a series of 500 cases. Br J Obstet Gynaecol 1997; 104:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/95\">",
"      Chapron C, Bourret A, Chopin N, et al. Surgery for bladder endometriosis: long-term results and concomitant management of associated posterior deep lesions. Hum Reprod 2010; 25:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/96\">",
"      Busacca M, Chiaffarino F, Candiani M, et al. Determinants of long-term clinically detected recurrence rates of deep, ovarian, and pelvic endometriosis. Am J Obstet Gynecol 2006; 195:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/97\">",
"      Vercellini P, Pietropaolo G, De Giorgi O, et al. Reproductive performance in infertile women with rectovaginal endometriosis: is surgery worthwhile? Am J Obstet Gynecol 2006; 195:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/98\">",
"      Darai E, Ackerman G, Bazot M, et al. Laparoscopic segmental colorectal resection for endometriosis: limits and complications. Surg Endosc 2007; 21:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/99\">",
"      Minelli L, Fanfani F, Fagotti A, et al. Laparoscopic colorectal resection for bowel endometriosis: feasibility, complications, and clinical outcome. Arch Surg 2009; 144:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/100\">",
"      Dara&iuml; E, Bazot M, Rouzier R, et al. Outcome of laparoscopic colorectal resection for endometriosis. Curr Opin Obstet Gynecol 2007; 19:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/101\">",
"      Dubernard G, Rouzier R, David-Montefiore E, et al. Urinary complications after surgery for posterior deep infiltrating endometriosis are related to the extent of dissection and to uterosacral ligaments resection. J Minim Invasive Gynecol 2008; 15:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/102\">",
"      Koninckx PR, Timmermans B, Meuleman C, Penninckx F. Complications of CO2-laser endoscopic excision of deep endometriosis. Hum Reprod 1996; 11:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/29/14810/abstract/103\">",
"      Roman H, Loisel C, Resch B, et al. Delayed functional outcomes associated with surgical management of deep rectovaginal endometriosis with rectal involvement: giving patients an informed choice. Hum Reprod 2010; 25:890.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7383 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AD134220F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_29_14810=[""].join("\n");
var outline_f14_29_14810=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT OF PELVIC PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Initial approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Analgesics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Estrogen-progestin oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Failure of initial medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - GnRH agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Progestins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2349339398\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Progesterone antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Danazol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31431413\">",
"      - Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Indications for surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Conservative surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Definitive surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Indications for combination medical/surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Preoperative medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Postoperative medical therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT OF INFERTILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT OF PELVIC MASS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT OF SYMPTOMS RELATED TO DEEP ENDOMETRIOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1775021786\">",
"      TREATMENT OF LESIONS OF NONREPRODUCTIVE ORGANS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Treatment of pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Treatment of infertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Treatment of pelvic mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Treatment of deep endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/7383\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7383|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/58/12203\" title=\"table 1\">",
"      Medical Rx pain endometriosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=related_link\">",
"      Depot medroxyprogesterone acetate for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5863?source=related_link\">",
"      Diagnosis and management of ovarian endometriomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31864?source=related_link\">",
"      Evaluation of chronic pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8761?source=related_link\">",
"      Gonadotropin releasing hormone agonists for long-term treatment of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3832?source=related_link\">",
"      Hormonal contraception for suppression of menstruation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=related_link\">",
"      Pathogenesis and treatment of infertility in women with endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/63/26611?source=related_link\">",
"      Patient information: Endometriosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/8/5251?source=related_link\">",
"      Patient information: Endometriosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25866?source=related_link\">",
"      Therapeutic use and adverse effects of progesterone receptor antagonists and selective progesterone receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25254?source=related_link\">",
"      Thoracic endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28969?source=related_link\">",
"      Treatment of chronic pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28233?source=related_link\">",
"      Treatment of primary dysmenorrhea in adult women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_29_14811="Immunogenicity RBC antigens";
var content_f14_29_14811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relative immunogenicity of the various red blood cell antigens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Red blood cell antigen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relative immunogenicity*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A, B",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rh(D)",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        K",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        c,E",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fy(a)",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jk(a)",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Defined as the percent of individuals negative for the antigen in question who will produce an antibody after receiving transfusion of a single unit of red cells positive for that antigen. Values are approximate.",
"    </div>",
"    <div class=\"reference\">",
"     Revised after Calhoun, L and Petz, L. Erythrocyte antigens and antibodies. In: Williams' Hematology, 6th ed, Beutler, E, Lichtman, MA, Coller, BS, et al, (Eds), McGraw-Hill, New York, 2001. p.1846.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_29_14811=[""].join("\n");
var outline_f14_29_14811=null;
var title_f14_29_14812="Etiology of massive hemoptysis";
var content_f14_29_14812=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiologies of massive hemoptysis in several series",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        South Africa&bull;",
"1983-1990",
"       </td>",
"       <td class=\"subtitle1\">",
"        New York City&Delta;",
"1991-1992",
"       </td>",
"       <td class=\"subtitle1\">",
"        Jerusalem&loz; 1980-1995",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchiectasis",
"       </td>",
"       <td>",
"        51 percent*",
"       </td>",
"       <td>",
"        25 percent",
"       </td>",
"       <td>",
"        20 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberculosis",
"       </td>",
"       <td>",
"        73 percent",
"       </td>",
"       <td>",
"        16 percent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchogenic carcinoma",
"       </td>",
"       <td>",
"        5 percent",
"       </td>",
"       <td>",
"        12 percent",
"       </td>",
"       <td>",
"        15 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspergilloma",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        12 percent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumonia",
"       </td>",
"       <td>",
"        4 percent",
"       </td>",
"       <td>",
"        5 percent",
"       </td>",
"       <td>",
"        23 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleeding diathesis",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        15 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        10 percent",
"       </td>",
"       <td>",
"        5 percent",
"       </td>",
"       <td>",
"        20 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Undefined",
"       </td>",
"       <td>",
"        8 percent",
"       </td>",
"       <td>",
"        19 percent",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Bronchitis\"",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5 percent",
"       </td>",
"       <td>",
"        7 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All patients with bronchiectasis had tuberculosis.",
"    </div>",
"    <div class=\"reference\">",
"     &bull; Data from Knott-Craig, CJ, Oostuizen, JB, Rossouw, G, et al, J Thorac Cardiovasc Surg 1993; 105:394.",
"     <br>",
"      &Delta; Data from McGuiness, G, Beacher, JR, Harkin, TJ, et al, Chest 1994; 105:1155.",
"      <br>",
"       &loz; Data from Hirshberg, B, Biran, I, Glazer, M, Kramer, M, Chest 1997; 112:440.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_29_14812=[""].join("\n");
var outline_f14_29_14812=null;
var title_f14_29_14813="Stone recurrence rate";
var content_f14_29_14813=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Recurrence rate after first kidney stone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 239px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative incidence of stone recurrence after a first kidney stone in men and women. The data represent a summary of six studies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Uribarri, J, Oh, MS, Carroll, HJ, Ann Intern Med 1989; 111:1006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_29_14813=[""].join("\n");
var outline_f14_29_14813=null;
var title_f14_29_14814="PERT preparations";
var content_f14_29_14814=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oral preparations for pancreatic enzyme replacement therapy (PERT)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pancrelipase preparations",
"        <br/>",
"        (US trade name)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description and US manufacturer",
"        <br/>",
"        (see NOTE)",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lipase",
"        <br/>",
"        (USP units)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Amylase",
"        <br/>",
"        (USP units)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Protease",
"        <br/>",
"        (USP units)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pancreaze&trade;&nbsp; 4,200",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Delayed release capsule containing enteric coated microtablets, porcine origin.",
"        </p>",
"        <p>",
"         (Janssen Pharmaceuticals, Inc)",
"        </p>",
"       </td>",
"       <td rowspan=\"14\">",
"        <p>",
"         Applies to Pancreaze&trade;, Creon&reg;, &nbsp;Zenpep&reg;:",
"        </p>",
"        <p>",
"         Swallow capsules whole or sprinkle capsule contents on small amount of acidic soft food with pH of 4.5 or less (eg, applesauce, yogurt, commercially prepared bananas or pears), consume immediately and follow with water, juice or other liquid.&nbsp; Do not mix directly into infant formula or breast milk. Do not crush or chew capsule shell or contents.",
"        </p>",
"       </td>",
"       <td>",
"        4200",
"       </td>",
"       <td>",
"        17,500",
"       </td>",
"       <td>",
"        10,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreaze&trade; 10,500",
"       </td>",
"       <td>",
"        10,500",
"       </td>",
"       <td>",
"        43,750",
"       </td>",
"       <td>",
"        25,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreaze&trade; 16,800",
"       </td>",
"       <td>",
"        16,800",
"       </td>",
"       <td>",
"        70,000",
"       </td>",
"       <td>",
"        40,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreaze&trade; 21,000",
"       </td>",
"       <td>",
"        21,000",
"       </td>",
"       <td>",
"        61,000",
"       </td>",
"       <td>",
"        37,000",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Creon&reg; 3",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Delayed release capsule containing enteric coated mini-microspheres, porcine origin.",
"        </p>",
"        <p>",
"         (Abbott Products, Inc)",
"        </p>",
"       </td>",
"       <td>",
"        3000",
"       </td>",
"       <td>",
"        15,000",
"       </td>",
"       <td>",
"        9500",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Creon&reg; 6",
"       </td>",
"       <td>",
"        6000",
"       </td>",
"       <td>",
"        30,000",
"       </td>",
"       <td>",
"        19,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Creon&reg; 12&nbsp;",
"       </td>",
"       <td>",
"        12,000&nbsp;",
"       </td>",
"       <td>",
"        60,000&nbsp;",
"       </td>",
"       <td>",
"        38,000&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Creon&reg; 24",
"       </td>",
"       <td>",
"        24,000",
"       </td>",
"       <td>",
"        120,000",
"       </td>",
"       <td>",
"        76,000",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Zenpep&reg; 3",
"       </td>",
"       <td rowspan=\"6\">",
"        <p>",
"         Delayed release capsule containing enteric coated beads, porcine origin.",
"        </p>",
"        <p>",
"         (Aptalis Pharma)",
"        </p>",
"       </td>",
"       <td>",
"        3000",
"       </td>",
"       <td>",
"        16,000",
"       </td>",
"       <td>",
"        10,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zenpep&reg; 5",
"       </td>",
"       <td>",
"        5000",
"       </td>",
"       <td>",
"        27,000",
"       </td>",
"       <td>",
"        17,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zenpep&reg; 10&nbsp;",
"       </td>",
"       <td>",
"        10,000&nbsp;",
"       </td>",
"       <td>",
"        55,000&nbsp;",
"       </td>",
"       <td>",
"        34,000&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zenpep&reg; 15",
"       </td>",
"       <td>",
"        15,000",
"       </td>",
"       <td>",
"        82,000",
"       </td>",
"       <td>",
"        51,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zenpep&reg; 20&nbsp;",
"       </td>",
"       <td>",
"        20,000&nbsp;",
"       </td>",
"       <td>",
"        109,000&nbsp;",
"       </td>",
"       <td>",
"        68,000&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zenpep&reg; 25",
"       </td>",
"       <td>",
"        25,000",
"       </td>",
"       <td>",
"        136,000",
"       </td>",
"       <td>",
"        85,000",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Ultresa&trade;* 13,800&nbsp;",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Delayed release capsule containing enteric coated minitablets, porcine origin",
"        </p>",
"        <p>",
"         (Aptalis Pharma)&nbsp;",
"        </p>",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Not recommended&nbsp;for infants or children aged &lt;4 years who weigh less than 14 kg.",
"        </p>",
"        <p>",
"         Swallow capsules whole or sprinkle capsule contents on small amount of acidic soft food with pH of 4.5 or less (eg, applesauce, yogurt, commercially prepared bananas or pears), consume immediately and follow with water, juice or other liquid.&nbsp;Do not crush or chew capsule shell or contents.",
"        </p>",
"       </td>",
"       <td>",
"        13,800&nbsp;",
"       </td>",
"       <td>",
"        27,600&nbsp;",
"       </td>",
"       <td>",
"        27,600&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ultresa&trade;* 20,700&nbsp;",
"       </td>",
"       <td>",
"        20,700&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        41,400&nbsp;",
"       </td>",
"       <td>",
"        41,400&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ultresa&trade;* 23,000&nbsp;",
"       </td>",
"       <td>",
"        23,000&nbsp;",
"       </td>",
"       <td>",
"        46,000&nbsp;",
"       </td>",
"       <td>",
"        46,000&nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Viokace&trade;* 10,440&nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Regular release (NON enteric coated) tablet, porcine origin",
"        </p>",
"        <p>",
"         (Aptalis Pharma)&nbsp;",
"        </p>",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Only indicated for use in adult patients also treated with a proton pump inhibitor.",
"        </p>",
"        <p>",
"         Swallow tablets whole with sufficient liquid. Do not crush or chew.",
"        </p>",
"        <p>",
"         Preparation is not&nbsp;suited for infants or children who do not readily swallow whole pills.&nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        10,440&nbsp;",
"       </td>",
"       <td>",
"        39,150&nbsp;",
"       </td>",
"       <td>",
"        39,150&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viokace&trade;* 22,880&nbsp;",
"       </td>",
"       <td>",
"        22,880&nbsp;",
"       </td>",
"       <td>",
"        78,300&nbsp;",
"       </td>",
"       <td>",
"        &nbsp;78,300",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pertzye&trade; 8",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Delayed release capsule containing bicarbonate buffered enteric coated microspheres",
"        </p>",
"        <p>",
"         (Digestive Care, Inc)",
"        </p>",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Not recommended for infants or&nbsp;children aged &lt;4 years who weigh less than 8 kg.",
"        </p>",
"        <p>",
"         Swallow capsules whole or sprinkle capsule contents on small amount of acidic soft food with pH of 4.5 or less (eg, applesauce, yogurt, commercially prepared bananas or pears), consume immediately and follow with water, juice or other liquid.&nbsp;Do not crush or chew capsule shell or contents.",
"        </p>",
"       </td>",
"       <td>",
"        8000",
"       </td>",
"       <td>",
"        30,250",
"       </td>",
"       <td>",
"        &nbsp;28,750",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pertzye&trade; 16",
"       </td>",
"       <td>",
"        16,000",
"       </td>",
"       <td>",
"        60,500",
"       </td>",
"       <td>",
"        57,500",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table shows USP (US pharmacopeial) units of enzyme activity for product brands available in the United States. Individual product contents, preparation type and units of activity vary by country. The units of activity used in other countries are not equivalent to the USP units shown in this table (unless the data is specifically given as USP units). Consult local prescribing information before use or changing products.",
"    <br/>",
"    <strong>",
"     NOTE: Products are not equivalent to one another and are not automatically interchangeable with any other pancreatic enzyme replacement product.",
"    </strong>",
"    <div class=\"footnotes\">",
"     * Ultresa and Viokace were approved by the United States Food and Drug Administration in 2012. These products are expected to be commercially available in late 2012.",
"     <br/>",
"    </div>",
"    <div class=\"reference\">",
"     Data from US licensed prescribing information accessed on August 3, 2012 at",
"     <a href=\"file://dailymed.nlm.nih.gov/dailymed/about.cfm\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      file://dailymed.nlm.nih.gov/dailymed/about.cfm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_29_14814=[""].join("\n");
var outline_f14_29_14814=null;
var title_f14_29_14815="Peptic eso stricture Endosc";
var content_f14_29_14815=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peptic esophageal stricture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy shows a peptic esophageal stricture with adjacent areas of inflammation and ulceration due to reflux-induced injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_29_14815=[""].join("\n");
var outline_f14_29_14815=null;
